{'filename': 'EMA - Abstract 16_ Antibiotic Prophylaxis Need for Packed Anterior Epistaxis - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': 'Is antibiotic prophylaxis necessary for anterior epistaxis with packing? Insights from a large database Tran QK, Vashee I, Vanga R, et al. Am J Emerg Med. 2025;93:6472.', 'entities': []}
{'filename': 'EMA - Abstract 16_ Antibiotic Prophylaxis Need for Packed Anterior Epistaxis - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'section_header', 'text': 'SUMMARY:', 'entities': []}
{'filename': 'EMA - Abstract 16_ Antibiotic Prophylaxis Need for Packed Anterior Epistaxis - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': 'Whether patients receiving anterior packing for epistaxis in the ED should be administered antibiotic prophylaxis to prevent either acute sinusitis or toxic shock syndrome has been a topic of substantial discussion.', 'entities': []}
{'filename': 'EMA - Abstract 16_ Antibiotic Prophylaxis Need for Packed Anterior Epistaxis - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': 'This study examined the enormous Trinex data warehouse, which includes health information from approximately 130 million people worldwide, primarily visit-level, billing and coding, and laboratory information.', 'entities': []}
{'filename': 'EMA - Abstract 16_ Antibiotic Prophylaxis Need for Packed Anterior Epistaxis - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': 'The authors identified all patients in Trinex data who were treated with anterior packing in the ED over a 20-year period. Patients who received cautery or posterior packing were excluded. The intervention group comprised patients receiving antibiotics within 1 day of the ED visit, whereas the control group comprised a propensity-matched cohort of patients with anterior epistaxis who did not receive antibiotics.', 'entities': []}
{'filename': 'EMA - Abstract 16_ Antibiotic Prophylaxis Need for Packed Anterior Epistaxis - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': 'The key outcome of interest was the development of a clinically significant infection (sinusitis, otitis, toxic shock syndrome, or facial cellulitis) within 30 days.', 'entities': []}
{'filename': 'EMA - Abstract 16_ Antibiotic Prophylaxis Need for Packed Anterior Epistaxis - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': 'A total of 15,224 patients met the initial entry criteria: 3,161 (25%) who received antibiotics and 9,000 who did not. After propensity matching, each group included 3,151 patients.', 'entities': []}
{'filename': 'EMA - Abstract 16_ Antibiotic Prophylaxis Need for Packed Anterior Epistaxis - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': 'The clinically significant infection rate was extremely low and nearly identical between groups: 0.36% in patients not receiving antibiotics and 0.55% in patients receiving antibiotics. This difference was not statistically significant. Moreover, no evidence indicated elevated risk of adverse events in the antibiotic group (1% in each group).', 'entities': []}
{'filename': 'EMA - Abstract 16_ Antibiotic Prophylaxis Need for Packed Anterior Epistaxis - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': 'The study has a multitude of limitations, mostly related to the likelihood of undercounting some infections in both groups and to the propensity-score-matching technique. Nonetheless, the findings are consistent with most recent literature on this topic in suggesting that routine antibiotics are simply not indicated for patients packed following anterior epistaxis.', 'entities': []}
{'filename': 'EMA - Abstract 16_ Antibiotic Prophylaxis Need for Packed Anterior Epistaxis - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': 'A caveat is that antibiotic use might still be indicated for patients in a substantially immunocompromised state; however, this small group was not specifically examined in this study.', 'entities': []}
{'filename': 'EMA - Abstract 16_ Antibiotic Prophylaxis Need for Packed Anterior Epistaxis - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'section_header', 'text': 'PMID: 40147155', 'entities': []}
{'filename': 'EMA - Abstract 16_ Antibiotic Prophylaxis Need for Packed Anterior Epistaxis - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': "EDITOR'S COMMENTARY: This large study of real-world antibiotic use in patients receiving anterior nasal packing in the ED did not show any benefit of routine antibiotics. Current data strongly indicate that the large majority of patients who have had anterior packing should not receive prophylactic antibiotics.", 'entities': []}
{'filename': 'EMA - Abstract 16_ Antibiotic Prophylaxis Need for Packed Anterior Epistaxis - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'section_header', 'text': 'RELATED CONTENT:', 'entities': []}
{'filename': 'EMA - Abstract 16_ Antibiotic Prophylaxis Need for Packed Anterior Epistaxis - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'section_header', 'text': 'CorePendium : Epistaxis', 'entities': []}
{'filename': 'EMA - Abstract 16_ Antibiotic Prophylaxis Need for Packed Anterior Epistaxis - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': 'Copyright 2025 by Emergency Medical Abstracts - All Rights Reserved 06/25 - #16', 'entities': []}
{'filename': 'EMA - Abstract 16_ Antibiotic Prophylaxis Need for Packed Anterior Epistaxis - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': 'Tags: Antibiotics', 'entities': []}
{'filename': 'EMA - Abstract 16_ Antibiotic Prophylaxis Need for Packed Anterior Epistaxis - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': 'Epistaxis', 'entities': []}
{'filename': 'EMA - Abstract 16_ Antibiotic Prophylaxis Need for Packed Anterior Epistaxis - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': 'Pharmacology', 'entities': []}
{'filename': 'EMA - Abstract 16_ Antibiotic Prophylaxis Need for Packed Anterior Epistaxis - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'section_header', 'text': 'CorePendium Chapters', 'entities': []}
{'filename': 'EMA - Abstract 16_ Antibiotic Prophylaxis Need for Packed Anterior Epistaxis - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'section_header', 'text': 'Epistaxis', 'entities': []}
{'filename': 'EMA - Abstract 4_ Noninvasive Cardiac Stress Testing_ Impact on MI and Mortality - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': 'Association of early noninvasive cardiac stress testing with acute myocardial infarction and mortality Kawatkar AA, Baecker AS, Sharp AL, et al. Ann Emerg Med. Published online April 8, 2025. doi:10.1016/j.annemergmed.2025.02.024', 'entities': []}
{'filename': 'EMA - Abstract 4_ Noninvasive Cardiac Stress Testing_ Impact on MI and Mortality - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'section_header', 'text': 'SUMMARY:', 'entities': []}
{'filename': 'EMA - Abstract 4_ Noninvasive Cardiac Stress Testing_ Impact on MI and Mortality - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': 'Just when providers might have thought that patients with low-risk chest pain could be safely discharged, this very provocative article by highly respected researchers from the Kaiser Permanente system and the University of Pennsylvania might call that idea into question.', 'entities': []}
{'filename': 'EMA - Abstract 4_ Noninvasive Cardiac Stress Testing_ Impact on MI and Mortality - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': 'The study assessed whether early noninvasive cardiac stress testing (NIT) might be associated with mortality among patients discharged from the ED. Recommending or obtaining early NIT was a time-honored approach to ED and outpatient chest pain management; consequently, many patients would wait in hospitals and EDs for hours to days to receive these studies. However, over time, the value of this practice was called into question, and a recent general trend has been to increasingly aggressively discharge patients with seemingly low or even moderate risk to primary-care follow-up. Urgent NIT has often been deemphasized, particularly in the era of high-sensitivity troponin assays. However, this study might challenge this practice.', 'entities': []}
{'filename': 'EMA - Abstract 4_ Noninvasive Cardiac Stress Testing_ Impact on MI and Mortality - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': 'The authors examined the association between early NIT and a variety of patient-centered outcomes, including 30-day and 1-year mortality, in patients in whom myocardial infarction (MI) was ruled out through cardiac enzyme testing. This observational retrospective cohort study was conducted in the Kaiser Permanente Southern California system. Patients seen at any of the 13 EDs operated by Kaiser Permanente between 2015 and 2020 were included if they had documentation of the HEART score, as was standard for this system at the time. Only patients with continuous Kaiser Permanente enrollment were included, to decrease or eliminate the risk of loss to follow-up.', 'entities': []}
{'filename': 'EMA - Abstract 4_ Noninvasive Cardiac Stress Testing_ Impact on MI and Mortality - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': 'Participants were followed in the integrated electronic health record for 1 year after the index ED visit.', 'entities': []}
{'filename': 'EMA - Abstract 4_ Noninvasive Cardiac Stress Testing_ Impact on MI and Mortality - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': 'The primary outcome was a composite of all-cause death or acute MI during the 1-year followup. The secondary outcomes included the same composite within 30 days, as well as each component of the composite. The exposure variable was NIT performance within 3 days of the ED index visit (stress ECG, stress echocardiography, nuclear stress, or coronary CT angiography).', 'entities': []}
{'filename': 'EMA - Abstract 4_ Noninvasive Cardiac Stress Testing_ Impact on MI and Mortality - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': 'Because this study was observational, the authors performed propensity score analysis to control for observable confounders and instrumental variable analysis to further control for unobservable confounding.', 'entities': []}
{'filename': 'EMA - Abstract 4_ Noninvasive Cardiac Stress Testing_ Impact on MI and Mortality - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': 'The analytic sample included 174,917 patients: 61% with low risk, 36% with moderate risk, and 3% with high risk, according to HEART scores. Unsurprisingly, NIT was performed within 3 days in 5% of the low-risk group, 18% of the intermediate-risk group, and 23% of the high-risk group.', 'entities': []}
{'filename': 'EMA - Abstract 4_ Noninvasive Cardiac Stress Testing_ Impact on MI and Mortality - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': 'After the researchers controlled for many potential confounders, NIT within 3 days was associated with a diminished risk of the composite outcome in all 3 HEART score categories, and the differences were not trivial.', 'entities': []}
{'filename': 'EMA - Abstract 4_ Noninvasive Cardiac Stress Testing_ Impact on MI and Mortality - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': 'In the low-risk HEART group, the rate death or acute MI within 1 year was 1.1% in the early NIT group and 2.8% in the comparator group (absolute risk difference, 1.7%). The corresponding', 'entities': []}
{'filename': 'EMA - Abstract 4_ Noninvasive Cardiac Stress Testing_ Impact on MI and Mortality - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': 'risks were 3.6% vs 11.3% (risk difference, 7.7%) in the intermediate-risk group, and 9.2% vs 20.3% In the high-risk group. Given that the study included approximately 170,000 patients, all these results were highly statistically significant.', 'entities': []}
{'filename': 'EMA - Abstract 4_ Noninvasive Cardiac Stress Testing_ Impact on MI and Mortality - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': 'Importantly, the differences in the primary outcome were not nearly as impressive at 365 days than at 30 days. The mortality rates were 0.2% in the early-invasive group vs 0.4% in the comparator group among low-risk patients, and 0.7% in the early-invasive group vs 1.6% in the comparator group among moderate-risk patients.', 'entities': []}
{'filename': 'EMA - Abstract 4_ Noninvasive Cardiac Stress Testing_ Impact on MI and Mortality - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': 'Further exploration of mechanistic pathways indicated that the groups receiving early NIT were much more likely to start a variety of cardiac-risk-factor-modifying drugs than the comparator groups. This aspect was likely to have driven the 1-year mortality benefit, because the rates of early invasive treatment were generally only very modestly increased with respect to increases in medications.', 'entities': []}
{'filename': 'EMA - Abstract 4_ Noninvasive Cardiac Stress Testing_ Impact on MI and Mortality - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': "Although this thought-provoking article is likely to receive substantial attention, many reasons for skepticism exist. Foremost, although the authors are highly respected, the study was observational, and why some patients in each category received early NIT and others did not is unknown. Paradoxically, providers might be expected to recommend or perform early NIT on patients with higher risk, which might be associated with poorer outcomes. Therefore, the finding that early NIT was associated with better outcomes is surprising. Nonetheless, unobservable variables such as patient motivation might have accounted for the differences. Highly motivated and concerned patients are likely to be less ill; to modify behaviors that would otherwise place them at risk; and, of course, to seek early NIT. In addition, patients with multiple possible chest pain etiologies (eg, acute coronary syndrome, pulmonary embolism, or pneumonia) are probably less likely to receive early NIT than patients for whom coronary artery disease is the only real concern. Such patients might inherently be more ill (at risk of MI, pulmonary embolism, or cancer) than the comparators, thus potentially explaining the observed differences. The authors correctly suggest that trial data are necessary to support reversion to the 'stress everyone early' practice. Finally, this study occurred in an environment without highsensitivity troponin testing- a major issue, given the marked changes in definitions of low or moderate risk since 2017. Whether these findings might be replicated now is unclear.", 'entities': []}
{'filename': 'EMA - Abstract 4_ Noninvasive Cardiac Stress Testing_ Impact on MI and Mortality - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'section_header', 'text': 'PMID:', 'entities': []}
{'filename': 'EMA - Abstract 4_ Noninvasive Cardiac Stress Testing_ Impact on MI and Mortality - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': '40196978', 'entities': []}
{'filename': 'EMA - Abstract 4_ Noninvasive Cardiac Stress Testing_ Impact on MI and Mortality - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': "EDITOR'S COMMENTARY: This very large observational study of a cohort of patients seen at an integrated health system in Southern California found an association between early NIT and improved 1-year clinical outcomes among patients seen in the ED with apparent concerns of cardiac chest pain, regardless of risk category. Overall, the risks of adverse events were still very low in low-risk and moderate-risk patients within 30 days, but were higher in the group that did not get cardiac testing within 72 hours. The limitations of retrospective studies make these findings interesting but not practice changing.", 'entities': []}
{'filename': 'EMA - Abstract 4_ Noninvasive Cardiac Stress Testing_ Impact on MI and Mortality - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'section_header', 'text': 'RELATED CONTENT:', 'entities': []}
{'filename': 'EMA - Abstract 4_ Noninvasive Cardiac Stress Testing_ Impact on MI and Mortality - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'section_header', 'text': 'EM:RAP 2020 January: CCTA in Chest Pain', 'entities': []}
{'filename': 'EMA - Abstract 4_ Noninvasive Cardiac Stress Testing_ Impact on MI and Mortality - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': 'CorePendium : Approach to Chest Pain', 'entities': []}
{'filename': 'EMA - Abstract 9_ Brain Injury Guidelines Evaluation_ Australian Trauma Centre Study - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': 'Evaluating the brain injury guidelines (BIG) in an Australian trauma centre: a retrospective cohort analysis Chelepy W, Williamson T, Jayalath R. J Clin Neurosci. 2025;134:111092.', 'entities': []}
{'filename': 'EMA - Abstract 9_ Brain Injury Guidelines Evaluation_ Australian Trauma Centre Study - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'section_header', 'text': 'SUMMARY:', 'entities': []}
{'filename': 'EMA - Abstract 9_ Brain Injury Guidelines Evaluation_ Australian Trauma Centre Study - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': 'Traumatic brain injury is associated with high morbidity and mortality; consequently, a bleed found on CT usually triggers a cascade of expensive resources, including multiple imaging studies, ICU admission, neurosurgical consultation, and patient transfer, if none of these services are locally available. Recent evidence has suggested that this protocol might actually be unnecessary for most bleeds.', 'entities': []}
{'filename': 'EMA - Abstract 9_ Brain Injury Guidelines Evaluation_ Australian Trauma Centre Study - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': 'To improve resource utilization, the Brain Injury Guidelines (BIG) were developed. Clinical and radiological criteria are used to divide patients into 3 groups to estimate the risk of deterioration and the need for intervention: BIG 1 is least severe, whereas BIG 3 is most severe.', 'entities': []}
{'filename': 'EMA - Abstract 9_ Brain Injury Guidelines Evaluation_ Australian Trauma Centre Study - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': 'This single-center, retrospective validation study is the first effort assessing the BIG in Australia. Potential participants were identified from a database of radiology studies, and all charts were manually reviewed, in a manner mirroring the data collection strategies in the original derivation work. A largely explicit chart review appears to have been performed, but information is lacking regarding how missing or conflicting data were handled.', 'entities': []}
{'filename': 'EMA - Abstract 9_ Brain Injury Guidelines Evaluation_ Australian Trauma Centre Study - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': 'The study reports on 878 patients: 106 (12.1%) with BIG 1, 113 (13.2%) with BIG 2, and 659 (75.1%) with BIG 3. Subdural hemorrhage and subarachnoid hemorrhage were the most common ICH types in all groups, whereas intraparenchymal hemorrhage was approximately 3 to 5 times more common in the BIG 3 group.', 'entities': []}
{'filename': 'EMA - Abstract 9_ Brain Injury Guidelines Evaluation_ Australian Trauma Centre Study - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': 'No patients in the BIG 1 or BIG 2 groups showed clinical neurological deterioration or required neurosurgical intervention. Only 3 (7%) BIG 1 patients and 2 (3.4%) BIG 2 patients showed progression on repeat head CT, but this finding did not prompt any changes in management. One ED representation associated with traumatic brain injury occurred in the BIG 1 group for headache, but the patient had a reassuring CT and was discharged. No readmissions occurred in the BIG 1 or BIG 2 groups. All patients needing intervention or readmission were classified as BIG 3. In the study sample, following the BIG would have avoided 101 CT scans, 208 neurosurgical consultations, and 189 inpatient days.', 'entities': []}
{'filename': 'EMA - Abstract 9_ Brain Injury Guidelines Evaluation_ Australian Trauma Centre Study - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': 'Overall, the strength of the methods is moderate, and the authors do provide more external validation for the BIG, which is required before widespread use. However, study limitations include a sample size smaller than that in the original American validation studies, a lack of assessment of long-term outcomes beyond 30 days, and low incidence of epidural hematomas in the study cohort. Additionally, because the data are not prospective, the patients were not discharged after a short observation period in accordance with the BIG, but instead were admitted, stayed, and were reimaged. Finally, whether an unmeasured value might have influenced patient outcomes in the BIG 1 and 2 groups, and would have been lost if the patients had actually been discharged, is unknown.', 'entities': []}
{'filename': 'EMA - Abstract 9_ Brain Injury Guidelines Evaluation_ Australian Trauma Centre Study - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'section_header', 'text': 'PMID: 39889522', 'entities': []}
{'filename': 'EMA - Abstract 9_ Brain Injury Guidelines Evaluation_ Australian Trauma Centre Study - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': "EDITOR'S COMMENTARY: In this retrospective external validation of the BIG conducted in Australia, the authors found that, similarly to the original derivation work, no patients categorized as BIG 1 or 2 needed a surgical intervention or any form of escalation of care. The sample size was not huge, the patients were not actually discharged as recommended by the guidelines, and the data are retrospective. However, the study provides more evidence challenging the dogma that all patients with traumatic bleeds must be admitted or transferred for neurosurgical evaluation and monitoring. We are getting closer to the BIG becoming a real practice changer in emergency medicine.", 'entities': []}
{'filename': 'EMA - Abstract 9_ Brain Injury Guidelines Evaluation_ Australian Trauma Centre Study - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'section_header', 'text': 'RELATED CONTENT:', 'entities': []}
{'filename': 'EMA - Abstract 9_ Brain Injury Guidelines Evaluation_ Australian Trauma Centre Study - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'section_header', 'text': 'EM:RAP 2025 March: Neurocritical Care Mailbag: TBI Management', 'entities': []}
{'filename': 'EMA - Abstract 9_ Brain Injury Guidelines Evaluation_ Australian Trauma Centre Study - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': 'CorePendium : Traumatic Brain Injury (Minor)', 'entities': []}
{'filename': 'EMA - Abstract 9_ Brain Injury Guidelines Evaluation_ Australian Trauma Centre Study - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': 'Copyright 2025 by Emergency Medical Abstracts - All Rights Reserved 07/25 - #09', 'entities': []}
{'filename': 'EMA - Abstract 9_ Brain Injury Guidelines Evaluation_ Australian Trauma Centre Study - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': 'Tag:', 'entities': []}
{'filename': 'EMA - Abstract 9_ Brain Injury Guidelines Evaluation_ Australian Trauma Centre Study - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': 'Brain Injury', 'entities': []}
{'filename': 'EMA - Abstract 9_ Brain Injury Guidelines Evaluation_ Australian Trauma Centre Study - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'section_header', 'text': 'CorePendium Chapters', 'entities': []}
{'filename': 'EMA - Abstract 9_ Brain Injury Guidelines Evaluation_ Australian Trauma Centre Study - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': 'Traumatic Brain Injury (Minor)', 'entities': []}
{'filename': 'EMA - Abstract 13_ Nebulized Tranexamic Acid for Post-Tonsillectomy Bleeding - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': 'Nebulized tranexamic acid for treatment of post-tonsillectomy bleeding: a systematic review and meta-analysis \xa0Alghamdi AS, Hazzazi GS, Shaheen MH, et al. Eur Arch Otorhinolaryngol. 2025;282(3):1135-1146.', 'entities': []}
{'filename': 'EMA - Abstract 13_ Nebulized Tranexamic Acid for Post-Tonsillectomy Bleeding - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'section_header', 'text': 'SUMMARY:', 'entities': []}
{'filename': 'EMA - Abstract 13_ Nebulized Tranexamic Acid for Post-Tonsillectomy Bleeding - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': 'Post-tonsillectomy hemorrhage (PTH) is not a common complication, but when it occurs, patients may be very ill or in extremis at presentation. Common treatment modalities include cold-water gargle; nebulized racemic epinephrine; direct pressure, if possible; or topical treatment with oxymetazoline, epinephrine, or silver nitrate cautery. Despite these options, many patients are sent to the operating room.', 'entities': []}
{'filename': 'EMA - Abstract 13_ Nebulized Tranexamic Acid for Post-Tonsillectomy Bleeding - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': 'Nebulized tranexamic acid (TXA) has emerged as a treatment option. Because of substantial increases in evidence in the past few years, the authors performed the first-ever systematic review on the topic. Using best-practice PRISMA guidelines, they identified 9 studies for review, including 2 case reports, 4 case series, and 3 retrospective studies involving a total of 448 patients. Somewhat surprisingly, the studies were assessed to have overall good quality and low risk of bias. Because of significant heterogeneity among study populations and designs, as well as the primarily descriptive nature of the data, the authors provided qualitative summaries of each article individually.', 'entities': []}
{'filename': 'EMA - Abstract 13_ Nebulized Tranexamic Acid for Post-Tonsillectomy Bleeding - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': 'Overall, nebulized TXA was found to significantly contribute to achieving hemostasis during emergency department visits and to help stabilize bleeding in acute circumstances before definitive surgical involvement. Additionally, patients receiving nebulized TXA had significantly less need for reoperation to control bleeding than patients without nebulized TXA administration. The narrative highlights several advantages of nebulized TXA over other modalities, including the lack of requirement for direct oral access and insertion, thus eliminating the chance of a gag reflex, and the ability for rapid administration even in prehospital settings.', 'entities': []}
{'filename': 'EMA - Abstract 13_ Nebulized Tranexamic Acid for Post-Tonsillectomy Bleeding - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': 'However, several limitations warrant caution, including the predominance of retrospective study designs with small sample sizes, high likelihood of selection bias, heterogeneity in TXA doses (ranging from 250 mg to 1,000 mg), lack of standardized severity criteria for PTH, and inconsistent use of adjunctive interventions.', 'entities': []}
{'filename': 'EMA - Abstract 13_ Nebulized Tranexamic Acid for Post-Tonsillectomy Bleeding - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'section_header', 'text': 'PMID: 39356357', 'entities': []}
{'filename': 'EMA - Abstract 13_ Nebulized Tranexamic Acid for Post-Tonsillectomy Bleeding - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': "EDITOR'S COMMENTARY: If you want to know everything there is to know about the evidence behind nebulized TXA for post-tonsillectomy hemorrhage, this is the article for you. The authors go over all 9 studies on the topic and provide easy-to-follow summaries of each. In sum, although nebulized TXA appears promising as a first-line intervention for PTH, higher-quality prospective studies with standardized protocols are needed before this modality can be universally recommended as standard practice in emergency departments.", 'entities': []}
{'filename': 'EMA - Abstract 13_ Nebulized Tranexamic Acid for Post-Tonsillectomy Bleeding - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'section_header', 'text': 'RELATED CONTENT:', 'entities': []}
{'filename': 'EMA - Abstract 13_ Nebulized Tranexamic Acid for Post-Tonsillectomy Bleeding - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'section_header', 'text': 'EM:RAP 2018 June: Cool Peds Tricks', 'entities': []}
{'filename': 'EMA - Abstract 13_ Nebulized Tranexamic Acid for Post-Tonsillectomy Bleeding - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': 'CorePendium : Post-Tonsillectomy Hemorrhage', 'entities': []}
{'filename': 'EMA - Abstract 13_ Nebulized Tranexamic Acid for Post-Tonsillectomy Bleeding - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': 'Copyright 2025 by Emergency Medical Abstracts - All Rights Reserved 06/25 - #13', 'entities': []}
{'filename': 'EMA - Abstract 13_ Nebulized Tranexamic Acid for Post-Tonsillectomy Bleeding - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': 'Tags:', 'entities': []}
{'filename': 'EMA - Abstract 13_ Nebulized Tranexamic Acid for Post-Tonsillectomy Bleeding - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': 'Bleeding Pharmacology', 'entities': []}
{'filename': 'EMA - Abstract 13_ Nebulized Tranexamic Acid for Post-Tonsillectomy Bleeding - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'section_header', 'text': 'CorePendium Chapters', 'entities': []}
{'filename': 'EMA - Abstract 13_ Nebulized Tranexamic Acid for Post-Tonsillectomy Bleeding - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': 'Post-Tonsillectomy Hemorrhage', 'entities': []}
{'filename': "EMA - Abstract 18_ Negative Prehn's Sign for Diagnosing Testicular Torsion - EMA 2025 July _ EM_RAP.pdf", 'page': None, 'block_label': 'text', 'text': "In emergency settings, can a negative Prehn's sign be used to aid diagnosis of testicular torsion? Edwards LG, Feldman JW, Ferguson C. Emerg Med J. 2025;42(6):411-412.", 'entities': []}
{'filename': "EMA - Abstract 18_ Negative Prehn's Sign for Diagnosing Testicular Torsion - EMA 2025 July _ EM_RAP.pdf", 'page': None, 'block_label': 'section_header', 'text': 'SUMMARY:', 'entities': []}
{'filename': "EMA - Abstract 18_ Negative Prehn's Sign for Diagnosing Testicular Torsion - EMA 2025 July _ EM_RAP.pdf", 'page': None, 'block_label': 'list_item', 'text': 'This study targeting the Prehn sign is from the Best Evidence Topics series, an abbreviated systematic review and summary of the data for highly specific questions. A positive Prehn sign is indicated by relief of testicular pain when the testicle is elevated. This finding is generally believed to indicate that torsion is unlikely, and epididymitis is the likely diagnosis.', 'entities': []}
{'filename': "EMA - Abstract 18_ Negative Prehn's Sign for Diagnosing Testicular Torsion - EMA 2025 July _ EM_RAP.pdf", 'page': None, 'block_label': 'list_item', 'text': 'Unchanged pain is considered a negative Prehn sign and is believed to suggest torsion.', 'entities': []}
{'filename': "EMA - Abstract 18_ Negative Prehn's Sign for Diagnosing Testicular Torsion - EMA 2025 July _ EM_RAP.pdf", 'page': None, 'block_label': 'list_item', 'text': 'Notably, this sign has no relation to the cremasteric reflex.', 'entities': []}
{'filename': "EMA - Abstract 18_ Negative Prehn's Sign for Diagnosing Testicular Torsion - EMA 2025 July _ EM_RAP.pdf", 'page': None, 'block_label': 'list_item', 'text': 'The authors examined the literature to determine whether the Prehn sign might be used to rule in or rule out torsion.', 'entities': []}
{'filename': "EMA - Abstract 18_ Negative Prehn's Sign for Diagnosing Testicular Torsion - EMA 2025 July _ EM_RAP.pdf", 'page': None, 'block_label': 'list_item', 'text': 'After a systematic search, only 4 published studies involving 157 torsion cases were identified; all were retrospective cohort studies.', 'entities': []}
{'filename': "EMA - Abstract 18_ Negative Prehn's Sign for Diagnosing Testicular Torsion - EMA 2025 July _ EM_RAP.pdf", 'page': None, 'block_label': 'list_item', 'text': 'In 3 of the 4 studies, approximately one-third of patients with testicular torsion had a positive Prehn sign; therefore, this sign alone cannot be used to rule out torsion (66% sensitive). Very scant available data indicated how many patients with epididymitis had a positive or negative Prehn sign; this information might have been used to determine the specificity of the maneuver.', 'entities': []}
{'filename': "EMA - Abstract 18_ Negative Prehn's Sign for Diagnosing Testicular Torsion - EMA 2025 July _ EM_RAP.pdf", 'page': None, 'block_label': 'list_item', 'text': 'The clinical bottom line is that essentially no data support relying on the Prehn sign to exclude torsion. If the clinical history and examination findings are highly suggestive, physicians should call urology and obtain an ultrasound.', 'entities': []}
{'filename': "EMA - Abstract 18_ Negative Prehn's Sign for Diagnosing Testicular Torsion - EMA 2025 July _ EM_RAP.pdf", 'page': None, 'block_label': 'section_header', 'text': 'PMID: 40199561', 'entities': []}
{'filename': "EMA - Abstract 18_ Negative Prehn's Sign for Diagnosing Testicular Torsion - EMA 2025 July _ EM_RAP.pdf", 'page': None, 'block_label': 'text', 'text': "EDITOR'S COMMENTARY: This review of the literature concludes that the Prehn sign, or relief of pain when the testicle is elevated, is insensitive and cannot be used in isolation to rule out testicular torsion. The data underpinning this conclusion are extremely weak.", 'entities': []}
{'filename': "EMA - Abstract 18_ Negative Prehn's Sign for Diagnosing Testicular Torsion - EMA 2025 July _ EM_RAP.pdf", 'page': None, 'block_label': 'section_header', 'text': 'RELATED CONTENT:', 'entities': []}
{'filename': "EMA - Abstract 18_ Negative Prehn's Sign for Diagnosing Testicular Torsion - EMA 2025 July _ EM_RAP.pdf", 'page': None, 'block_label': 'section_header', 'text': 'EM:RAP 2017 December: Medico Legal Briefs - Testicular Torsion', 'entities': []}
{'filename': "EMA - Abstract 18_ Negative Prehn's Sign for Diagnosing Testicular Torsion - EMA 2025 July _ EM_RAP.pdf", 'page': None, 'block_label': 'text', 'text': 'CorePendium : Testicular Torsion', 'entities': []}
{'filename': "EMA - Abstract 18_ Negative Prehn's Sign for Diagnosing Testicular Torsion - EMA 2025 July _ EM_RAP.pdf", 'page': None, 'block_label': 'text', 'text': 'Copyright 2025 by Emergency Medical Abstracts - All Rights Reserved 07/25 - #18', 'entities': []}
{'filename': "EMA - Abstract 18_ Negative Prehn's Sign for Diagnosing Testicular Torsion - EMA 2025 July _ EM_RAP.pdf", 'page': None, 'block_label': 'caption', 'text': 'Tag: Testicular Torsion', 'entities': []}
{'filename': "EMA - Abstract 18_ Negative Prehn's Sign for Diagnosing Testicular Torsion - EMA 2025 July _ EM_RAP.pdf", 'page': None, 'block_label': 'section_header', 'text': 'CorePendium Chapters', 'entities': []}
{'filename': "EMA - Abstract 18_ Negative Prehn's Sign for Diagnosing Testicular Torsion - EMA 2025 July _ EM_RAP.pdf", 'page': None, 'block_label': 'section_header', 'text': 'Testicular Torsion', 'entities': []}
{'filename': 'EMA - Abstract 10_ Nasal High-Flow O2 During Apnea in Pediatric ED_ICU_ RCT - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': 'Effectiveness of nasal high-flow oxygen during apnoea on hypoxaemia and intubation success in paediatric emergency and ICU settings: a randomised, controlled, open-label trial George S, Williams T, Humphreys S, et al. Lancet Respir Med. Published online March 20, 2025. doi:10.1016/S2213-2600(25)00074-8', 'entities': []}
{'filename': 'EMA - Abstract 10_ Nasal High-Flow O2 During Apnea in Pediatric ED_ICU_ RCT - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'section_header', 'text': 'SUMMARY:', 'entities': []}
{'filename': 'EMA - Abstract 10_ Nasal High-Flow O2 During Apnea in Pediatric ED_ICU_ RCT - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': 'Pediatric intubation is challenging. Children, compared with adults, tend to desaturate faster, have emotions that run higher, and face greater risks of first-pass failure and hypoxemia. Maintaining good oxygen saturation is key in ensuring sufficient time to intubate. This study assessed whether apneic oxygenation with a nasal high flow (NHF) cannula might provide additional benefits over standard-of-care techniques in maintaining apneic oxygenation.', 'entities': []}
{'filename': 'EMA - Abstract 10_ Nasal High-Flow O2 During Apnea in Pediatric ED_ICU_ RCT - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': 'The open-label randomized clinical trial compared NHF vs standard of care for the apneic phase of the intubation. The study was conducted in neonatal intensive care units (ICUs), pediatric ICUs, and EDs at 10 centers in Australia, New Zealand, and Switzerland. The inclusion criteria were patients <16 years of age requiring emergency intubation.', 'entities': []}
{'filename': 'EMA - Abstract 10_ Nasal High-Flow O2 During Apnea in Pediatric ED_ICU_ RCT - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': 'The primary outcomes were (1) successful first-attempt intubation without oxygen desaturation and (2) a hypoxemic event during the first intubation attempt. Numerous secondary endpoints were examined. The first pass was considered the time from blade insertion to withdrawal.', 'entities': []}
{'filename': 'EMA - Abstract 10_ Nasal High-Flow O2 During Apnea in Pediatric ED_ICU_ RCT - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': 'All patients were preoxygenated, and at the time of intubation, the patients randomized to NHF had the oxygen turned on, whereas apneic oxygenation for patients randomized to standard care was performed at the discretion of the intubator. Clinical outcomes were recorded by the intubator on a case report form and verified through video review of the intubations.', 'entities': []}
{'filename': 'EMA - Abstract 10_ Nasal High-Flow O2 During Apnea in Pediatric ED_ICU_ RCT - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': 'From 2017 to 2022, 950 intubation events were analyzed: 60% in children <1 year of age and <10% in children >7 years of age. Most intubations were performed in the ICU (usually the pediatric ICU, 10%), and approximately 10% were performed in the ED. Video laryngoscopy was used in approximately 35% of cases, and a junior operator performed 74% of intubations. The median oxygen saturation just before intubation was 100%. The groups were well balanced between treatment arms. The primary outcome of a successful first pass without desaturation was similar between groups (63% in the NHF group vs 59% in the standard-care group; OR, 1.18; CI, 0.88-1.59); hypoxemic events occurred in 13% of the NHF group and 16% of the standard-care group (OR, 0.76; CI, 0.5-1.15).', 'entities': []}
{'filename': 'EMA - Abstract 10_ Nasal High-Flow O2 During Apnea in Pediatric ED_ICU_ RCT - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': 'The results were similar across a host of subgroups based on intubation location, intubator experience, and patient age. No strong signal indicated that NHF was superior to standard care, although the trial protocol was slightly biased toward finding a difference favoring NHF, possibly because the apneic oxygenation methods in the standard-care group might have been illadvised. Under current real-world conditions, the standard-care group would have had to receive continuous oxygen via the nasal cannula, thereby minimizing the differences between groups.', 'entities': []}
{'filename': 'EMA - Abstract 10_ Nasal High-Flow O2 During Apnea in Pediatric ED_ICU_ RCT - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': 'The use of direct laryngoscopy for most intubations might have affected the results, but whether the findings would have been biased toward or away from the intervention is difficult to predict.', 'entities': []}
{'filename': 'EMA - Abstract 10_ Nasal High-Flow O2 During Apnea in Pediatric ED_ICU_ RCT - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': 'This article indicates no reason to spend the time to connect to NHF for most pediatric intubations.', 'entities': []}
{'filename': 'EMA - Abstract 10_ Nasal High-Flow O2 During Apnea in Pediatric ED_ICU_ RCT - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'section_header', 'text': 'PMID: 40127666', 'entities': []}
{'filename': 'EMA - Abstract 10_ Nasal High-Flow O2 During Apnea in Pediatric ED_ICU_ RCT - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': "EDITOR'S COMMENTARY: In this large multicenter study of children requiring emergency intubation, the key finding was that apneic oxygenation with NHF did not result in a statistically greater chance of first-pass intubation without hypoxemia. Clinicians should not feel compelled to routinely use this form of respiratory support during intubations.", 'entities': []}
{'filename': 'EMA - Abstract 10_ Nasal High-Flow O2 During Apnea in Pediatric ED_ICU_ RCT - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'section_header', 'text': 'RELATED CONTENT:', 'entities': []}
{'filename': 'EMA - Abstract 10_ Nasal High-Flow O2 During Apnea in Pediatric ED_ICU_ RCT - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': 'CorePendium : Non-Invasive Positive Pressure Ventilation and High-Flow Nasal Cannula', 'entities': []}
{'filename': 'EMA - Abstract 10_ Nasal High-Flow O2 During Apnea in Pediatric ED_ICU_ RCT - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'section_header', 'text': 'CorePendium : Pediatric Cardiac Arrest', 'entities': []}
{'filename': 'EMA - Abstract 10_ Nasal High-Flow O2 During Apnea in Pediatric ED_ICU_ RCT - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': 'Copyright 2025 by Emergency Medical Abstracts - All Rights Reserved 06/25 - #10', 'entities': []}
{'filename': 'EMA - Abstract 10_ Nasal High-Flow O2 During Apnea in Pediatric ED_ICU_ RCT - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': 'Tags: Intubation pediatric resuscitation Procedural Skills', 'entities': []}
{'filename': 'EMA - Abstract 10_ Nasal High-Flow O2 During Apnea in Pediatric ED_ICU_ RCT - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'section_header', 'text': 'CorePendium Chapters', 'entities': []}
{'filename': 'EMA - Abstract 10_ Nasal High-Flow O2 During Apnea in Pediatric ED_ICU_ RCT - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': 'Non-Invasive Positive Pressure Ventilation and High-Flow Nasal Cannula Pediatric Cardiac Arrest', 'entities': []}
{'filename': 'EMA - Abstract 12_ Consent in Antenatal PE Imaging_ Outcomes & Delayed Diagnosis Risks - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': 'Consent to advanced imaging in antenatal pulmonary embolism diagnostics: prevalence, outcomes of nonconsent and opportunities to mitigate delayed diagnosis risk Vinson DR, Somers MJ, Qiao E, et al. Acad Emerg Med. 2025;32(3):260-273.', 'entities': []}
{'filename': 'EMA - Abstract 12_ Consent in Antenatal PE Imaging_ Outcomes & Delayed Diagnosis Risks - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'section_header', 'text': 'SUMMARY:', 'entities': []}
{'filename': 'EMA - Abstract 12_ Consent in Antenatal PE Imaging_ Outcomes & Delayed Diagnosis Risks - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': 'This somewhat complicated article examined the prevalence of refusal to consent to CT pulmonary angiography among pregnant patients. A retrospective cohort chart review was conducted among pregnant patients who were undergoing a diagnostic VTE workup and were recommended to receive advanced imaging.', 'entities': []}
{'filename': 'EMA - Abstract 12_ Consent in Antenatal PE Imaging_ Outcomes & Delayed Diagnosis Risks - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': 'The main goal of the investigation was to determine the proportion of patients who declined imaging, and to examine any differences in the proportions of patients declining in ED vs obstetrics and gynecology (OB/GYN) settings.', 'entities': []}
{'filename': 'EMA - Abstract 12_ Consent in Antenatal PE Imaging_ Outcomes & Delayed Diagnosis Risks - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': 'The authors identified 405 pregnant patients during an 18-month study period in 2022 to 2023 across 21 Northern California Kaiser Permanente sites: 82% were seen in the ED, 16% were seen in OB/GYN practice, and 1% were seen in primary-care locations; moreover, 55% were classified as having a low pretest probability, whereas only 4% were classified as having a high pretest probability of pulmonary embolism (PE).', 'entities': []}
{'filename': 'EMA - Abstract 12_ Consent in Antenatal PE Imaging_ Outcomes & Delayed Diagnosis Risks - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': 'Among patients seen in the ED setting, 73% consented (27% did not consent) to advanced imaging, compared with 99% of patients seen in OB/GYN practice.', 'entities': []}
{'filename': 'EMA - Abstract 12_ Consent in Antenatal PE Imaging_ Outcomes & Delayed Diagnosis Risks - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': 'Of the 91 patients who did not consent, few were admitted to the hospital (4%), a small fraction signed out against medical advice (17%), and most were seen in follow-up, usually within 7 days.', 'entities': []}
{'filename': 'EMA - Abstract 12_ Consent in Antenatal PE Imaging_ Outcomes & Delayed Diagnosis Risks - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': 'Only 12 of these 91 patients had persistent potentially PE-related symptoms at follow-up, and those for whom imaging was recommended at that time did provide consent.', 'entities': []}
{'filename': 'EMA - Abstract 12_ Consent in Antenatal PE Imaging_ Outcomes & Delayed Diagnosis Risks - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': 'None of the 91 patients had PE diagnosed within 90 days (although 1 patient had a deep vein thrombosis diagnosed).', 'entities': []}
{'filename': 'EMA - Abstract 12_ Consent in Antenatal PE Imaging_ Outcomes & Delayed Diagnosis Risks - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': "The authors examined numerous clinical features potentially influencing the patients' willingness to consent to pulmonary vascular imaging, but the only factor associated with enhanced odds of consent was OB/GYN treatment.", 'entities': []}
{'filename': 'EMA - Abstract 12_ Consent in Antenatal PE Imaging_ Outcomes & Delayed Diagnosis Risks - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': 'The risk of fetal injury from CT scanning is extremely low, and this high nonconsent rate probably reflects poor risk communication, which might serve as a target for further intervention.', 'entities': []}
{'filename': 'EMA - Abstract 12_ Consent in Antenatal PE Imaging_ Outcomes & Delayed Diagnosis Risks - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'section_header', 'text': 'PMID:', 'entities': []}
{'filename': 'EMA - Abstract 12_ Consent in Antenatal PE Imaging_ Outcomes & Delayed Diagnosis Risks - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': '39552252', 'entities': []}
{'filename': 'EMA - Abstract 12_ Consent in Antenatal PE Imaging_ Outcomes & Delayed Diagnosis Risks - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'section_header', 'text': 'FULL ARTICLE: https://onlinelibrary.wiley.com/doi/epdf/10.1111/acem.15045', 'entities': []}
{'filename': 'EMA - Abstract 12_ Consent in Antenatal PE Imaging_ Outcomes & Delayed Diagnosis Risks - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': "EDITOR'S COMMENTARY: Refusal rates for ED-recommended pulmonary vascular imaging to rule out PE among pregnant patients were surprisingly high, particularly in comparison to the refusal rates among patients receiving OB/GYN treatment. More research is needed to help ED providers communicate risks effectively to pregnant patients.", 'entities': []}
{'filename': 'EMA - Abstract 12_ Consent in Antenatal PE Imaging_ Outcomes & Delayed Diagnosis Risks - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'section_header', 'text': 'RELATED CONTENT:', 'entities': []}
{'filename': 'EMA - Abstract 12_ Consent in Antenatal PE Imaging_ Outcomes & Delayed Diagnosis Risks - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'section_header', 'text': 'EM:RAP 2025 May: Cardiology Corner: PE in Pregnancy', 'entities': []}
{'filename': 'EMA - Abstract 12_ Consent in Antenatal PE Imaging_ Outcomes & Delayed Diagnosis Risks - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'section_header', 'text': 'CorePendium : Chest Pain in Pregnancy', 'entities': []}
{'filename': 'EMA - Abstract 12_ Consent in Antenatal PE Imaging_ Outcomes & Delayed Diagnosis Risks - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': 'Copyright 2025 by Emergency Medical Abstracts - All Rights Reserved 06/25 - #12', 'entities': []}
{'filename': 'EMA - Abstract 12_ Consent in Antenatal PE Imaging_ Outcomes & Delayed Diagnosis Risks - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': 'Tags: Imaging Pulmonary Embolism', 'entities': []}
{'filename': 'EMA - Abstract 12_ Consent in Antenatal PE Imaging_ Outcomes & Delayed Diagnosis Risks - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'section_header', 'text': 'CorePendium Chapters', 'entities': []}
{'filename': 'EMA - Abstract 12_ Consent in Antenatal PE Imaging_ Outcomes & Delayed Diagnosis Risks - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': 'Chest Pain in Pregnancy', 'entities': []}
{'filename': 'EMA - Abstract 6_ Risk of Delayed Intubation After Presumed Opioid Overdose in the ED - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': 'Risk of delayed intubation after presumed opioid overdose in the emergency department McCabe DJ, Gibbs H, Pratt AA, et al. Ann Emerg Med. Published online March 3, 2025. doi:10.1016/j.annemergmed.2025.01.022', 'entities': []}
{'filename': 'EMA - Abstract 6_ Risk of Delayed Intubation After Presumed Opioid Overdose in the ED - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'section_header', 'text': 'SUMMARY:', 'entities': []}
{'filename': 'EMA - Abstract 6_ Risk of Delayed Intubation After Presumed Opioid Overdose in the ED - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': 'During the American opioid crisis, the illegal supply of opioids has changed considerably. Since the mid-2000s, fentanyl, fentanyl derivatives and precursors, and other adulterants have come to dominate the illegal opioid supply. This change has prompted reconsideration of the timehonored approach of watching patients with opioid overdose for approximately 4 hours after naloxone administration to ensure that a recurrent respiratory failure event does not occur.', 'entities': []}
{'filename': 'EMA - Abstract 6_ Risk of Delayed Intubation After Presumed Opioid Overdose in the ED - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': 'This study was aimed at quantifying the risk of delayed intubation in such patients in the modern fentanyl era.', 'entities': []}
{'filename': 'EMA - Abstract 6_ Risk of Delayed Intubation After Presumed Opioid Overdose in the ED - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': 'This analysis is from Fentalog, a prospective multicenter observational study at 10 U.S. centers from 2020 to 2024. Consecutive adult patients were enrolled if they had a suspected opioid overdose and received naloxone in either the ED or prehospital setting. Patients with traumatic injuries were excluded.', 'entities': []}
{'filename': 'EMA - Abstract 6_ Risk of Delayed Intubation After Presumed Opioid Overdose in the ED - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': 'The key outcome of interest was the need for intubation >4 hours after arrival.', 'entities': []}
{'filename': 'EMA - Abstract 6_ Risk of Delayed Intubation After Presumed Opioid Overdose in the ED - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': 'Clinical histories of patients with delayed intubation were comprehensively described. A total of 1,591 patients were included, 75% of whom were men. The age distribution was quite wide but peaked at 30 to 40 years. Overall, only 9 patients (0.6%) experienced a delayed intubation event, 8 of whom had nonrespiratory issues that markedly affected the decision to intubate. Consequently, only 1/1,591 patients experienced delayed intubation because of persistent toxicity 4 hours after arrival. The other 8 patients had serious medical issues that might prompt questions regarding why they were not intubated immediately.', 'entities': []}
{'filename': 'EMA - Abstract 6_ Risk of Delayed Intubation After Presumed Opioid Overdose in the ED - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': 'Another interesting nonprimary finding was the detection of many substances, including amphetamine, cocaine, benzodiazepines, quinine, and xylazine, in these patients.', 'entities': []}
{'filename': 'EMA - Abstract 6_ Risk of Delayed Intubation After Presumed Opioid Overdose in the ED - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': 'The study has a host of limitations, including that it is not nationally representative but instead reflects a consortium of centers strongly interested in toxicology. The lack of differentiation among ingestion types (Injection drug, oral, or other) might have affected the probability of delayed decompensation. The authors additionally do not describe the intubation timing for the 9 patients, although these findings might have been interesting (eg, 4.1 hours vs 3 days). Overall, the study tends to suggest that a 4-hour watch period after opioid reversal is sufficiently long and remains appropriate in this new era, and need not be longer.', 'entities': []}
{'filename': 'EMA - Abstract 6_ Risk of Delayed Intubation After Presumed Opioid Overdose in the ED - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'section_header', 'text': 'PMID: 40047773', 'entities': []}
{'filename': 'EMA - Abstract 6_ Risk of Delayed Intubation After Presumed Opioid Overdose in the ED - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': "EDITOR'S COMMENTARY: This large prospective study included consecutive patients treated with naloxone for presumed opioid overdose at 10 major toxicology centers in the U.S. Only 1/1,591 patients (0.1%) required an intubation more than 4 hours after arrival, ostensibly because of ongoing toxic drug effects. Although the study has substantial limitations, the findings generally confirm that a 4-hour watch window is sufficient to identify almost all patients who will experience respiratory arrest.", 'entities': []}
{'filename': 'EMA - Abstract 6_ Risk of Delayed Intubation After Presumed Opioid Overdose in the ED - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'section_header', 'text': 'RELATED CONTENT:', 'entities': []}
{'filename': 'EMA - Abstract 6_ Risk of Delayed Intubation After Presumed Opioid Overdose in the ED - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'section_header', 'text': 'EM:RAP 2017 May: Naloxone', 'entities': []}
{'filename': 'EMA - Abstract 6_ Risk of Delayed Intubation After Presumed Opioid Overdose in the ED - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'section_header', 'text': 'CorePendium : Opioid Toxicity and Poisoning', 'entities': []}
{'filename': 'EMA - Abstract 6_ Risk of Delayed Intubation After Presumed Opioid Overdose in the ED - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': 'Copyright 2025 by Emergency Medical Abstracts - All Rights Reserved 06/25 - #06', 'entities': []}
{'filename': 'EMA - Abstract 6_ Risk of Delayed Intubation After Presumed Opioid Overdose in the ED - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': 'Tag:', 'entities': []}
{'filename': 'EMA - Abstract 6_ Risk of Delayed Intubation After Presumed Opioid Overdose in the ED - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': 'Intubation', 'entities': []}
{'filename': 'EMA - Abstract 6_ Risk of Delayed Intubation After Presumed Opioid Overdose in the ED - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'section_header', 'text': 'CorePendium Chapters', 'entities': []}
{'filename': 'EMA - Abstract 6_ Risk of Delayed Intubation After Presumed Opioid Overdose in the ED - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': 'Opioid Toxicity and Poisoning', 'entities': []}
{'filename': 'EMA - Abstract 7_ Novel Closed Reduction for Shoulder Dislocation - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': 'An original closed reduction technique for acute shoulder dislocation: the wristclamping and shoulder-lifting Dai W, Liu L, Zong S, et al. Int J Emerg Med. 2025;18(1):60.', 'entities': []}
{'filename': 'EMA - Abstract 7_ Novel Closed Reduction for Shoulder Dislocation - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'section_header', 'text': 'SUMMARY:', 'entities': []}
{'filename': 'EMA - Abstract 7_ Novel Closed Reduction for Shoulder Dislocation - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': "Acute shoulder dislocations should be reduced as soon as possible to avoid damage to blood vessels and nerves. Many techniques have been described to accomplish this reduction, each with benefits and drawbacks. This article describes a new technique called the wrist-clamping and shoulder-lifting technique, which the authors say 'makes full use of the sensitivity of the hand for reduction and avoids violence.' This article reports a case series of 36 patients with anterior dislocations reduced with this technique.", 'entities': []}
{'filename': 'EMA - Abstract 7_ Novel Closed Reduction for Shoulder Dislocation - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': 'The inclusion criteria were patients who had x-ray-confirmed anterior shoulder dislocation with no significant fractures or clinically suspected neurovascular injury, and were able to cooperate and follow instructions. The mean patient age was 47 years, and the mean time from dislocation to reduction was approximately 1.5 hours. Importantly, no patients received any analgesia or sedation before or during the reduction attempt.', 'entities': []}
{'filename': 'EMA - Abstract 7_ Novel Closed Reduction for Shoulder Dislocation - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': "The steps of the technique are as follows: the patient is instructed to sit in a chair, and the provider holds the patient's wrists with both hands. Gentle axial traction is applied while the patient's arm is slowly raised up to 90 while the hand and arm are externally rotated to 90 to relax the shoulder muscles. The patient's arm is then lowered to 45 while full external rotation is maintained, and the wrist is held in place with the provider's knees. The provider's hands are placed near the axilla at the location of the humeral head, which is pushed up and back.", 'entities': []}
{'filename': 'EMA - Abstract 7_ Novel Closed Reduction for Shoulder Dislocation - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': 'In this sample, all 36 dislocations were successfully reduced, and no new fractures were found after reduction. Notably, no sedation, anesthesia, or intraarticular injections were used in any patients. All reduction procedures were performed by a single operator without assistance in a chair with no need for a gurney, with a mean procedure time of 3 minutes. No neurovascular injuries were identified after reduction in physical examinations, and no new fractures were found on postreduction radiography.', 'entities': []}
{'filename': 'EMA - Abstract 7_ Novel Closed Reduction for Shoulder Dislocation - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': "The authors' tips based on their clinical experience included the following: (1) traction applied in abduction and external rotation should be slow and gradually increasing in force; (2) when the patient has obvious pain and is unable to cooperate with the traction force, fracture risk is a concern, and providers should pause and adjust the force and direction; and (3) the hands, when used as a lever fulcrum, should be placed at the humeral head of the axilla, not the humeral shaft.", 'entities': []}
{'filename': 'EMA - Abstract 7_ Novel Closed Reduction for Shoulder Dislocation - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': 'The success rate of 100% with no complications might be too good to be true, and is likely to have resulted from a combination of factors including a small overall sample size and a high potential for selection bias, given that the sample was nonconsecutive. Moreover, no evidence is provided of how this technique compares with other more established approaches.', 'entities': []}
{'filename': 'EMA - Abstract 7_ Novel Closed Reduction for Shoulder Dislocation - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'section_header', 'text': 'PMID: 40140973', 'entities': []}
{'filename': 'EMA - Abstract 7_ Novel Closed Reduction for Shoulder Dislocation - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': 'FULL ARTICLE: https://intjem.biomedcentral.com/articles/10.1186/s12245-025-00866-8', 'entities': []}
{'filename': 'EMA - Abstract 7_ Novel Closed Reduction for Shoulder Dislocation - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': "EDITOR'S COMMENTARY: In this case series, the authors describe their experience in successfully reducing 36 anterior shoulder dislocations with a new technique that they invented called the wristclamping and shoulder-lifting technique. The success rate was 100% but might have resulted from small overall numbers and selection bias in enrollment. Things I like about the technique include that it does not require analgesia or sedation, you can do it with your patient in a chair, and you can do it by yourself without a second set of hands. The technique seems safe, and although an estimate of efficacy is lacking, I am looking forward to trying it.", 'entities': []}
{'filename': 'EMA - Abstract 7_ Novel Closed Reduction for Shoulder Dislocation - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'section_header', 'text': 'RELATED CONTENT:', 'entities': []}
{'filename': 'EMA - Abstract 7_ Novel Closed Reduction for Shoulder Dislocation - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': 'EM:RAP 2024 November: Rural Medicine: Repeat Shoulder Dislocation - Dj Vu', 'entities': []}
{'filename': 'EMA - Abstract 7_ Novel Closed Reduction for Shoulder Dislocation - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'section_header', 'text': 'CorePendium : Shoulder Dislocations', 'entities': []}
{'filename': 'EMA - Abstract 7_ Novel Closed Reduction for Shoulder Dislocation - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': 'Copyright 2025 by Emergency Medical Abstracts - All Rights Reserved 06/25 - #07', 'entities': []}
{'filename': 'EMA - Abstract 7_ Novel Closed Reduction for Shoulder Dislocation - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': 'Tags: Shoulder Shoulder Reductions', 'entities': []}
{'filename': 'EMA - Abstract 7_ Novel Closed Reduction for Shoulder Dislocation - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'section_header', 'text': 'CorePendium Chapters', 'entities': []}
{'filename': 'EMA - Abstract 7_ Novel Closed Reduction for Shoulder Dislocation - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': 'Shoulder Dislocations', 'entities': []}
{'filename': 'EMA - Abstract 9_ Hypertonic Saline vs Mannitol Outcomes in Pediatric TBI - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': 'Clinical outcomes of hypertonic saline vs mannitol treatment among children with traumatic brain injury Chong S-L, Zhu Y, Wang Q, et al. JAMA Netw Open. 2025;8(3):e250438.', 'entities': []}
{'filename': 'EMA - Abstract 9_ Hypertonic Saline vs Mannitol Outcomes in Pediatric TBI - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'section_header', 'text': 'SUMMARY:', 'entities': []}
{'filename': 'EMA - Abstract 9_ Hypertonic Saline vs Mannitol Outcomes in Pediatric TBI - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': 'Children with traumatic brain injury (TBI) who develop elevated intracranial pressure (ICP) should receive timely and effective interventions to prevent secondary brain damage. In the management of elevated ICP in severe TBI, the Brain Trauma Foundation recommends 3% hypertonic saline (HTS) as the first-line hyperosmolar therapy. According to the authors of this study, ICP changes were the outcome of interest in most of the literature on which this recommendation was based, whereas less published evidence has indicated that use of HTS rather than mannitol improves clinical outcomes.', 'entities': []}
{'filename': 'EMA - Abstract 9_ Hypertonic Saline vs Mannitol Outcomes in Pediatric TBI - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': 'This prospective multicenter observational cohort study examined data collected between June 2018 and December 2022 at 28 participating pediatric intensive care units (PICUs) in the Pediatric Acute and Critical Care Medicine in Asia Network (PACCMAN) and the Red Colaborativa Peditrica de Latinoamrica (LARed Network) in Asia, Latin America, and Europe. Children (<18 years of age) with moderate to severe TBI (Glasgow Coma Scale score  13) who were admitted to a participating PICU were recruited. The descriptive analysis presents all 4 groups: children receiving neither hyperosmolar agent, those receiving 3% HTS only, those receiving 20% mannitol only, and those receiving both agents.', 'entities': []}
{'filename': 'EMA - Abstract 9_ Hypertonic Saline vs Mannitol Outcomes in Pediatric TBI - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': 'Overall, 445 children were included in the analysis. A total of 344 patients (77.3%) had severe TBI, and 106 (23.8%) underwent ICP monitoring. A total of 184 children (41.3%) received only 3% HTS, 82 (18.4%) received only 20% mannitol, 69 (15.5%) received both agents, and 110 (24.7%) received neither agent. Overall, 200 of 445 patients (44.9%) required neurosurgical intervention. The mortality rate was 7.1% (13 of 184 patients) in the HTS group and 11.0% (9 of 82 patients) in the mannitol group ( P = .34). After adjustment for age, sex, presence of child abuse, time between injury and hospital arrival, lowest Glasgow Coma Scale score in the first 24 hours, and presence of extradural hemorrhage, no between-group differences in mortality, hospital discharge Pediatric Cerebral Performance Category scores, or 3-month GOS-E-Peds scores were observed.', 'entities': []}
{'filename': 'EMA - Abstract 9_ Hypertonic Saline vs Mannitol Outcomes in Pediatric TBI - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': 'In the comparison of all 4 groups (3% HTS only, 20% mannitol only, both agents, and neither agent), children receiving both agents had the highest mortality. In addition, among all groups, the children receiving both agents had the longest durations of intubation, hospitalization, and PICU stay, as well as the highest frequency of poor GOS-E-Peds outcomes.', 'entities': []}
{'filename': 'EMA - Abstract 9_ Hypertonic Saline vs Mannitol Outcomes in Pediatric TBI - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': "Overall, the comparison between 3% HTS and 20% mannitol showed no significant differences in mortality or functional outcomes among children with moderate to severe TBI. This finding challenges the current Brain Trauma Foundation's preference for HTS as the first-line therapy. However, the study's observational design limits causal inference from being drawn, and the lack of ICP monitoring in most patients (only 23.8% received ICP) represents a major departure from guideline-recommended care. The heterogeneity in times between injury and hospital arrival (median 2.4-6.0 hours across groups) reflects differences in prehospital systems and", 'entities': []}
{'filename': 'EMA - Abstract 9_ Hypertonic Saline vs Mannitol Outcomes in Pediatric TBI - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': 'might potentially have confounded the outcomes. Additionally, the inclusion of patients with moderate to severe TBI created a more diverse cohort than examined in most prior studies.', 'entities': []}
{'filename': 'EMA - Abstract 9_ Hypertonic Saline vs Mannitol Outcomes in Pediatric TBI - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'section_header', 'text': 'PMID: 40067302', 'entities': []}
{'filename': 'EMA - Abstract 9_ Hypertonic Saline vs Mannitol Outcomes in Pediatric TBI - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'section_header', 'text': 'FULL ARTICLE: https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2831220', 'entities': []}
{'filename': 'EMA - Abstract 9_ Hypertonic Saline vs Mannitol Outcomes in Pediatric TBI - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': "EDITOR'S COMMENTARY: This prospective multicenter cohort study on pediatric TBI provides valuable insights but has important limitations. The use of 3% HTS vs 20% mannitol showed no significant differences in mortality or functional outcomes among children with moderate to severe TBI. Relevant limitations include the observational study design with high potential for confounding, and the inclusion of patients with moderate to severe brain injury. For practicing physicians, the findings suggest that either agent might be reasonable in resource-limited settings, but neither appears superior. However, larger randomized trials are needed before current practice recommendations should be changed.", 'entities': []}
{'filename': 'EMA - Abstract 9_ Hypertonic Saline vs Mannitol Outcomes in Pediatric TBI - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'section_header', 'text': 'RELATED CONTENT:', 'entities': []}
{'filename': 'EMA - Abstract 9_ Hypertonic Saline vs Mannitol Outcomes in Pediatric TBI - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'section_header', 'text': 'EM:RAP 2022 October: Critical Care Mailbag: Neurocritical Care Intubation', 'entities': []}
{'filename': 'EMA - Abstract 9_ Hypertonic Saline vs Mannitol Outcomes in Pediatric TBI - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': 'CorePendium : Pediatric Head Trauma (major and minor)', 'entities': []}
{'filename': 'EMA - Abstract 9_ Hypertonic Saline vs Mannitol Outcomes in Pediatric TBI - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': 'Copyright 2025 by Emergency Medical Abstracts - All Rights Reserved 06/25 - #09', 'entities': []}
{'filename': 'EMA - Abstract 9_ Hypertonic Saline vs Mannitol Outcomes in Pediatric TBI - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': 'Tags: Head Injury pediatric resuscitation Pharmacology', 'entities': []}
{'filename': 'EMA - Abstract 9_ Hypertonic Saline vs Mannitol Outcomes in Pediatric TBI - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'section_header', 'text': 'CorePendium Chapters', 'entities': []}
{'filename': 'EMA - Abstract 9_ Hypertonic Saline vs Mannitol Outcomes in Pediatric TBI - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': 'Pediatric Head Trauma (major and minor)', 'entities': []}
{'filename': 'EMA - Abstract 20_ Short-Stay Hospitalizations and Hospital Capacity Constraints - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': 'Short-stay hospitalizations and hospital capacity constraints Janke AT, Sun WW, Gibson C, et al. Ann Emerg Med. Published online April 11, 2025. doi:10.1016/j.annemergmed.2025.03.012', 'entities': []}
{'filename': 'EMA - Abstract 20_ Short-Stay Hospitalizations and Hospital Capacity Constraints - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'section_header', 'text': 'SUMMARY:', 'entities': []}
{'filename': 'EMA - Abstract 20_ Short-Stay Hospitalizations and Hospital Capacity Constraints - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': 'Hospital EDs are severely overcrowded, because hospitals are full of inpatients. Many inpatients come from the ED. Approximately one-third of ED admissions are short stays, lasting <48 hours. The fraction of admissions that are short stays markedly varies at the hospital and physician levels. Short-stay hospitalizations have long been an improvement target and are often assumed to be unnecessary. Consequently, to encourage fewer short stays in favor of outpatient treatment, hospitals are paid less for short stays, and this metric is frequently reported at the physician level.', 'entities': []}
{'filename': 'EMA - Abstract 20_ Short-Stay Hospitalizations and Hospital Capacity Constraints - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': 'A related assumption is that if the ED could stop admitting all unnecessary short-stay admissions, hospitals would not be full, you could admit the patients who need to be admitted, and the ED would not be crowded. Essentially, the ED is assumed to be crowded because physicians unnecessarily fill up the hospital, and therefore to be responsible for fixing this problem by decreasing the large burden of short-stay admissions.', 'entities': []}
{'filename': 'EMA - Abstract 20_ Short-Stay Hospitalizations and Hospital Capacity Constraints - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': 'The authors of this study sought to determine how many inpatient hours are actually consumed by short-stay admissions, identify temporal trends in short-stay admissions, and correlate those temporal trends with crowding measures.', 'entities': []}
{'filename': 'EMA - Abstract 20_ Short-Stay Hospitalizations and Hospital Capacity Constraints - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': 'This retrospective observational analysis included 4 independent and geographically academic EDs. The total number of inpatient hours at each hospital was calculated for patients admitted through the ED. This measure started when the decision to admit was made and ended when the patient was ultimately discharged from the hospital. Short stays were defined as hospitalizations lasting <48 hours.', 'entities': []}
{'filename': 'EMA - Abstract 20_ Short-Stay Hospitalizations and Hospital Capacity Constraints - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': 'During this 6-year, 4-site study, 2,147,255 ED visits and 625,000 admissions (29%) occurred, and 33.6% of the admissions were short stays. Although this percentage might seem high, short-stay admissions accounted for only 7.6% of the >85 million total inpatient occupancy hours that came through the ED. Therefore, dramatically lowering short stays from 33% to 20% would decrease the total number of inpatient hours used by patients admitted through the ED by only approximately 2%.', 'entities': []}
{'filename': 'EMA - Abstract 20_ Short-Stay Hospitalizations and Hospital Capacity Constraints - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': 'Furthermore, during the study period, short-stay admissions decreased by approximately 1% annually, but ED boarding increased during that timeframe. This finding markedly contradicts the idea that these admissions drive crowding.', 'entities': []}
{'filename': 'EMA - Abstract 20_ Short-Stay Hospitalizations and Hospital Capacity Constraints - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': 'The main estimates in fact overstate the findings, because the paltry 7.6% of admission hours reflected only the admissions coming through the ED. Other admissions occurring through scheduled surgery, direct admissions, or transfer would clearly increase the denominator of total inpatient hours, thus making the actual contribution of ED short stays to overall hospital admission hours even smaller. The study has multiple limitations, most importantly that it is not likely to reflect the full picture of emergency medicine in the U.S. Nonetheless, the results seem telling and are likely to be true in most facilities. Short-stay admissions are not a major issue,', 'entities': []}
{'filename': 'EMA - Abstract 20_ Short-Stay Hospitalizations and Hospital Capacity Constraints - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': 'and efforts to markedly limit them might be useful from quality or patient-centered perspectives, but would probably have very limited effects on ED boarding or other measures of throughput.', 'entities': []}
{'filename': 'EMA - Abstract 20_ Short-Stay Hospitalizations and Hospital Capacity Constraints - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'section_header', 'text': 'PMID: 40220007', 'entities': []}
{'filename': 'EMA - Abstract 20_ Short-Stay Hospitalizations and Hospital Capacity Constraints - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': "EDITOR'S COMMENTARY: Although short-stay hospitalizations reflect a relatively large fraction of overall admissions to the hospital from the ED (33%), they contribute only 7% of the total hospital admission hours. The number of short-stay admissions declined through the study period, yet measures of boarding time increased. Together, the findings suggest that efforts to substantially decrease short-stay admissions are unlikely to meaningfully influence throughput measures.", 'entities': []}
{'filename': 'EMA - Abstract 20_ Short-Stay Hospitalizations and Hospital Capacity Constraints - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': 'Copyright 2025 by Emergency Medical Abstracts - All Rights Reserved 07/25 - #20', 'entities': []}
{'filename': 'EMA - Abstract 12_ REBOA in Surgical and Trauma Patients - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'section_header', 'text': 'from the Eastern Association for the Surgery of Trauma Harfouche MN, Bugaev N, Como JJ, et al. Trauma Surg acute care open. 2025;10(1):e001730.', 'entities': []}
{'filename': 'EMA - Abstract 12_ REBOA in Surgical and Trauma Patients - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'section_header', 'text': 'SUMMARY:', 'entities': []}
{'filename': 'EMA - Abstract 12_ REBOA in Surgical and Trauma Patients - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': 'This is a great article for anyone at all interested in resuscitative endovascular balloon occlusion of the aorta (REBOA).', 'entities': []}
{'filename': 'EMA - Abstract 12_ REBOA in Surgical and Trauma Patients - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': 'The authors asked 6 clinical questions related to REBOA use for various indications, then conducted a systematic review; combined the data to form a meta-analysis, when appropriate; and synthesized the findings to provide practice-management guidelines reflecting the current position of the Eastern Association for the Surgery of Trauma (EAST).', 'entities': []}
{'filename': 'EMA - Abstract 12_ REBOA in Surgical and Trauma Patients - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': 'The first 4 questions pertained to REBOA use in traumatic subdiaphragmatic bleeding-the indications that initially drove interest in REBOA in the ED setting. The differences in the questions related to bleeding location and patient stability. Two additional questions related to REBOA use for (1) nontraumatic bleeding and (2) prophylaxis for placenta accreta in cesarean delivery.', 'entities': []}
{'filename': 'EMA - Abstract 12_ REBOA in Surgical and Trauma Patients - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': 'In short, the authors do not recommend REBOA in any circumstance, on the basis of their review of the literature.', 'entities': []}
{'filename': 'EMA - Abstract 12_ REBOA in Surgical and Trauma Patients - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': 'For hemodynamically unstable patients who are not in arrest or imminent periarrest, the authors are firmly opposed to REBOA, citing elevated mortality, according to the U.K. REBOA trial and other observational data.', 'entities': []}
{'filename': 'EMA - Abstract 12_ REBOA in Surgical and Trauma Patients - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': 'For patients in arrest or periarrest, in whom the only option is REBOA or thoracotomy, the authors conclude that the evidence is of extremely low quality and hopelessly confounded. Therefore, they do not make a recommendation.', 'entities': []}
{'filename': 'EMA - Abstract 12_ REBOA in Surgical and Trauma Patients - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': 'For those other 2 categories, the authors conclude that the data are limited. They therefore do not make a recommendation.', 'entities': []}
{'filename': 'EMA - Abstract 12_ REBOA in Surgical and Trauma Patients - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': 'After a decade of debate regarding REBOA, the EAST writing group did not find any indication for which they would recommend REBOA. In fact, they recommend against it in hemodynamically unstable patients with subdiaphragmatic hemorrhage-the population associated with the original enthusiasm.', 'entities': []}
{'filename': 'EMA - Abstract 12_ REBOA in Surgical and Trauma Patients - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': 'The article itself is very well written and provides excellent summaries of the underlying data. Anyone very interested, or medical students or residents giving lectures, should read this article.', 'entities': []}
{'filename': 'EMA - Abstract 12_ REBOA in Surgical and Trauma Patients - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'section_header', 'text': 'PMID: 40166770', 'entities': []}
{'filename': 'EMA - Abstract 12_ REBOA in Surgical and Trauma Patients - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'section_header', 'text': 'FULL ARTICLE: https://tsaco.bmj.com/content/10/1/e001730', 'entities': []}
{'filename': 'EMA - Abstract 12_ REBOA in Surgical and Trauma Patients - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': "EDITOR'S COMMENTARY: In this impressive comprehensive analysis of potential indications for REBOA from the EAST writing group, the authors concluded that they cannot recommend REBOA for any of the 6 evaluated clinical scenarios. Moreover, for the most pressing clinical conditions-unstable patients with life-threatening hemorrhage who are not in cardiac arrest-the authors conclude that REBOA is not recommended.", 'entities': []}
{'filename': 'EMA - Abstract 12_ REBOA in Surgical and Trauma Patients - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'section_header', 'text': 'RELATED CONTENT:', 'entities': []}
{'filename': 'EMA - Abstract 12_ REBOA in Surgical and Trauma Patients - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': 'EM:RAP Breaking News 2023 August: The UK REBOA Trial', 'entities': []}
{'filename': 'EMA - Abstract 12_ REBOA in Surgical and Trauma Patients - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': 'CorePendium : REBOA', 'entities': []}
{'filename': 'EMA - Abstract 12_ REBOA in Surgical and Trauma Patients - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': 'CorePendium : Multisystem Trauma', 'entities': []}
{'filename': 'EMA - Abstract 12_ REBOA in Surgical and Trauma Patients - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': 'Copyright 2025 by Emergency Medical Abstracts - All Rights Reserved 07/25 - #12', 'entities': []}
{'filename': 'EMA - Abstract 12_ REBOA in Surgical and Trauma Patients - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': 'Tag:', 'entities': []}
{'filename': 'EMA - Abstract 12_ REBOA in Surgical and Trauma Patients - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': 'REBOA', 'entities': []}
{'filename': 'EMA - Abstract 12_ REBOA in Surgical and Trauma Patients - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'section_header', 'text': 'CorePendium Chapters', 'entities': []}
{'filename': 'EMA - Abstract 12_ REBOA in Surgical and Trauma Patients - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': 'REBOA', 'entities': []}
{'filename': 'EMA - Abstract 12_ REBOA in Surgical and Trauma Patients - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': 'Multisystem Trauma', 'entities': []}
{'filename': 'EMA - Abstract 6_ Epinephrine vs Norepinephrine for Pediatric Septic Shock - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': 'Epinephrine vs norepinephrine as initial treatment in children with septic shock Eisenberg MA, Georgette N, Baker AH, et al. JAMA Netw Open. 2025;8(4):e254720.', 'entities': []}
{'filename': 'EMA - Abstract 6_ Epinephrine vs Norepinephrine for Pediatric Septic Shock - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'section_header', 'text': 'SUMMARY:', 'entities': []}
{'filename': 'EMA - Abstract 6_ Epinephrine vs Norepinephrine for Pediatric Septic Shock - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': "The Surviving Sepsis guidelines recommend norepinephrine rather than epinephrine for firstline treatment of fluid-refractory septic shock in adults, because epinephrine's beta-adrenergic activity can induce severe tachycardia. However, no such recommendation exists for children. In fact, these agents have not undergone a head-to-head comparison in a pediatric population.", 'entities': []}
{'filename': 'EMA - Abstract 6_ Epinephrine vs Norepinephrine for Pediatric Septic Shock - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': "This single-site retrospective cohort study examined children with confirmed septic shock. Participants were included if they developed septic shock within 24 hours of ED presentation. Septic shock was determined by review of physicians' notes in the electronic health records. Participants were excluded if they had been in cardiac arrest, had known cardiac dysfunction, had anaphylaxis, or had a documented reason other than septic shock for vasopressor administration. The reliability of the physicians' notes explaining the reason for vasopressor use was not described.", 'entities': []}
{'filename': 'EMA - Abstract 6_ Epinephrine vs Norepinephrine for Pediatric Septic Shock - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': 'The key exposure variable was the initially administered vasopressor (norepinephrine or epinephrine).', 'entities': []}
{'filename': 'EMA - Abstract 6_ Epinephrine vs Norepinephrine for Pediatric Septic Shock - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': 'The primary outcome of interest was major adverse kidney events by 30 days. The secondary outcomes included 3-day and 30-day mortality, and a variety of ICU measures (including ventilator-free days).', 'entities': []}
{'filename': 'EMA - Abstract 6_ Epinephrine vs Norepinephrine for Pediatric Septic Shock - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': 'The study also used propensity score analysis to account for observable variables.', 'entities': []}
{'filename': 'EMA - Abstract 6_ Epinephrine vs Norepinephrine for Pediatric Septic Shock - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': 'Over the 6-year study period, 231 identified participants met the criteria: 63% receiving epinephrine and 36% receiving norepinephrine as the initial agent. The median age was 10 years. Most children (60%) had a predisposing condition for sepsis, usually malignant neoplasm.', 'entities': []}
{'filename': 'EMA - Abstract 6_ Epinephrine vs Norepinephrine for Pediatric Septic Shock - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': 'Very few outcomes were found: major adverse kidney events by 30 days occurred in 6% of the epinephrine group and 4% of the norepinephrine group (difference not statistically significant). Death occurred in 4% of the epinephrine group vs 0% of the norepinephrine group-a difference of marginal statistical significance. Other outcomes were similar and indicated a slight benefit of marginal or unclear significance in the norepinephrine group.', 'entities': []}
{'filename': 'EMA - Abstract 6_ Epinephrine vs Norepinephrine for Pediatric Septic Shock - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': 'We have every reason to believe that the children receiving epinephrine first were more likely to be more ill or undifferentiated, or to have a history of cardiac disease than those receiving norepinephrine. Consequently, that the norepinephrine group fared better is unsurprising. In terms of generalizability, the participants had very low risk of death, so we cannot be sure that the findings reflect pediatric sepsis patients in general.', 'entities': []}
{'filename': 'EMA - Abstract 6_ Epinephrine vs Norepinephrine for Pediatric Septic Shock - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': 'The authors are properly tepid in their conclusion that norepinephrine might have benefits. The findings would need to be validated in other studies before a serious guideline recommendation could be made.', 'entities': []}
{'filename': 'EMA - Abstract 6_ Epinephrine vs Norepinephrine for Pediatric Septic Shock - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'section_header', 'text': 'PMID: 40214988', 'entities': []}
{'filename': 'EMA - Abstract 6_ Epinephrine vs Norepinephrine for Pediatric Septic Shock - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': 'FULL ARTICLE: https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2832544', 'entities': []}
{'filename': 'EMA - Abstract 6_ Epinephrine vs Norepinephrine for Pediatric Septic Shock - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': "EDITOR'S COMMENTARY: This single-center retrospective cohort study from a children's hospital indicated that use of norepinephrine (rather than epinephrine) as the first-line vasopressor was associated with outcome improvements in patients with septic shock. However, study limitations render this finding interesting and worthy of further study but do not suggest that providers need to change practice at this time.", 'entities': []}
{'filename': 'EMA - Abstract 6_ Epinephrine vs Norepinephrine for Pediatric Septic Shock - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'section_header', 'text': 'RELATED CONTENT:', 'entities': []}
{'filename': 'EMA - Abstract 6_ Epinephrine vs Norepinephrine for Pediatric Septic Shock - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'section_header', 'text': 'CorePendium : Pediatric Fever and Serious Bacterial Infections', 'entities': []}
{'filename': 'EMA - Abstract 6_ Epinephrine vs Norepinephrine for Pediatric Septic Shock - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'section_header', 'text': 'CorePendium : Sepsis', 'entities': []}
{'filename': 'EMA - Abstract 6_ Epinephrine vs Norepinephrine for Pediatric Septic Shock - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': 'Copyright 2025 by Emergency Medical Abstracts - All Rights Reserved 07/25 - #06', 'entities': []}
{'filename': 'EMA - Abstract 6_ Epinephrine vs Norepinephrine for Pediatric Septic Shock - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': 'Tags: pediatric resuscitation Shock', 'entities': []}
{'filename': 'EMA - Abstract 6_ Epinephrine vs Norepinephrine for Pediatric Septic Shock - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'section_header', 'text': 'CorePendium Chapters', 'entities': []}
{'filename': 'EMA - Abstract 6_ Epinephrine vs Norepinephrine for Pediatric Septic Shock - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': 'Pediatric Fever and Serious Bacterial Infections', 'entities': []}
{'filename': 'EMA - Abstract 6_ Epinephrine vs Norepinephrine for Pediatric Septic Shock - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': 'Sepsis', 'entities': []}
{'filename': 'EMA - Abstract 2_ Alteplase for Posterior Circulation Ischemic Stroke at 4.5-24h - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': 'Alteplase for posterior circulation ischemic stroke at 4.5 to 24 hours Yan S, Zhou Y, Lansberg MG, et al. N Engl J Med. 2025;392(13):1288-1296.', 'entities': []}
{'filename': 'EMA - Abstract 2_ Alteplase for Posterior Circulation Ischemic Stroke at 4.5-24h - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'section_header', 'text': 'SUMMARY:', 'entities': []}
{'filename': 'EMA - Abstract 2_ Alteplase for Posterior Circulation Ischemic Stroke at 4.5-24h - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': "This stroke article is yet another whose stated goal was to extend the IV thrombolysis window in a subset of patients with stroke. Depending on one's perspective, the results will seem either encouraging or an absolute nightmare. IV thrombolysis is indicated for strokes <4.5 hours in duration.", 'entities': []}
{'filename': 'EMA - Abstract 2_ Alteplase for Posterior Circulation Ischemic Stroke at 4.5-24h - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': "IV tissue plasminogen activator (TPA) may be indicated in some patients with stroke who are beyond the 4.5-hour window. Typically, administration is guided by MRI findings or CT perfusion findings in patients otherwise not undergoing endovascular therapy (EVT). Using TPA in such patients typically occurs only in comprehensive stroke centers using 'wake-up stroke' protocols and is directed entirely by stroke neurologists.", 'entities': []}
{'filename': 'EMA - Abstract 2_ Alteplase for Posterior Circulation Ischemic Stroke at 4.5-24h - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': 'The authors attempted to extend the thrombolysis window in a subset of patients with stroke who (1) had posterior circulation stroke, (2) had no requirement for perfusion mismatches or MRI findings indicating very early stroke, and (3) were otherwise not EVT candidates.', 'entities': []}
{'filename': 'EMA - Abstract 2_ Alteplase for Posterior Circulation Ischemic Stroke at 4.5-24h - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': 'This open-label RCT of IV TPA vs standard of care (no placebo) was conducted at 30 Chinese stroke centers from 2022 to 2024. Participants had stroke (NIH Stroke Scale score  1) between 4.5 and 24 hours, and essentially normal head CT findings (with minimal signs of ischemia). MRI or CT angiography was not strictly necessary to indicate stroke occurrence.', 'entities': []}
{'filename': 'EMA - Abstract 2_ Alteplase for Posterior Circulation Ischemic Stroke at 4.5-24h - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': 'A total of 234 patients, who were not very ill, were randomized. The mean age was 65 years, and the median NIH Stroke Scale score was only 3. Most patients had a last known well time >9 hours prior. The groups were fairly well balanced between treatment arms.', 'entities': []}
{'filename': 'EMA - Abstract 2_ Alteplase for Posterior Circulation Ischemic Stroke at 4.5-24h - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': 'The primary outcome of a modified Rankin Scale score  2 at 90 days occurred in 89.6% of the TPA group and 72.6% of the standard-care group (OR, 1.16 [CI 1.03-1.30]; NNT = 7). A score of 0/1 occurred in 74% of the TPA group and 61% of the standard-care group.', 'entities': []}
{'filename': 'EMA - Abstract 2_ Alteplase for Posterior Circulation Ischemic Stroke at 4.5-24h - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': 'Intracranial hemorrhage occurred in 9.5% of the TPA group vs 4.3% of the standard-care group.', 'entities': []}
{'filename': 'EMA - Abstract 2_ Alteplase for Posterior Circulation Ischemic Stroke at 4.5-24h - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': 'The results generally showed modest beneficial treatment effects across a large range of patient subsets, including those with stroke confirmed by MRI and those receiving only plain CT imaging before randomization. The treatment effect was not much larger for the group with confirmed LVO (OR, 1.51) and was scarcely observed for those without confirmed LVO (OR, 1.05).', 'entities': []}
{'filename': 'EMA - Abstract 2_ Alteplase for Posterior Circulation Ischemic Stroke at 4.5-24h - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': 'How do we synthesize the findings? First, we note the limitations: this was an open-label study, a design that usually biases findings toward the intervention for a variety of reasons, including possible crossover. Second, most patients received an MRI before enrollment, although MRI was not required; therefore, the findings do not necessarily reflect practice at most hospitals. In addition, the treatment effect was concentrated in patients with LVO. Most stroke centers would try to perform thrombectomy in these patients, if at all possible. Why thrombectomy was not undertaken in these cases is unclear. The strokes were quite small, thus affecting the generalizability of the findings, yet elevated bleeding risk was observed.', 'entities': []}
{'filename': 'EMA - Abstract 2_ Alteplase for Posterior Circulation Ischemic Stroke at 4.5-24h - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': 'Ultimately, this study is not a game changer, because it is too small and has too many limitations to both internal and external validity. However, it does complicate considerations regarding the treatment of patients with stroke symptoms between 4.5 and 24 hours in duration. Given the', 'entities': []}
{'filename': 'EMA - Abstract 2_ Alteplase for Posterior Circulation Ischemic Stroke at 4.5-24h - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': 'conflicting and ambiguous data, along with the challenges in diagnosing posterior stroke and the high risk, ED physicians must follow their hospital protocols. Therefore, physicians should probably call the stroke code if they believe that the symptoms are related to stroke rather than a stroke mimic, include stroke neurologists, order according to the protocol, and force them to be responsible for determining whether the patient is within 1 of the small groups that might benefit from extended-window TPA or EVT.', 'entities': []}
{'filename': 'EMA - Abstract 2_ Alteplase for Posterior Circulation Ischemic Stroke at 4.5-24h - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'section_header', 'text': 'PMID: 40174223', 'entities': []}
{'filename': 'EMA - Abstract 2_ Alteplase for Posterior Circulation Ischemic Stroke at 4.5-24h - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': "EDITOR'S COMMENTARY: This study is yet another showing a small benefit of IV TPA in the subset of patients who had posterior circulation stroke between 4.5 and 24 hours from the last known well time and did not undergo EVT. The strokes were small, and the study was small and open-label, occurred in China, and generally indicated that the benefit of TPA was concentrated in patients with LVO who would be likely EVT candidates. Furthermore, the TPA group did have elevated risk of intracranial hemorrhage. Altogether, the results weakly support using TPA in this population, which is likely to reflect only a tiny subset of all patients with stroke. Still, the findings highlight the increasingly complex landscape of acute stroke management and, for me, suggest that this nuance exceeds ED MDs' ability to comfortably manage care without emergent stroke neurology guidance.", 'entities': []}
{'filename': 'EMA - Abstract 2_ Alteplase for Posterior Circulation Ischemic Stroke at 4.5-24h - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'section_header', 'text': 'RELATED CONTENT:', 'entities': []}
{'filename': 'EMA - Abstract 2_ Alteplase for Posterior Circulation Ischemic Stroke at 4.5-24h - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': 'EM:RAP 2022 February: Posterior Stroke', 'entities': []}
{'filename': 'EMA - Abstract 2_ Alteplase for Posterior Circulation Ischemic Stroke at 4.5-24h - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'section_header', 'text': 'CorePendium : Acute Ischemic Stroke', 'entities': []}
{'filename': 'EMA - Abstract 2_ Alteplase for Posterior Circulation Ischemic Stroke at 4.5-24h - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': 'Copyright 2025 by Emergency Medical Abstracts - All Rights Reserved 07/25 - #02', 'entities': []}
{'filename': 'EMA - Abstract 2_ Alteplase for Posterior Circulation Ischemic Stroke at 4.5-24h - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': 'Tags: Ischemic Stroke', 'entities': []}
{'filename': 'EMA - Abstract 2_ Alteplase for Posterior Circulation Ischemic Stroke at 4.5-24h - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': 'Pharmacology', 'entities': []}
{'filename': 'EMA - Abstract 2_ Alteplase for Posterior Circulation Ischemic Stroke at 4.5-24h - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'section_header', 'text': 'CorePendium Chapters', 'entities': []}
{'filename': 'EMA - Abstract 2_ Alteplase for Posterior Circulation Ischemic Stroke at 4.5-24h - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': 'Acute Ischemic Stroke', 'entities': []}
{'filename': 'EMA - Abstract 13_ Nebulized Glucocorticoids for Acute Pharyngitis in the ED - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': 'Efficacy of nebulized glucocorticoids for acute pharyngitis in an emergency department outpatient population: a multicenter, double-blind, randomized clinical trial Al Atbi AY, Al Khalasi U, Al Atbi A, et al. CJEM. Published online April 24, 2025. doi:10.1007/s43678-025-00906-5', 'entities': []}
{'filename': 'EMA - Abstract 13_ Nebulized Glucocorticoids for Acute Pharyngitis in the ED - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'section_header', 'text': 'SUMMARY:', 'entities': []}
{'filename': 'EMA - Abstract 13_ Nebulized Glucocorticoids for Acute Pharyngitis in the ED - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': 'For patients with acute pharyngitis, multiple studies and a Cochrane review have indicated that glucocorticoids moderately improve pain relief and symptom resolution when administered via oral, IM, or IV routes. Although nebulized glucocorticoids are used to manage other inflammatory airway conditions, such as croup and asthma, they had not been evaluated for pharyngitis pain relief.', 'entities': []}
{'filename': 'EMA - Abstract 13_ Nebulized Glucocorticoids for Acute Pharyngitis in the ED - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': 'This multicenter, double-blind, randomized clinical trial involved 3 EDs in Oman. The study enrolled patients older than 5 years with a clinical diagnosis of acute pharyngitis with a sore throat, and excluded patients with recent steroid or antibiotic use, or with a history of adenotonsillectomy. The dexamethasone group received 2 mL dexamethasone (4 mg/mL) mixed with 3 mL normal saline; the budesonide group received 2 mL budesonide (500 mcg/mL) mixed with 3 mL normal saline; and the placebo group received 5 mL normal saline.', 'entities': []}
{'filename': 'EMA - Abstract 13_ Nebulized Glucocorticoids for Acute Pharyngitis in the ED - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': 'The study enrolled and randomized 200 patients, but the primary outcome of complete resolution of symptoms at 24 hours could not be assessed in 37 patients lost to follow-up. Although the primary outcome was observed in more patients in the steroid groups (20% and 17%) than the placebo group (9%), this difference was not statistically significant. No clinically or statistically significant differences were found in any secondary outcomes, including time to pain relief, pain scores at 48 hours, ED reattendance, hospital admissions, or school absenteeism.', 'entities': []}
{'filename': 'EMA - Abstract 13_ Nebulized Glucocorticoids for Acute Pharyngitis in the ED - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': 'Generally, this quite well-done study made excellent efforts to maintain blinding. However, the study is limited by the high rate of loss to follow-up rate; potential underpowering; baseline differences among groups, particularly in age; and potential for confounding, given that almost all patients used over-the-counter analgesia (approximately 95% across arms) in a nonprotocolized manner.', 'entities': []}
{'filename': 'EMA - Abstract 13_ Nebulized Glucocorticoids for Acute Pharyngitis in the ED - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': 'In a larger sample, nebulized steroids might possibly have value over placebo, but no data indicate how the nebulized route might compare to the oral, IM, or IV routes, which are much easier to administer and operationalize in a busy ED setting.', 'entities': []}
{'filename': 'EMA - Abstract 13_ Nebulized Glucocorticoids for Acute Pharyngitis in the ED - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'section_header', 'text': 'PMID:', 'entities': []}
{'filename': 'EMA - Abstract 13_ Nebulized Glucocorticoids for Acute Pharyngitis in the ED - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': '40272745', 'entities': []}
{'filename': 'EMA - Abstract 13_ Nebulized Glucocorticoids for Acute Pharyngitis in the ED - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': "EDITOR'S COMMENTARY: In this multicenter, randomized trial from Oman evaluating the use of nebulized glucocorticoids among kids with acute pharyngitis, no clinically or statistically significant improvements were found in a variety of outcomes, including pain. This treatment might possibly work in a larger sample, but given that standard supportive care remains equally effective for overall symptom resolution, the added cost and time of nebulized therapy in busy EDs appears unjustified according to these findings.", 'entities': []}
{'filename': 'EMA - Abstract 13_ Nebulized Glucocorticoids for Acute Pharyngitis in the ED - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'section_header', 'text': 'RELATED CONTENT:', 'entities': []}
{'filename': 'EMA - Abstract 13_ Nebulized Glucocorticoids for Acute Pharyngitis in the ED - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'section_header', 'text': 'CorePendium : Pharyngitis', 'entities': []}
{'filename': 'EMA - Abstract 13_ Nebulized Glucocorticoids for Acute Pharyngitis in the ED - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': 'Copyright 2025 by Emergency Medical Abstracts - All Rights Reserved 07/25 - #13', 'entities': []}
{'filename': 'EMA - Abstract 13_ Nebulized Glucocorticoids for Acute Pharyngitis in the ED - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': 'Tags:', 'entities': []}
{'filename': 'EMA - Abstract 13_ Nebulized Glucocorticoids for Acute Pharyngitis in the ED - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'code', 'text': 'Infection Pharmacology', 'entities': []}
{'filename': 'EMA - Abstract 13_ Nebulized Glucocorticoids for Acute Pharyngitis in the ED - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'section_header', 'text': 'CorePendium Chapters', 'entities': []}
{'filename': 'EMA - Abstract 13_ Nebulized Glucocorticoids for Acute Pharyngitis in the ED - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': 'Pharyngitis', 'entities': []}
{'filename': 'EMA - Abstract 11_ Pharmacologic Therapies for Migraine in the ED - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': 'Effectiveness and safety of pharmacologic therapies for migraine in the emergency department: a systematic review and Bayesian network meta-analysis deSouza IS, Anthony N, Thode H, et al. Ann Emerg Med. 2025;85(4):313-329.', 'entities': []}
{'filename': 'EMA - Abstract 11_ Pharmacologic Therapies for Migraine in the ED - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'section_header', 'text': 'SUMMARY:', 'entities': []}
{'filename': 'EMA - Abstract 11_ Pharmacologic Therapies for Migraine in the ED - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': "Many classes of medications, including analgesics, triptans, antiemetics, and antiepileptics, have been studied and are commonly used for migraine headache treatment. Some providers have developed their own 'migraine cocktails' consisting of the fluids and medications that they believe to be most helpful. This practice has led to use of 'headache cocktails' for patients with all types of headaches. Although many individual articles and meta-analyses have compared single or combination agents with placebo, few have scientifically compared the agents.", 'entities': []}
{'filename': 'EMA - Abstract 11_ Pharmacologic Therapies for Migraine in the ED - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': "This network meta-analysis (NMA) was conducted to determine which individual pharmacologic therapies used to achieve rapid pain relief in adult patients presenting to the ED with migraine are most effective and safe. An NMA can calculate comparative effects of more than 2 competing interventions, even in the absence of head-to-head comparison in clinical trials. The authors used the best practices for this type of work, including the 'PICO' framework to determine study eligibility for inclusion, collection of data via a structured form by 3 authors, assessment of risk of bias in the included studies, and a rigorous statistical plan. The outcomes were (1) adequate pain relief at 2 hours, (2) change in pain intensity at 1 hour, (3) need for rescue drug administration at 2 hours, and (4) significant adverse reactions. After exclusions, 64 trials were included in the analysis.", 'entities': []}
{'filename': 'EMA - Abstract 11_ Pharmacologic Therapies for Migraine in the ED - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': 'Substantial amounts of data are presented, but the highlights (or lowlights) included that 4 agents were associated with adequate pain relief at 2 hours, including chlorpromazine (Thorazine) IV/IM, which was most likely to be superior (OR, 9.79; 95%CrI, 3.42-24.42) as well as prochlorperazine (Compazine) IV/IM (OR, 8.10; 95%CrI, 2.91-22.44), propofol (OR, 5.77; 95%CrI, 1.45-24.04), and metoclopramide IV/IM (OR, 3.91; 95%CrI, 1.93-8.11). The authors were unable to assess the best agent in terms of change in pain intensity at 1 hour in the network. Nine combinations and single agents were associated with relatively less need for rescue agents, and metoclopramide IV combined with ibuprofen IV was the slight overall winner. In comparison with placebo, 2 drugs were associated with greater likelihood of significant adverse reactions: propofol (OR, 11.11; 95%CrI, 1.25-100.00) and chlorpromazine IV (OR, 4.17; 95%CrI, 1.64-12.50).', 'entities': []}
{'filename': 'EMA - Abstract 11_ Pharmacologic Therapies for Migraine in the ED - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': "The methods and statistical approach in this article are truly stellar and represent gold-standardquality work for this study design. However, the strength of the findings is limited by significant heterogeneity in the individual included studies in terms of outcome assessment; doses administered; routes of administration; concomitant therapies (eg, IV fluids); and reporting of adverse events and criteria for enrollment. Despite the authors' excellent work, the certainty of the findings is too low to markedly change practice.", 'entities': []}
{'filename': 'EMA - Abstract 11_ Pharmacologic Therapies for Migraine in the ED - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'section_header', 'text': 'PMID: 39674934', 'entities': []}
{'filename': 'EMA - Abstract 11_ Pharmacologic Therapies for Migraine in the ED - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': 'EDITOR\'S COMMENTARY: This study was aimed at determining which agents should go into your migraine cocktail. Despite the super high quality of this network meta-analysis, the findings were blah, because of "low" or "very low" certainty of evidence, and significant clinical heterogeneity in the', 'entities': []}
{'filename': 'EMA - Abstract 11_ Pharmacologic Therapies for Migraine in the ED - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': "included studies in terms of diagnostic criteria, pain assessment methods, and drug regimens. Chlorpromazine might have worked best but also had the most adverse effects, and ketorolac was among the least effective. On a personal note, I don't love the idea of a headache or migraine cocktail in general, because I prefer individualized symptom-based treatment over a one-size-fits-all approach, particularly if your cocktail is the medication equivalent of a Long Island iced tea.", 'entities': []}
{'filename': 'EMA - Abstract 11_ Pharmacologic Therapies for Migraine in the ED - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'section_header', 'text': 'RELATED CONTENT:', 'entities': []}
{'filename': 'EMA - Abstract 11_ Pharmacologic Therapies for Migraine in the ED - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'section_header', 'text': 'EM:RAP 2025 June: Neurocritical Care Mailbag: Migraine Management', 'entities': []}
{'filename': 'EMA - Abstract 11_ Pharmacologic Therapies for Migraine in the ED - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'section_header', 'text': 'CorePendium : Primary Headache', 'entities': []}
{'filename': 'EMA - Abstract 11_ Pharmacologic Therapies for Migraine in the ED - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': 'Copyright 2025 by Emergency Medical Abstracts - All Rights Reserved 07/25 - #11', 'entities': []}
{'filename': 'EMA - Abstract 11_ Pharmacologic Therapies for Migraine in the ED - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': 'Tags:', 'entities': []}
{'filename': 'EMA - Abstract 11_ Pharmacologic Therapies for Migraine in the ED - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': 'Headache', 'entities': []}
{'filename': 'EMA - Abstract 11_ Pharmacologic Therapies for Migraine in the ED - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': 'Pharmacology', 'entities': []}
{'filename': 'EMA - Abstract 11_ Pharmacologic Therapies for Migraine in the ED - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'section_header', 'text': 'CorePendium Chapters', 'entities': []}
{'filename': 'EMA - Abstract 11_ Pharmacologic Therapies for Migraine in the ED - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': 'Primary Headache', 'entities': []}
{'filename': 'EMA - Abstract 18_ Patient Attitudes on IV Fluids for Common Cold in ED - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': "Patients' attitude and information-seeking behaviour on intra-venous fluid therapy in emergency department for common cold: a cross-sectional study Malekian A, Mudgal SK, Kalal N, et al. Int J Emerg Med. 2025;18(1):59.", 'entities': []}
{'filename': 'EMA - Abstract 18_ Patient Attitudes on IV Fluids for Common Cold in ED - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'section_header', 'text': 'SUMMARY:', 'entities': []}
{'filename': 'EMA - Abstract 18_ Patient Attitudes on IV Fluids for Common Cold in ED - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': "This very limited study has a somewhat important message. The study examined patients' attitudes regarding the utility of intravenous fluids for conditions other than dehydration, specifically the common cold and associated symptoms.", 'entities': []}
{'filename': 'EMA - Abstract 18_ Patient Attitudes on IV Fluids for Common Cold in ED - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': "This cross-sectional survey included adult patients at a single ED in Iran who were diagnosed with a 'common cold.'", 'entities': []}
{'filename': 'EMA - Abstract 18_ Patient Attitudes on IV Fluids for Common Cold in ED - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': 'Over a 4-month study period in 2024, the authors obtained 365 responses (out of 381 attempts)', 'entities': []}
{'filename': 'EMA - Abstract 18_ Patient Attitudes on IV Fluids for Common Cold in ED - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': 'The mean patient age was 39 years, 50% were men, and two-thirds had at least a high school diploma.', 'entities': []}
{'filename': 'EMA - Abstract 18_ Patient Attitudes on IV Fluids for Common Cold in ED - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': "Most patients either strongly agreed or agreed with statements regarding IV fluids' effectiveness in eliminating infection. For example, 70% agreed with the statement 'administering IV fluids eliminates the infection.'", 'entities': []}
{'filename': 'EMA - Abstract 18_ Patient Attitudes on IV Fluids for Common Cold in ED - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': 'The patients were also asked, in general terms, what symptoms require IV fluids for treatment. More than 80% agreed that fever, fatigue, sore throat, rhinorrhea, sneezing, and headache require intravenous fluid treatment. Ironically, only 6% to 7% agreed that vomiting or diarrhea requires IV fluid treatment.', 'entities': []}
{'filename': 'EMA - Abstract 18_ Patient Attitudes on IV Fluids for Common Cold in ED - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': 'The strength of this study is that it involved patients in the ED with these symptoms, and therefore was likely to reflect the real attitudes of patients who are feeling ill. Limitations include that the study was conducted at a single center in Iran; therefore, the findings might not be generalizable to other populations.', 'entities': []}
{'filename': 'EMA - Abstract 18_ Patient Attitudes on IV Fluids for Common Cold in ED - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': 'Nonetheless, the study provides insights into somewhat odd patient expectations, and serves as a reminder to ask patients what they expect/want/think they need, to fully educate and treat them.', 'entities': []}
{'filename': 'EMA - Abstract 18_ Patient Attitudes on IV Fluids for Common Cold in ED - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'section_header', 'text': 'PMID: 40114054', 'entities': []}
{'filename': 'EMA - Abstract 18_ Patient Attitudes on IV Fluids for Common Cold in ED - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': 'FULL ARTICLE: https://intjem.biomedcentral.com/articles/10.1186/s12245-025-00852-0', 'entities': []}
{'filename': 'EMA - Abstract 18_ Patient Attitudes on IV Fluids for Common Cold in ED - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': "EDITOR'S COMMENTARY: In this single-site study of patients with upper respiratory infections, a very high proportion believed that IV fluids are needed to treat common minor concerns, such as sneezing, fever, and sore throat. In addition, the respondents generally expressed strong beliefs that IV fluids eliminate causes of upper respiratory infections. Providers should be aware that patients harbor many nonscientific beliefs about the effectiveness of various therapies, and should consider routinely asking patients about these beliefs to prevent misunderstanding and increase satisfaction with treatment plans.", 'entities': []}
{'filename': 'EMA - Abstract 18_ Patient Attitudes on IV Fluids for Common Cold in ED - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': 'Copyright 2025 by Emergency Medical Abstracts - All Rights Reserved 06/25 - #18', 'entities': []}
{'filename': 'EMA - Abstract 18_ Patient Attitudes on IV Fluids for Common Cold in ED - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'caption', 'text': 'Tag: IV Fluids', 'entities': []}
{'filename': 'EMA - Abstract 5_ Fiberoptic Laryngoscopy Findings in Pediatric Burn ED Referrals - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': 'Fiberoptic laryngoscopy findings in pediatric burn patients referred to the pediatric emergency department Cahan LOS, Kotovich D, Hamo M Ben, et al. Am J Emerg Med. 2025;89:195-198.', 'entities': []}
{'filename': 'EMA - Abstract 5_ Fiberoptic Laryngoscopy Findings in Pediatric Burn ED Referrals - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'section_header', 'text': 'SUMMARY:', 'entities': []}
{'filename': 'EMA - Abstract 5_ Fiberoptic Laryngoscopy Findings in Pediatric Burn ED Referrals - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': 'Facial burns can be particularly dangerous in children, because upper airway apertures are much smaller in children than adults, and therefore are predisposed to airway obstruction secondary to edema. The challenging decision to secure an airway in patients with burns is usually based on a set of clinical criteria including singed nasal hairs, nasal soot, voice change, throat pain or abnormal sensation, shortness of breath, carbonaceous sputum, wheezing, or stridor.', 'entities': []}
{'filename': 'EMA - Abstract 5_ Fiberoptic Laryngoscopy Findings in Pediatric Burn ED Referrals - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': 'Fiber optic laryngoscopy (FOL) is being adopted by many EDs. FOL enables rapid assessment of the upper airway, provides a deeper view than direct laryngoscopy, and does not require full patient sedation. This retrospective study investigated the potential utility of early flexible FOL in identifying pediatric patients with burns requiring immediate airway intervention.', 'entities': []}
{'filename': 'EMA - Abstract 5_ Fiberoptic Laryngoscopy Findings in Pediatric Burn ED Referrals - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': 'This retrospective study from the Hebrew University Medical Center in Israel used manual chart review for data collection in a cohort of patients with facial burns, identified via International Classification of Diseases codes, who also received FOL in the ED. Unfortunately, no details are provided regarding the chart-review protocol, methods, outcome assessment, or number of patients with facial burns who did not receive FOL. Over a 12-year period, 149 children with a mean age of 1.8 years met the inclusion criteria.', 'entities': []}
{'filename': 'EMA - Abstract 5_ Fiberoptic Laryngoscopy Findings in Pediatric Burn ED Referrals - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': 'Clinical findings suggestive of inhalation injury, including shortness of breath, wheezing or stridor, carbonaceous sputum, or singed nasal hair, were observed in 17 (11.4%) children. FOL findings suggestive of inhalation injury were observed in 11 (7.3%) patients: 5 (45.4%) with clinical findings suggestive of inhalation injury and 6 (54.5%) with normal physical examination findings. FOL had a sensitivity of 29% and a specificity of 95% with respect to the clinical findings, which served as the gold standard for assessing inhalation injury related to airway patency. Among the 149 pediatric cases, 10 (6.7%) required intubation: 5 (50%) with both positive FOL findings and positive clinical findings, and 5 (50%) with no signs of inhalation injury according to either the FOL or clinical findings.', 'entities': []}
{'filename': 'EMA - Abstract 5_ Fiberoptic Laryngoscopy Findings in Pediatric Burn ED Referrals - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': 'Overall, the study findings are somewhat mixed, because the FOL findings were not generally consistent with the clinical findings, and included false positives and negatives with respect to the gold-standard clinical findings. The authors concluded that FOL would be best applied to provide confirmation in cases with clinical findings. However, the study has many important limitations. The retrospective design introduced potential documentation biases, and the relatively small sample of positive FOL findings (only 11 patients, or 7.3%) limited the statistical power. The lack of standardized FOL interpretation criteria is particularly problematic for emergency physicians, who need reliable, examiner-independent assessment tools to guide time-sensitive decisions. The reported 29% sensitivity of FOL vs clinical assessment is concerningly low: FOL therefore might miss many cases requiring intervention. Furthermore, the study did not adequately address the risk-benefit analysis of performing FOL in the emergency setting. Finally, the data are at risk of selection and incorporation biases.', 'entities': []}
{'filename': 'EMA - Abstract 5_ Fiberoptic Laryngoscopy Findings in Pediatric Burn ED Referrals - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': 'PMID:', 'entities': []}
{'filename': 'EMA - Abstract 5_ Fiberoptic Laryngoscopy Findings in Pediatric Burn ED Referrals - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': '39736249', 'entities': []}
{'filename': 'EMA - Abstract 5_ Fiberoptic Laryngoscopy Findings in Pediatric Burn ED Referrals - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': "EDITOR'S COMMENTARY: In this interesting paper, the authors used retrospective data to estimate the value of FOL among pediatric patients with facial burns. Unfortunately, the methods were not strong enough to alter clinical practice, because no details are provided on data collection, potential exists for both selection and incorporation bias, and the reported sensitivity is frankly terrible. For emergency physicians, the most valuable finding might be that patients with both positive clinical signs and positive FOL findings appeared to have the highest likelihood of requiring airway intervention. Therefore, FOL might have a potential role as a confirmatory tool rather than a screening tool in pediatric emergency departments.", 'entities': []}
{'filename': 'EMA - Abstract 5_ Fiberoptic Laryngoscopy Findings in Pediatric Burn ED Referrals - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'section_header', 'text': 'RELATED CONTENT:', 'entities': []}
{'filename': 'EMA - Abstract 5_ Fiberoptic Laryngoscopy Findings in Pediatric Burn ED Referrals - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'section_header', 'text': 'EM:RAP 2016 April: Severe Burn Management', 'entities': []}
{'filename': 'EMA - Abstract 5_ Fiberoptic Laryngoscopy Findings in Pediatric Burn ED Referrals - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': 'CorePendium : Major Burns (Thermal Burns)', 'entities': []}
{'filename': 'EMA - Abstract 5_ Fiberoptic Laryngoscopy Findings in Pediatric Burn ED Referrals - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': 'Copyright 2025 by Emergency Medical Abstracts - All Rights Reserved 06/25 - #05', 'entities': []}
{'filename': 'EMA - Abstract 5_ Fiberoptic Laryngoscopy Findings in Pediatric Burn ED Referrals - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': 'Tags: Laryngoscopy', 'entities': []}
{'filename': 'EMA - Abstract 5_ Fiberoptic Laryngoscopy Findings in Pediatric Burn ED Referrals - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': 'Procedural Skills', 'entities': []}
{'filename': 'EMA - Abstract 5_ Fiberoptic Laryngoscopy Findings in Pediatric Burn ED Referrals - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'section_header', 'text': 'CorePendium Chapters', 'entities': []}
{'filename': 'EMA - Abstract 5_ Fiberoptic Laryngoscopy Findings in Pediatric Burn ED Referrals - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': 'Major Burns (Thermal Burns)', 'entities': []}
{'filename': 'EMA - Abstract 20_ The Problem With How We View Medical Error in Emergency Medicine - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': 'The problem with how we view medical (and diagnostic) error in emergency medicine Ladell MM, Jacobson NL, Yale SC, et al. Acad Emerg Med. 2025;32(3):340347.', 'entities': []}
{'filename': 'EMA - Abstract 20_ The Problem With How We View Medical Error in Emergency Medicine - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'section_header', 'text': 'SUMMARY:', 'entities': []}
{'filename': 'EMA - Abstract 20_ The Problem With How We View Medical Error in Emergency Medicine - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': 'This really nice thought piece from Academic Emergency Medicine was included in a special issue on the science of errors in emergency care.', 'entities': []}
{'filename': 'EMA - Abstract 20_ The Problem With How We View Medical Error in Emergency Medicine - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': 'I will not be able to do this article justice, so I encourage anyone even obliquely interested in how safety should be conceived in the ED to read this article.', 'entities': []}
{'filename': 'EMA - Abstract 20_ The Problem With How We View Medical Error in Emergency Medicine - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': 'The central idea is that we have not made great strides in safety, even though safety is a major concern for practitioners and administrators alike. Why? The authors propose that we are applying the wrong model to the situation: specifically, we focus too much on errors and not enough on hazards, and more importantly do not consider the ED as a human-centered sociotechnical system, ie, one that is shaped by, but also shapes, how we think and interact.', 'entities': []}
{'filename': 'EMA - Abstract 20_ The Problem With How We View Medical Error in Emergency Medicine - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': "This concept of a sociotechnical system places humans, rather than some operator, at the middle of the system. In this context, the provider is a critical piece that actually holds together multiple poorly developed programs, processes, and physical conditions in the face of tremendous uncertainty and time pressure. The human is the variable, adaptable component in this system, and is responsible for all the difficult tasks. In the absence of the human, everyone would die, yet this aspect is not celebrated. Instead, when the STS breaks down, the usual response is to examine the variable component and ask why the human didn't do a better job of juggling tasks. The usual response is to blame and retrain.", 'entities': []}
{'filename': 'EMA - Abstract 20_ The Problem With How We View Medical Error in Emergency Medicine - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': "More nuanced thinkers might say that it is not the human but the system, and ask what can be done to make the system 'safer.' This notion underlies the 'Swiss cheese model,' in which more 'layers of cheese' are presumed to be necessary to build safety. The authors believe that this model is oversimplified and discounts clinical expertise. Errors are not solely system errors or human errors, but are part of the same system and interact with one another.", 'entities': []}
{'filename': 'EMA - Abstract 20_ The Problem With How We View Medical Error in Emergency Medicine - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': "A key issue is that error investigators often think about a problem by using a 'work as imagined' framework instead of a 'work as done' framework. Consequently, administrative remedies that do not necessarily improve outcomes are pursued.", 'entities': []}
{'filename': 'EMA - Abstract 20_ The Problem With How We View Medical Error in Emergency Medicine - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': "In fact, the authors argue that the safety and efficiency of emergency care are absolutely amazing. They offer several suggestions for advancing the science emphasizing by using a naturalistic decision-making framework; involving systems science and experts in human factors; not trying to determine the 'cause' of a poor outcome but instead being more open to learning about the system; and challenging agencies to reconsider the safety models used to determine hospital compliance with regulations.", 'entities': []}
{'filename': 'EMA - Abstract 20_ The Problem With How We View Medical Error in Emergency Medicine - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': "This article is a good read that highlights how understanding of the hazards that exist in health care, particularly emergency health care, is actually in its infancy, and praises ED providers' extraordinary achievements in keeping this system quite safe.", 'entities': []}
{'filename': 'EMA - Abstract 20_ The Problem With How We View Medical Error in Emergency Medicine - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'section_header', 'text': 'PMID: 40033164', 'entities': []}
{'filename': 'EMA - Abstract 20_ The Problem With How We View Medical Error in Emergency Medicine - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': 'FULL ARTICLE: https://onlinelibrary.wiley.com/doi/10.1111/acem.15076', 'entities': []}
{'filename': 'EMA - Abstract 20_ The Problem With How We View Medical Error in Emergency Medicine - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': "EDITOR'S COMMENTARY: This article is part of a special issue in this month's issue of Academic Emergency Medicine on the science of errors in emergency care. The article offers numerous insights into the current, inadequate conceptualization of errors in emergency care, and highlights that our complex environment is actually safe because of the professionals who are resilient and adaptive to the variable stresses present. This concept contrasts with most models that fundamentally focus on blame and try to identify specific causes and remedies, but usually ultimately make the system clunky and potentially unworkable.", 'entities': []}
{'filename': 'EMA - Abstract 20_ The Problem With How We View Medical Error in Emergency Medicine - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': 'Copyright 2025 by Emergency Medical Abstracts - All Rights Reserved 06/25 - #20', 'entities': []}
{'filename': 'EMA - Abstract 20_ The Problem With How We View Medical Error in Emergency Medicine - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': 'Tag: Medical Training', 'entities': []}
{'filename': 'EMA - Abstract 1_ Projected Cancer Risks From Current Computed Tomography Imaging - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': 'Projected lifetime cancer risks from current computed tomography imaging SmithBindman R, Chu PW, Azman Firdaus H, et al. JAMA Intern Med. 2025;185(6):710719.', 'entities': []}
{'filename': 'EMA - Abstract 1_ Projected Cancer Risks From Current Computed Tomography Imaging - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'section_header', 'text': 'SUMMARY:', 'entities': []}
{'filename': 'EMA - Abstract 1_ Projected Cancer Risks From Current Computed Tomography Imaging - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': "CT scans are invaluable in medicine, because they can be used to rapidly and accurately diagnose life-threatening conditions, thereby improving both short-term and long-term clinical outcomes. However, they expose patients to ionizing radiation at levels known to increase lifetime cancer risk. Radiation-induced cancer risk from CT examinations varies by radiation dose, which in turn depends on the clinical indication; body region imaged; patient's sex, age, and size; and acquisition technique. The purpose of this study was to update the previously projected lifetime cancer incidence associated with CT, by using the most recent utilization data available, empirical data on CT type by age and sex, and organ doses estimated directly from examination-level clinical data across the United States according to best-practice methods.", 'entities': []}
{'filename': 'EMA - Abstract 1_ Projected Cancer Risks From Current Computed Tomography Imaging - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': "This risk model used patient-level data from the University of California San Francisco International CT Dose Registry, which has assembled CT examination data from 143 US hospitals and outpatient facilities associated with 22 health care organizations across 20 states. The authors used data from the IMV Medical Information Division CT Market Outlook Report, based on an annual national survey of 235 hospitals and 78 imaging facilities, to quantify the number of CT examinations performed in the United States in 2023. Future lifetime radiationinduced cancer risk was projected with the National Cancer Institute's Radiation Risk Assessment Tool (RadRAT).", 'entities': []}
{'filename': 'EMA - Abstract 1_ Projected Cancer Risks From Current Computed Tomography Imaging - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': 'An estimated 61,510,000 patients underwent 93,000,000 CT examinations in 2023approximately 30 million more scans than performed in 2006. The patients included 2,570,000 (4.2%) children and 58,940,000 (95.8%) adults; 32,600,000 (53.0%) were female, and 28,910,000 (47.0%) were male.', 'entities': []}
{'filename': 'EMA - Abstract 1_ Projected Cancer Risks From Current Computed Tomography Imaging - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': 'The model estimated that approximately 103,000 future cancer cases (93,000 in adults and 9,700 in children) might be caused by the scans in 2023. Among patients exposed as adults, lung cancer, colon cancer, and leukemia were expected to predominate, whereas among patients exposed as children, thyroid, lung, and breast cancers were expected to predominate. Among children, the cancer risk was highest for those scanned at ages younger than 1 year and decreased with age thereafter. The risk among adults peaked for patients scanned between 50 and 59 years of age. Abdominal and pelvic CT examinations were estimated to contribute to the most cancer cases (40%) in adults (37,500 [90% UL, 32,900-42,600] cases), whereas head CT was estimated to contribute to the most cancer cases (53%) in children.', 'entities': []}
{'filename': 'EMA - Abstract 1_ Projected Cancer Risks From Current Computed Tomography Imaging - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': 'In summary, the top-line findings suggested that CT scans might be responsible for approximately 5% of new cancer diagnoses nationwide.', 'entities': []}
{'filename': 'EMA - Abstract 1_ Projected Cancer Risks From Current Computed Tomography Imaging - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': 'The study was exceptionally well done overall, and included detailed data on CT use and associated radiation doses, detailed calculation of risks with uncertainty limits, and sensitivity analyses providing a range of estimates under widely varying assumptions. However, many important limitations must be discussed to fully understand the potential effects. First, the numbers of cancer cases were derived from modeling and not observational outcomes, and the', 'entities': []}
{'filename': 'EMA - Abstract 1_ Projected Cancer Risks From Current Computed Tomography Imaging - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': 'models were largely based on the cancer rates observed among Japanese atomic-bomb survivors receiving massive doses of radiation; consequently, the true estimates among patients receiving low-dose medical imaging might be much lower, and the projection should be considered an upper-limit estimate at best. Second, the patients receiving CT scans in this cohort were likely to be more ill at baseline than the overall population as a whole, because they required a CT scan for some reason and consequently might have had a greater lifetime cancer risk and a lower average life expectancy than the population as whole, thus making the added cancer risk from CT negligible. Third, CT scans save lives in both acute settings, such as trauma, and chronic settings, such as monitoring patient responses to cancer therapy. Providers must not allow a fear of causing cancer in 30 years to prevent, eg, diagnosing an intracranial bleed today.', 'entities': []}
{'filename': 'EMA - Abstract 1_ Projected Cancer Risks From Current Computed Tomography Imaging - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': 'The take-home message is that CTs probably do increase cancer risk, and even if the estimate is an upper limit, providers should be mindful of this trade-off and limit scans to only those that are medically necessary; use alternative imaging, such as ultrasound or MRI, when appropriate; and develop CT protocols that minimize the amount of radiation delivered per scan.', 'entities': []}
{'filename': 'EMA - Abstract 1_ Projected Cancer Risks From Current Computed Tomography Imaging - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'section_header', 'text': 'PMID: 40227719', 'entities': []}
{'filename': 'EMA - Abstract 1_ Projected Cancer Risks From Current Computed Tomography Imaging - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': 'FULL ARTICLE: https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2832778', 'entities': []}
{'filename': 'EMA - Abstract 1_ Projected Cancer Risks From Current Computed Tomography Imaging - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': "EDITOR'S COMMENTARY: In this article that made news headlines, the authors used best-practice modeling and suggested that the CT scans performed in the U.S. in 2023 alone might eventually result in more than 100,000 new cancer diagnoses, representing 5% of all new cancer cases. This number is startlingly high, but we need to keep in mind that, even if true, the overall lifetime risk of cancer would change by just a few percent, from approximately 50% to 52%. The estimate itself was based on data from patients with atomic-bomb radiation exposure, not low-level medical-imaging exposure. In addition, the patients getting scanned were likely to have been sicker to start with and consequently had higher baseline cancer risk than the overall population. The bottom line is: don't let these data stop you from getting a CT that you think is medically necessary, but do let it make you think about whether the scan you are ordering is actually medically necessary, particularly among younger patients.", 'entities': []}
{'filename': 'EMA - Abstract 1_ Projected Cancer Risks From Current Computed Tomography Imaging - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': 'Copyright 2025 by Emergency Medical Abstracts - All Rights Reserved 07/25 - #01', 'entities': []}
{'filename': 'EMA - Abstract 1_ Projected Cancer Risks From Current Computed Tomography Imaging - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': 'Tag:', 'entities': []}
{'filename': 'EMA - Abstract 1_ Projected Cancer Risks From Current Computed Tomography Imaging - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': 'Imaging', 'entities': []}
{'filename': 'EMA - Abstract 8_ Antibiotic Sequence Effect on Mortality in Suspected Sepsis - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': 'Association between the sequence of  -lactam and vancomycin administration and mortality in patients with suspected sepsis Kondo Y, Klompas M, McKenna CS, et al. Clin Infect Dis. 2025;80(4):761-769.', 'entities': []}
{'filename': 'EMA - Abstract 8_ Antibiotic Sequence Effect on Mortality in Suspected Sepsis - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'section_header', 'text': 'SUMMARY:', 'entities': []}
{'filename': 'EMA - Abstract 8_ Antibiotic Sequence Effect on Mortality in Suspected Sepsis - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': 'Antibiotics work well in sepsis: early antibiotic administration is generally associated with better clinical outcomes, whereas most of the other elements of sepsis bundles are generally not independently associated with outcome improvement.', 'entities': []}
{'filename': 'EMA - Abstract 8_ Antibiotic Sequence Effect on Mortality in Suspected Sepsis - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': 'Most patients with undifferentiated sepsis receive some form of a beta-lactam antibiotic, eg, a third-generation cephalosporin or penicillin, and are often also prescribed vancomycin for methicillin-resistant Staphylococcus aureus (MRSA). Which antibiotics to administer first is an open question. The authors of this study note that vancomycin is found to be unnecessary in 90% of cases or more, and it requires 1 or 2 hours to administer. The study was aimed at determining whether administration of vancomycin before the beta-lactam might actually be associated with worsened outcomes.', 'entities': []}
{'filename': 'EMA - Abstract 8_ Antibiotic Sequence Effect on Mortality in Suspected Sepsis - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': 'This retrospective cohort analysis was conducted at 5 Mass General Brigham (MGB) hospitals in adults admitted to the ED between 2015 and 2022. All data came from the MGB electronic health record data warehouse. Patients were included if they received antibiotics, had blood cultures obtained near admission (suspected sepsis), and experienced acute organ dysfunction within 12 hours after arrival. The cohort was restricted to patients receiving a beta-lactam antibiotic plus vancomycin.', 'entities': []}
{'filename': 'EMA - Abstract 8_ Antibiotic Sequence Effect on Mortality in Suspected Sepsis - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': 'The key exposure of interest was the order of antibiotic administration, and the key outcome of interest was in-hospital mortality. The authors used propensity scores with both matching and inverse probability weighting to control for observable confounders.', 'entities': []}
{'filename': 'EMA - Abstract 8_ Antibiotic Sequence Effect on Mortality in Suspected Sepsis - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': 'The final sample included 25,391 adult patients during the study period. The mean age was 65 years, and a large fraction of patients had a cooccurring cancer diagnosis. The mean lactate level was 2.5.', 'entities': []}
{'filename': 'EMA - Abstract 8_ Antibiotic Sequence Effect on Mortality in Suspected Sepsis - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': 'A total of 84% of patients received the beta-lactam first. Overall, the group that received betalactam first was more ill, was older, had higher lactate, had higher HR, and was more likely to arrive by ambulance. However, the differences between groups were quite small. The betalactam was given a full 3 hours later in the group receiving vancomycin first than in the group receiving beta-lactam first.', 'entities': []}
{'filename': 'EMA - Abstract 8_ Antibiotic Sequence Effect on Mortality in Suspected Sepsis - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': 'In the main analysis using propensity scoring for adjustment, administration of beta-lactam first, compared with vancomycin first, was associated with lower odds of in-hospital mortality (aOR, 0.89; CI, 0.80-0.99). There were no subgroups in which the aOR favored vancomycin-first treatment, including (perhaps surprisingly) the group found to have MRSA-positive clinical cultures (OR, 0.91; CI, 0.55-1.51).', 'entities': []}
{'filename': 'EMA - Abstract 8_ Antibiotic Sequence Effect on Mortality in Suspected Sepsis - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': 'The study is limited by its observational nature, rather crude data abstraction method, and limited generalizability, given that only MGB hospitals participated. The findings do not demonstrate that administering beta-lactam first actually saves lives. Nonetheless, good reason exists to take the findings seriously. Because time to antibiotic administration matters, and', 'entities': []}
{'filename': 'EMA - Abstract 8_ Antibiotic Sequence Effect on Mortality in Suspected Sepsis - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': 'MRSA is rarely the offending agent, giving beta-lactam first when both antibiotics will be administered anyway makes sense.', 'entities': []}
{'filename': 'EMA - Abstract 8_ Antibiotic Sequence Effect on Mortality in Suspected Sepsis - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'section_header', 'text': 'PMID: 39657016', 'entities': []}
{'filename': 'EMA - Abstract 8_ Antibiotic Sequence Effect on Mortality in Suspected Sepsis - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': "EDITOR'S COMMENTARY: This large multisite observational study of patients receiving both a betalactam and vancomycin for suspected sepsis indicated that the order of administration mattered. Patients receiving the beta-lactam first had lower in-hospital mortality than those getting the vancomycin first. The study is limited, such that this association cannot be considered causal, but the underlying logic of the arguments coupled with these data is fairly compelling.", 'entities': []}
{'filename': 'EMA - Abstract 8_ Antibiotic Sequence Effect on Mortality in Suspected Sepsis - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'section_header', 'text': 'RELATED CONTENT:', 'entities': []}
{'filename': 'EMA - Abstract 8_ Antibiotic Sequence Effect on Mortality in Suspected Sepsis - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': 'EM:RAP 2020 August: Critical Care Mailbag: Sepsis Update Part 2', 'entities': []}
{'filename': 'EMA - Abstract 8_ Antibiotic Sequence Effect on Mortality in Suspected Sepsis - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': 'CorePendium : Sepsis', 'entities': []}
{'filename': 'EMA - Abstract 8_ Antibiotic Sequence Effect on Mortality in Suspected Sepsis - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': 'CorePendium : Vancomycin (IV)', 'entities': []}
{'filename': 'EMA - Abstract 8_ Antibiotic Sequence Effect on Mortality in Suspected Sepsis - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': 'Copyright 2025 by Emergency Medical Abstracts - All Rights Reserved 07/25 - #08', 'entities': []}
{'filename': 'EMA - Abstract 8_ Antibiotic Sequence Effect on Mortality in Suspected Sepsis - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': 'Tag:', 'entities': []}
{'filename': 'EMA - Abstract 8_ Antibiotic Sequence Effect on Mortality in Suspected Sepsis - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': 'Antibiotics', 'entities': []}
{'filename': 'EMA - Abstract 8_ Antibiotic Sequence Effect on Mortality in Suspected Sepsis - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'section_header', 'text': 'CorePendium Chapters', 'entities': []}
{'filename': 'EMA - Abstract 8_ Antibiotic Sequence Effect on Mortality in Suspected Sepsis - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': 'Sepsis', 'entities': []}
{'filename': 'EMA - Abstract 8_ Antibiotic Sequence Effect on Mortality in Suspected Sepsis - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': 'Vancomycin (IV)', 'entities': []}
{'filename': 'EMA - Abstract 5_ Ketamine+Midazolam vs Midazolam for Pediatric Status Epilepticus - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': 'Combined ketamine and midazolam versus midazolam alone for initial treatment of pediatric generalized convulsive status epilepticus (Ket-Mid Study): a randomized controlled trial Othman AA, Sadek AA, Ahmed EA, et al. Pediatr Neurol. 2025;167:24-32.', 'entities': []}
{'filename': 'EMA - Abstract 5_ Ketamine+Midazolam vs Midazolam for Pediatric Status Epilepticus - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'section_header', 'text': 'SUMMARY:', 'entities': []}
{'filename': 'EMA - Abstract 5_ Ketamine+Midazolam vs Midazolam for Pediatric Status Epilepticus - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': "The first-line treatment for generalized convulsive status epilepticus in children is benzodiazepines, but many children are resistant and require a second-line agent. Stopping seizures as soon as possible is critical, because treatment resistance and neurologic injury risk increase with prolongation of generalized convulsive status epilepticus. Several case reports and case series suggest ketamine's potential value as a fist-line agent for seizure cessation, but this possibility has not yet been evaluated in a rigorous prospective manner.", 'entities': []}
{'filename': 'EMA - Abstract 5_ Ketamine+Midazolam vs Midazolam for Pediatric Status Epilepticus - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': 'This randomized, 2-group, parallel, 1:1, superiority, double-blind, placebo-controlled trial in the ED was conducted in Egypt between March 2023 and August 2024. The study enrolled patients between 6 months and 16 years of age with generalized convulsive status epilepticus, operationally defined as seizure activity that persisted or recurred, without intervening periods of regained consciousness, for more than 5 minutes. The study excluded patients with traumatic brain injury and central nervous system mass lesions, and those who had received antiepileptic agents before enrollment. All patients received standard supportive care, including airway management, supplemental oxygen, treatment for hypoglycemia, and midazolam at 0.2 mg/kg. Patients in the treatment arm (Ket-Mid group) simultaneously received ketamine at 2 mg/kg IV.', 'entities': []}
{'filename': 'EMA - Abstract 5_ Ketamine+Midazolam vs Midazolam for Pediatric Status Epilepticus - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': 'The study enrolled and randomized 144 patients, 32% of whom were younger than 1 year. The most frequent causes of seizure were febrile seizure (43%) and known epilepsy (42%). The median seizure duration before hospital arrival was 34 minutes. No patients received therapy before enrollment.', 'entities': []}
{'filename': 'EMA - Abstract 5_ Ketamine+Midazolam vs Midazolam for Pediatric Status Epilepticus - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': 'The primary endpoint of seizure cessation at 5 minutes was observed in 76.4% of children in the Ket-Mid group and 20.8% of children in the placebo-midazolam group (risk ratio [RR], 3.7; 95% confidence interval [CI], 2.3-5.9; P <.001). The rate of seizure cessation was higher at all assessed time points in the Ket-Mid group than the placebo-midazolam group, as was the need for rescue medication at any point (23.6% vs 79.2%) or endotracheal intubation (4.2% vs 20.8%). These results were very positive.', 'entities': []}
{'filename': 'EMA - Abstract 5_ Ketamine+Midazolam vs Midazolam for Pediatric Status Epilepticus - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': "Generally, this well-done trial closely followed a thoughtfully designed study protocol in all cases, and no patients were lost to follow-up or had missing outcome data. Impressively, patient-level randomization was performed despite the time-sensitive nature of this clinical condition. The main limitation of this study is a substantial threat to generalizability, because the enrolled patients received no treatment for more than 30 minutes before receiving the assigned study medication. This scenario would be unlikely in highly resourced countries, where benzodiazepines are routinely administered in the prehospital setting. In fact, after approximately 15 minutes of continuous seizure, the chance that benzodiazepines alone will work is low, thus resulting in somewhat of a 'straw man' comparator in this study. Additionally, EEG was not used to assess the primary outcome, and if blinding failed, as is often the case with ketamine trials, further bias might have been introduced.", 'entities': []}
{'filename': 'EMA - Abstract 5_ Ketamine+Midazolam vs Midazolam for Pediatric Status Epilepticus - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'section_header', 'text': 'PMID: 40186980', 'entities': []}
{'filename': 'EMA - Abstract 5_ Ketamine+Midazolam vs Midazolam for Pediatric Status Epilepticus - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': "EDITOR'S COMMENTARY: This well-done, first-of-its-kind randomized trial from Egypt showed that ketamine plus midazolam, compared with midazolam alone, markedly increased seizure cessation rates and had massive effects on short-term patient-oriented outcomes among children with generalized convulsive status epilepticus. The main issue with the findings is that the patients received no treatment for more than half an hour before enrollment-an unlikely scenario for most ED physicians. Prehospital treatment is the norm, and benzodiazepines alone are known to lose effectiveness if they are not given early. I think, for now, this study might create equipoise on the topic and lead to more trials assessing ketamine for pediatric status epilepticus.", 'entities': []}
{'filename': 'EMA - Abstract 5_ Ketamine+Midazolam vs Midazolam for Pediatric Status Epilepticus - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'section_header', 'text': 'RELATED CONTENT:', 'entities': []}
{'filename': 'EMA - Abstract 5_ Ketamine+Midazolam vs Midazolam for Pediatric Status Epilepticus - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': 'EM:RAP 2024 June: Crit Bits: Status Epilepticus', 'entities': []}
{'filename': 'EMA - Abstract 5_ Ketamine+Midazolam vs Midazolam for Pediatric Status Epilepticus - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'section_header', 'text': 'CorePendium : Pediatric Seizures', 'entities': []}
{'filename': 'EMA - Abstract 5_ Ketamine+Midazolam vs Midazolam for Pediatric Status Epilepticus - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': 'Copyright 2025 by Emergency Medical Abstracts - All Rights Reserved 07/25 - #05', 'entities': []}
{'filename': 'EMA - Abstract 5_ Ketamine+Midazolam vs Midazolam for Pediatric Status Epilepticus - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': 'Tags: Ketamine', 'entities': []}
{'filename': 'EMA - Abstract 5_ Ketamine+Midazolam vs Midazolam for Pediatric Status Epilepticus - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': 'Seizures', 'entities': []}
{'filename': 'EMA - Abstract 5_ Ketamine+Midazolam vs Midazolam for Pediatric Status Epilepticus - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'section_header', 'text': 'CorePendium Chapters', 'entities': []}
{'filename': 'EMA - Abstract 5_ Ketamine+Midazolam vs Midazolam for Pediatric Status Epilepticus - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': 'Pediatric Seizures', 'entities': []}
{'filename': 'EMA - Abstract 14_ Biphasic Anaphylaxis_ Incidence and Risk Factors - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': 'Biphasic anaphylaxis in a Canadian tertiary care centre: an evaluation of incidence and risk factors from electronic health records and telephone interviews Ellis AK, Hossenbaccus L, Linton S, et al. Allergy Asthma Clin Immunol. 2025;21(1):7.', 'entities': []}
{'filename': 'EMA - Abstract 14_ Biphasic Anaphylaxis_ Incidence and Risk Factors - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'section_header', 'text': 'SUMMARY:', 'entities': []}
{'filename': 'EMA - Abstract 14_ Biphasic Anaphylaxis_ Incidence and Risk Factors - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': 'Biphasic reactions have been well described in patients experiencing anaphylaxis.', 'entities': []}
{'filename': 'EMA - Abstract 14_ Biphasic Anaphylaxis_ Incidence and Risk Factors - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': 'According to literature estimates, biphasic anaphylactic reaction has an incidence between 1% and 20%, and occurs between 1 and 10 hours after initial management.', 'entities': []}
{'filename': 'EMA - Abstract 14_ Biphasic Anaphylaxis_ Incidence and Risk Factors - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': 'Given this wide range, conservative guidelines generally suggest ED or hospital observation for a minimum of 6 hours.', 'entities': []}
{'filename': 'EMA - Abstract 14_ Biphasic Anaphylaxis_ Incidence and Risk Factors - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': 'This cross-retrospective survey-based cohort study was conducted to provide further details regarding these incidence and timing estimates. The methods are somewhat unusual. The authors queried ED records from their institution for the terms allergic reaction, anaphylaxis, drug allergy, or insect sting allergy between 2015 and 2017. They then contacted patients within 2 months of the ED visit to ask about symptom progression. Special attention was paid to symptoms that reoccurred after an initial period of complete resolution.', 'entities': []}
{'filename': 'EMA - Abstract 14_ Biphasic Anaphylaxis_ Incidence and Risk Factors - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': 'Biphasic anaphylactic reaction was defined as recurrence of at least 2 body symptoms after an initial phase of resolution. If only 1 symptom reoccurred, the event was considered a nonanaphylactic biphasic reaction.', 'entities': []}
{'filename': 'EMA - Abstract 14_ Biphasic Anaphylaxis_ Incidence and Risk Factors - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': 'A total of 148 patients were identified and called. The median age was 30 years, and most patients had a prior history of anaphylaxis. The median time to resolution of the initial symptoms was approximately 3 hours.', 'entities': []}
{'filename': 'EMA - Abstract 14_ Biphasic Anaphylaxis_ Incidence and Risk Factors - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': 'A second reaction occurred in 29 patients with 22 biphasic reactions (16%). Remarkably, the mean time to recurrence was 19 hours. Only one-third started within 8 hours. No relationship was observed between the time to initial symptom resolution and the presence of a biphasic reaction. The second reactions were generally much milder than the original reactions. Only 4 of the 29 patients were treated with epinephrine.', 'entities': []}
{'filename': 'EMA - Abstract 14_ Biphasic Anaphylaxis_ Incidence and Risk Factors - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': 'The study has many limitations, including its single-center design, use of old data, and potential for substantial recall bias. However, the findings mostly confirm prior knowledge. Biphasic reactions occur occasionally but not very commonly, tend to be mild, and occur relatively late. In most circumstances, patients are managed with an epinephrine prescription and detailed return precautions.', 'entities': []}
{'filename': 'EMA - Abstract 14_ Biphasic Anaphylaxis_ Incidence and Risk Factors - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'section_header', 'text': 'PMID: 39923108', 'entities': []}
{'filename': 'EMA - Abstract 14_ Biphasic Anaphylaxis_ Incidence and Risk Factors - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': 'FULL ARTICLE: https://aacijournal.biomedcentral.com/articles/10.1186/s13223-024-00919-2', 'entities': []}
{'filename': 'EMA - Abstract 14_ Biphasic Anaphylaxis_ Incidence and Risk Factors - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': "EDITOR'S COMMENTARY: In this single-center study, the authors estimate that biphasic anaphylaxis has an incidence of 16%, occurs an average of 21 hours after the initial reaction, and is generally mild. Emergency providers can use this information to provide anticipatory guidance and return precautions for patients being discharged after successful treatment for anaphylaxis.", 'entities': []}
{'filename': 'EMA - Abstract 14_ Biphasic Anaphylaxis_ Incidence and Risk Factors - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'section_header', 'text': 'RELATED CONTENT:', 'entities': []}
{'filename': 'EMA - Abstract 14_ Biphasic Anaphylaxis_ Incidence and Risk Factors - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'section_header', 'text': 'EM:RAP 2024 September: Case of the Week', 'entities': []}
{'filename': 'EMA - Abstract 14_ Biphasic Anaphylaxis_ Incidence and Risk Factors - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': 'CorePendium : Allergy, Hypersensitivity, and Anaphylaxis', 'entities': []}
{'filename': 'EMA - Abstract 14_ Biphasic Anaphylaxis_ Incidence and Risk Factors - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': 'Copyright 2025 by Emergency Medical Abstracts - All Rights Reserved 06/25 - #14', 'entities': []}
{'filename': 'EMA - Abstract 14_ Biphasic Anaphylaxis_ Incidence and Risk Factors - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'section_header', 'text': 'CorePendium Chapters', 'entities': []}
{'filename': 'EMA - Abstract 14_ Biphasic Anaphylaxis_ Incidence and Risk Factors - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': 'Allergy, Hypersensitivity, and Anaphylaxis', 'entities': []}
{'filename': 'EMA - Abstract 11_ Evaluation of Ketorolac Ceiling Dose Effects in Peds ED Patients - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': 'Evaluation of ketorolac ceiling dose effects in pediatric patients in the emergency department Bindseil I, Soderstrom R, Balmat R. Am J Emerg Med. 2025;89:139-143.', 'entities': []}
{'filename': 'EMA - Abstract 11_ Evaluation of Ketorolac Ceiling Dose Effects in Peds ED Patients - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'section_header', 'text': 'SUMMARY:', 'entities': []}
{'filename': 'EMA - Abstract 11_ Evaluation of Ketorolac Ceiling Dose Effects in Peds ED Patients - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': "Determining the safest, most effective management strategy for pain is an important part of treatment and triage, and suboptimal pain control can have harmful short-term and long-term effects on patients. Ketorolac is highly effective but carries a risk of largely dose-dependent adverse effects. In adults, a 'ceiling effect' is observed, in which ketorolac reaches maximum efficacy after a threshold dose, whereas higher doses add no benefit and only increase the risk of harm from adverse effects. However, such a relationship has not been established among children, for whom the current recommended parenteral dose is 0.5 mg/kg, and the maximum dose is 30 mg.", 'entities': []}
{'filename': 'EMA - Abstract 11_ Evaluation of Ketorolac Ceiling Dose Effects in Peds ED Patients - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': 'This retrospective observational study identified all pediatric patients who had received IV ketorolac monotherapy at a minimum dose of 15 mg, and excluded those taking chronic pain medications and those who had received prior analgesic medications. Data were collected via manual chart review, but few details are provided regarding the data-collection approach and strategy.', 'entities': []}
{'filename': 'EMA - Abstract 11_ Evaluation of Ketorolac Ceiling Dose Effects in Peds ED Patients - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': 'After application of the inclusion and exclusion criteria, 178 patients remained for analysis, 50% receiving a dose capped at 15 mg and 50% receiving a dose above 15 mg. The baseline demographics were similar between groups: the average age was approximately 14.5 years, and two-thirds were girls. The average dose in the higher-dose group was 26.9 mg.', 'entities': []}
{'filename': 'EMA - Abstract 11_ Evaluation of Ketorolac Ceiling Dose Effects in Peds ED Patients - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': 'No between-group differences in any level of pain decrease after medication administration (83% vs 82%) were observed. Additionally, no significant difference was found in the magnitude of pain reduction (4.3 in the 15-mg group vs 3.5 in the group receiving a higher weight-based dose). Interestingly, baseline pain scores for each group are not reported yet are important for understanding the dose-based efficacy estimates. No significant adverse events were reported, and the need for rescue analgesia was low and similar between groups (10.1% vs 12.3%).', 'entities': []}
{'filename': 'EMA - Abstract 11_ Evaluation of Ketorolac Ceiling Dose Effects in Peds ED Patients - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': 'This study is the first to evaluate the presence of a cieling effect for ketorolac in pediatric patients. However, the strength of the conclusions is limited by the retrospective study design, which prevents causal inference; the lack of standardized pain score assessment timing relative to medication administration or rescue interventions; the predominance of adolescent participants, which limits the generalizability of the findings to younger children; and the singlecenter design, which might not reflect broader practice patterns.', 'entities': []}
{'filename': 'EMA - Abstract 11_ Evaluation of Ketorolac Ceiling Dose Effects in Peds ED Patients - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'section_header', 'text': 'PMID:', 'entities': []}
{'filename': 'EMA - Abstract 11_ Evaluation of Ketorolac Ceiling Dose Effects in Peds ED Patients - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': '39729680', 'entities': []}
{'filename': 'EMA - Abstract 11_ Evaluation of Ketorolac Ceiling Dose Effects in Peds ED Patients - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': "EDITOR'S COMMENTARY: This study takes an important first step in optimizing ketorolac-based pain control strategies in pediatric emergency medicine practice by addressing a key knowledge gap in ketorolac dosing. The finding that 15 mg IV ketorolac provided similar pain relief to doses >15 mg aligns with the literature suggesting a ceiling effect in adults but importantly extends this finding to pediatric patients. However, the results should be considered hypothesis generating for now, because of major limitations in study execution and design. Future prospective studies with", 'entities': []}
{'filename': 'EMA - Abstract 11_ Evaluation of Ketorolac Ceiling Dose Effects in Peds ED Patients - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': 'standardized assessment timepoints, broader age ranges, and multiple centers would strengthen the preliminary evidence supporting lower ketorolac doses in pediatric emergency settings.', 'entities': []}
{'filename': 'EMA - Abstract 11_ Evaluation of Ketorolac Ceiling Dose Effects in Peds ED Patients - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'section_header', 'text': 'RELATED CONTENT:', 'entities': []}
{'filename': 'EMA - Abstract 11_ Evaluation of Ketorolac Ceiling Dose Effects in Peds ED Patients - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'section_header', 'text': 'EM:RAP SNACK 2016 December: Just Enough Ketorolac', 'entities': []}
{'filename': 'EMA - Abstract 11_ Evaluation of Ketorolac Ceiling Dose Effects in Peds ED Patients - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'section_header', 'text': 'CorePendium : Ketorolac', 'entities': []}
{'filename': 'EMA - Abstract 11_ Evaluation of Ketorolac Ceiling Dose Effects in Peds ED Patients - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': 'Copyright 2025 by Emergency Medical Abstracts - All Rights Reserved 06/25 - #11', 'entities': []}
{'filename': 'EMA - Abstract 11_ Evaluation of Ketorolac Ceiling Dose Effects in Peds ED Patients - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': 'Tags:', 'entities': []}
{'filename': 'EMA - Abstract 11_ Evaluation of Ketorolac Ceiling Dose Effects in Peds ED Patients - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': 'NSAID Pharmacology', 'entities': []}
{'filename': 'EMA - Abstract 11_ Evaluation of Ketorolac Ceiling Dose Effects in Peds ED Patients - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'section_header', 'text': 'CorePendium Chapters', 'entities': []}
{'filename': 'EMA - Abstract 11_ Evaluation of Ketorolac Ceiling Dose Effects in Peds ED Patients - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'section_header', 'text': 'Ketorolac', 'entities': []}
{'filename': 'EMA - Abstract 7_ HVNI vs NPPV for Moderate COPD Exacerbation in ED - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': 'High-velocity nasal insufflation versus noninvasive positive pressure ventilation for moderate acute exacerbation of chronic obstructive pulmonary disease in the emergency department: a randomized clinical trial Yamane DP, Jones CW, Wilkerson RG, et al. Acad Emerg Med. 2025;32(4):403-413.', 'entities': []}
{'filename': 'EMA - Abstract 7_ HVNI vs NPPV for Moderate COPD Exacerbation in ED - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'section_header', 'text': 'SUMMARY:', 'entities': []}
{'filename': 'EMA - Abstract 7_ HVNI vs NPPV for Moderate COPD Exacerbation in ED - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': 'Standard ED treatment for acute chronic obstructive pulmonary disease (COPD) exacerbation includes oxygen, inhalational bronchodilators, and corticosteroids. For patients with persistent respiratory distress, hypoxemia, or respiratory acidosis, noninvasive positive pressure ventilation (NiPPV) is used. This treatment decreases patient discomfort and the need for intubation. However, because some patients do not tolerate bilevel positive airway pressure, the authors asked whether high-velocity nasal insufflation (HVNI), which provides warm humidified oxygenated air to the nares at a higher rate than possible with a standard nasal cannula, might serve as an alternative. Notably, the recently published RENOVATE trial suggested that HVFI is in fact noninferior across several patient populations with respiratory distress including COPD.', 'entities': []}
{'filename': 'EMA - Abstract 7_ HVNI vs NPPV for Moderate COPD Exacerbation in ED - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': 'This prospective, multicenter, randomized, noninferiority study from 7 EDs in the U.S. enrolled adult patients with COPD with blood gas analysis indicating a partial pressure of carbon dioxide of  60 mm Hg, and serum pH between 7.00 and 7.35. Patients were randomized to receive either NiPPV (initial settings of 10-12 cm H2O end-inspiratory pressure and 5-6 cm H2O endexpiratory pressure, with goal tidal volumes of 6-8 mL/kg ideal body weight) or HVNI (initial flow rate of 30 L/min, FiO2of 0.50) for 4 hours.', 'entities': []}
{'filename': 'EMA - Abstract 7_ HVNI vs NPPV for Moderate COPD Exacerbation in ED - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': 'The study enrolled 73 patients, 5 of whom were excluded after randomization. The mean age was 65.6 years, and the groups were well matched at baseline in terms of the severity of illness and respiratory distress. HVNI was noninferior to NiPPV at the following time points: 30 minutes (Borg dyspnea scale scores, 3.97  2.82 and 4.54  1.65; P = .006), 60 minutes (3.09  2.70 and 4.07  1.77; P <.001), and 4 hours (3.17  2.59 and 3.34  2.04; P = .03). At 4 h, no difference was observed between groups in the partial pressure of carbon dioxide (68.76 and 67.29 mm Hg; P = .63). Patients reported better overall comfort levels in the HVNI group than the NiPPV group at 30 min, 60 min, and 4 hours ( P = .003).', 'entities': []}
{'filename': 'EMA - Abstract 7_ HVNI vs NPPV for Moderate COPD Exacerbation in ED - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': 'Importantly, although no patients were intubated, the patients receiving HVNI rather than NiPPV were more likely to be admitted to the ICU (38% vs 27%); this difference was relatively large but not statistically significant.', 'entities': []}
{'filename': 'EMA - Abstract 7_ HVNI vs NPPV for Moderate COPD Exacerbation in ED - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': 'Although this study has many strengths, including use of largely patient-oriented outcomes and high adherence to treatment rates, several limitations warrant consideration. The primary outcome was subjective, the assessors were not blinded, and substantial conflicts of interest existed among the authors. Moreover, the study population was not as ill as suggested by the overall summary, because although the inclusion criteria allowed for a pH as low as 7.00, only 10% of patients had a pH below 7.20. Finally, the study was not powered to detect rarer serious outcomes such as respiratory arrest and intubation.', 'entities': []}
{'filename': 'EMA - Abstract 7_ HVNI vs NPPV for Moderate COPD Exacerbation in ED - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': 'PMID:', 'entities': []}
{'filename': 'EMA - Abstract 7_ HVNI vs NPPV for Moderate COPD Exacerbation in ED - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': '39663589', 'entities': []}
{'filename': 'EMA - Abstract 7_ HVNI vs NPPV for Moderate COPD Exacerbation in ED - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': 'FULL ARTICLE: https://onlinelibrary.wiley.com/doi/10.1111/acem.15038', 'entities': []}
{'filename': 'EMA - Abstract 7_ HVNI vs NPPV for Moderate COPD Exacerbation in ED - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': "EDITOR'S COMMENTARY: This randomized trial indicated that HVNI was noninferior to NiPPV for managing moderate acute COPD exacerbations in the emergency department. This finding is in line with those from the recently published and much larger RENOVATE trial, but I feel this study has substantial limitations, including its unblinded nature and inclusion of patients with only moderate respiratory distress (not imminent respiratory arrest). The higher ICU admission rate in the HVNI group, although not statistically significant, also deserves further investigation in larger studies. HVNI might be an option, but providers should be vigilant about the need to escalate care.", 'entities': []}
{'filename': 'EMA - Abstract 7_ HVNI vs NPPV for Moderate COPD Exacerbation in ED - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'section_header', 'text': 'RELATED CONTENT:', 'entities': []}
{'filename': 'EMA - Abstract 7_ HVNI vs NPPV for Moderate COPD Exacerbation in ED - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': 'EM:RAP 2020 November: Crit Bits: High Flow Nasal Cannula', 'entities': []}
{'filename': 'EMA - Abstract 7_ HVNI vs NPPV for Moderate COPD Exacerbation in ED - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': 'CorePendium : Approach to Acute Dyspnea and Respiratory Distress', 'entities': []}
{'filename': 'EMA - Abstract 7_ HVNI vs NPPV for Moderate COPD Exacerbation in ED - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': 'CorePendium : Chronic Obstructive Pulmonary Disease', 'entities': []}
{'filename': 'EMA - Abstract 7_ HVNI vs NPPV for Moderate COPD Exacerbation in ED - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': 'CorePendium : Non-Invasive Positive Pressure Ventilation and High-Flow Nasal Cannula', 'entities': []}
{'filename': 'EMA - Abstract 7_ HVNI vs NPPV for Moderate COPD Exacerbation in ED - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': 'Copyright 2025 by Emergency Medical Abstracts - All Rights Reserved 07/25 - #07', 'entities': []}
{'filename': 'EMA - Abstract 7_ HVNI vs NPPV for Moderate COPD Exacerbation in ED - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': 'Tag:', 'entities': []}
{'filename': 'EMA - Abstract 7_ HVNI vs NPPV for Moderate COPD Exacerbation in ED - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': 'Respiratory', 'entities': []}
{'filename': 'EMA - Abstract 7_ HVNI vs NPPV for Moderate COPD Exacerbation in ED - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'section_header', 'text': 'CorePendium Chapters', 'entities': []}
{'filename': 'EMA - Abstract 7_ HVNI vs NPPV for Moderate COPD Exacerbation in ED - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': 'Approach to Acute Dyspnea and Respiratory Distress Chronic Obstructive Pulmonary Disease Non-Invasive Positive Pressure Ventilation and High-Flow Nasal Cannula', 'entities': []}
{'filename': 'EMA - Abstract 8_ Adherence to _Choosing Wisely_ Recommendations in Pediatric Care - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': "Adherence to 'Choosing Wisely' recommendations in pediatric emergency medicine Corcoran TF, Ramgopal S, Hoffmann JA, et al. Published online Ann Emerg Med. March 17, 2025. doi:10.1016/j.annemergmed.2025.02.004", 'entities': []}
{'filename': 'EMA - Abstract 8_ Adherence to _Choosing Wisely_ Recommendations in Pediatric Care - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'section_header', 'text': 'SUMMARY:', 'entities': []}
{'filename': 'EMA - Abstract 8_ Adherence to _Choosing Wisely_ Recommendations in Pediatric Care - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': "The Choosing Wisely campaign has targeted several 'low-value' tests in a variety of fields. In 2022, 5 diagnostic tests relevant to pediatric emergency medicine were identified as targets for the Choosing Wisely campaign: (1) x-rays for respiratory tract infections, (2) laboratory screening for psychiatric medical clearance, (3) laboratory testing or head CT for unprovoked generalized seizures or simple febrile seizures with return to baseline mental status, (4) abdominal radiographs for suspected constipation, and (5) comprehensive viral panels for suspected respiratory viral illness.", 'entities': []}
{'filename': 'EMA - Abstract 8_ Adherence to _Choosing Wisely_ Recommendations in Pediatric Care - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': 'The aim of this study was to determine how often these low-value tests are performed. The study used emergency department data from 8 states from 2014 to 2020. Importantly, the data came from administrative/billing data rather than any form of clinical chart review.', 'entities': []}
{'filename': 'EMA - Abstract 8_ Adherence to _Choosing Wisely_ Recommendations in Pediatric Care - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': 'Children <18 years of age were included if they had 1 of the aforementioned diagnostic codes and were excluded under certain circumstances. For example, a diagnosis code of generalized seizure would have led to inclusion, but a concurrent diagnosis of trauma or age <180 days would have led to exclusion.', 'entities': []}
{'filename': 'EMA - Abstract 8_ Adherence to _Choosing Wisely_ Recommendations in Pediatric Care - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': 'During the study period, 6,778,296 visits for the conditions of interest were recorded across participating states. After application of the exclusion criteria, 5,628,276 visits were included in the analysis.', 'entities': []}
{'filename': 'EMA - Abstract 8_ Adherence to _Choosing Wisely_ Recommendations in Pediatric Care - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': 'Low-value testing occurred in 1,088,845 (19.3%) visits, including 31% of respiratory illness visits, 17% of mental or behavioral visits, 43% of seizure visits, 66% of constipation visits, and 3% of respiratory viral illness visits. No consistent relationship was observed between the proportion of visits with a low-value test performed and the volume of pediatric cases in the EDs.', 'entities': []}
{'filename': 'EMA - Abstract 8_ Adherence to _Choosing Wisely_ Recommendations in Pediatric Care - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': 'Temporal analysis indicated that the rates of testing for these conditions were fairly consistent from 2014 to 2020, except for viral respiratory panel testing, which increased.', 'entities': []}
{'filename': 'EMA - Abstract 8_ Adherence to _Choosing Wisely_ Recommendations in Pediatric Care - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': 'The authors propose benchmark testing levels based on the top performing 10% of hospitals (4% for chest x-ray in respiratory illness, 0% for laboratory testing in mental health cases, 8% for seizures, 16% for constipation, and 0% for viral panel testing).', 'entities': []}
{'filename': 'EMA - Abstract 8_ Adherence to _Choosing Wisely_ Recommendations in Pediatric Care - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': 'The testing estimates might be questionable for several reasons. Most importantly, the testing might well have been necessary to rule out other serious conditions; however, in such cases, the testing might have appeared to have been performed for nonserious conditions. In a simple example, for respiratory tract infections, if a chest x-ray had been performed and indicated pneumonia, the child would have been diagnosed with pneumonia and not included in this cohort. In addition, the measure of head CT for seizure is problematic, because the Choosing Wisely campaign specifically states that a head CT for new seizure is OK, but the data did not indicate whether children were scanned for a first-time seizure vs a known seizure disorder. Most of the biases would have inflated the estimate of low-value testing. Overall, I believe that this analysis overestimates the clinical significance of this problem.', 'entities': []}
{'filename': 'EMA - Abstract 8_ Adherence to _Choosing Wisely_ Recommendations in Pediatric Care - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': "EDITOR'S COMMENTARY: This analysis of large statewide administrative data sets ostensibly shows that around 20% of ED visits for low-risk conditions result in low-value testing. I believe that these findings are overestimates, because the methods could not determine whether the test was initially indicated to rule out a more serious condition. So, although I do believe that low-value testing is a problem in adult and pediatric emergency medicine, I have little confidence that these estimates reflect the true incidence of such testing or really provide significant estimates of the potential benefit of full-scale adoption of the Choosing Wisely campaign.", 'entities': []}
{'filename': 'EMA - Abstract 8_ Adherence to _Choosing Wisely_ Recommendations in Pediatric Care - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': 'Copyright 2025 by Emergency Medical Abstracts - All Rights Reserved 06/25 - #08', 'entities': []}
{'filename': 'EMA - Abstract 8_ Adherence to _Choosing Wisely_ Recommendations in Pediatric Care - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'caption', 'text': 'Tags: Decision Instruments Imaging', 'entities': []}
{'filename': 'EMA - Abstract 15_ Single-Dose Corticosteroid for Early Intussusception - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': 'Successful treatment of early presenting intussusception with a single dose of corticosteroid: a prospective randomized controlled trial Acer-Demir T, Gltekingil A, Fako  lu E, et al. J Pediatr Surg. 2025;60(4):162198.', 'entities': []}
{'filename': 'EMA - Abstract 15_ Single-Dose Corticosteroid for Early Intussusception - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'section_header', 'text': 'SUMMARY:', 'entities': []}
{'filename': 'EMA - Abstract 15_ Single-Dose Corticosteroid for Early Intussusception - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': 'Although some subtypes of intussusceptions resolve spontaneously over observation, ileocolic intussusceptions usually require hydrostatic or pneumatic reduction, or surgical intervention. Several studies have concluded that corticosteroids might decrease recurrence after reduction, and a few studies, primarily case reports, have suggested that corticosteroids might actually serve as a primary treatment by mitigating inflammation and edema.', 'entities': []}
{'filename': 'EMA - Abstract 15_ Single-Dose Corticosteroid for Early Intussusception - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': 'This prospective randomized study from Turkey enrolled patients 0 to 4 years old who were diagnosed with intussusception in the ED via ultrasound and had a symptom duration <24 hours. Critically ill patients and those receiving emergent surgery were excluded. Most of the overall standard care was not protocolized, but patients randomized to the intervention received a single intravenous dose of methylprednisolone (1 mg/kg). The primary outcome of interest was resolution of the intussusception at 4 hours, assessed through repeat ultrasound.', 'entities': []}
{'filename': 'EMA - Abstract 15_ Single-Dose Corticosteroid for Early Intussusception - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': 'The methods section provides details regarding some important aspects, such as the randomization strategy, but is missing other important information, such as enrollment rates and whether a convenience or consecutive sample was used. The study was stopped early at an interim analysis, because the findings favored the steroid group. At that point, the enrollment was asymmetric, comprising 60 children in the intervention group and 32 children in the control group. The groups differed in other important aspects, such as intussusception type/location. Steroid treatment was successful in 49 of 60 cases (81.7%), whereas no treatment was successful in 18 of 32 cases (56.3%; P = .009). For ileocolic intussusceptions, steroid treatment was successful in 17 of 22 cases (77.3%), compared with 2 of 9 cases (22.2%) in the control group ( P = .012).', 'entities': []}
{'filename': 'EMA - Abstract 15_ Single-Dose Corticosteroid for Early Intussusception - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': 'The authors conclude that steroids do work; however, many limitations must be considered. This nonblinded study used a somewhat subjective outcome assessment; a massive failure of randomization occurred; the enrollment strategy is not well described, thus influencing the generalizability of the findings; and the probability of confounding was high.', 'entities': []}
{'filename': 'EMA - Abstract 15_ Single-Dose Corticosteroid for Early Intussusception - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': 'Thus, the study is thought-provoking but far from definitive.', 'entities': []}
{'filename': 'EMA - Abstract 15_ Single-Dose Corticosteroid for Early Intussusception - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'section_header', 'text': 'PMID:', 'entities': []}
{'filename': 'EMA - Abstract 15_ Single-Dose Corticosteroid for Early Intussusception - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': '39914152', 'entities': []}
{'filename': 'EMA - Abstract 15_ Single-Dose Corticosteroid for Early Intussusception - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': "EDITOR'S COMMENTARY: In this randomized trial from Turkey, the authors suggest that a single IV dose of methylprednisolone might help resolve cases of intussusception and significantly decrease the need for more invasive treatments. This is the first trial testing this idea. Although the underlying pathophysiology does make some sense, the study has too many weaknesses in its design and execution to be considered anything but hypothesis generating. I'm not going to incorporate steroids into my practice, but if a specialist were to ask for steroids to be given, I would have no issue with it, and now I know why specialists might ask for them.", 'entities': []}
{'filename': 'EMA - Abstract 15_ Single-Dose Corticosteroid for Early Intussusception - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'section_header', 'text': 'RELATED CONTENT:', 'entities': []}
{'filename': 'EMA - Abstract 15_ Single-Dose Corticosteroid for Early Intussusception - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'section_header', 'text': 'CorePendium : Intussusception', 'entities': []}
{'filename': 'EMA - Abstract 15_ Single-Dose Corticosteroid for Early Intussusception - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': 'Copyright 2025 by Emergency Medical Abstracts - All Rights Reserved 07/25 - #15', 'entities': []}
{'filename': 'EMA - Abstract 15_ Single-Dose Corticosteroid for Early Intussusception - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': 'Tags:', 'entities': []}
{'filename': 'EMA - Abstract 15_ Single-Dose Corticosteroid for Early Intussusception - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'code', 'text': 'Gastrointestinal Pharmacology', 'entities': []}
{'filename': 'EMA - Abstract 15_ Single-Dose Corticosteroid for Early Intussusception - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'section_header', 'text': 'CorePendium Chapters', 'entities': []}
{'filename': 'EMA - Abstract 15_ Single-Dose Corticosteroid for Early Intussusception - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': 'Intussusception', 'entities': []}
{'filename': 'EMA - Abstract 17_ Benefit of AI-Based Fracture Detection in a Pediatric ED - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': 'Real-life benefit of artificial intelligence-based fracture detection in a pediatric emergency department Ziegner M, Pape J, Lacher M, et al. Eur Radiol. Published online April 7, 2025. doi:10.1007/s00330-025-11554-9', 'entities': []}
{'filename': 'EMA - Abstract 17_ Benefit of AI-Based Fracture Detection in a Pediatric ED - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'section_header', 'text': 'SUMMARY:', 'entities': []}
{'filename': 'EMA - Abstract 17_ Benefit of AI-Based Fracture Detection in a Pediatric ED - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': 'Reading pediatric plain films is challenging, because the fracture patterns markedly differ from those in adults: in children, normal architecture can appear as avulsions, and growth plates can mimic fracture lines. The clinical consequences of missed fractures in children are often severe and may potentially result in long-term complications, such as restricted joint mobility or impaired growth, as well as substantial medicolegal implications.', 'entities': []}
{'filename': 'EMA - Abstract 17_ Benefit of AI-Based Fracture Detection in a Pediatric ED - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': "RBFracture is an AI software explicitly trained on children's x-rays to detect fractures. In this prospective study, the authors evaluated RBFracture's standalone performance in a pediatric 'real-life' cohort and in a set of selected medicolegally relevant fractures. In addition, they evaluated the influence of AI assistance on the diagnostic performance of inexperienced residents in (1) a 'real-life' cohort, comprising a consecutive sample of 1,672 x-rays obtained over a 6-month period for trauma at a single pediatric ED in Germany and (2) a medicolegal cohort comprising a separate set of radiographs from children with 1 of 3 pediatric-specific fracture types, which were retrospectively identified from the institutional radiological information system from 2008 to 2023. All films were read by the AI, 3 residents (2 in surgery and 1 in radiology), and attending physicians. Follow-up imaging and clinical follow-up served as the gold standard.", 'entities': []}
{'filename': 'EMA - Abstract 17_ Benefit of AI-Based Fracture Detection in a Pediatric ED - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': "In the cohort (median patient age, 10.9 years; 59% boys), the AI demonstrated an overall sensitivity of 92%, specificity of 83%, and accuracy of 87%. However, the individual test characteristics markedly varied across body regions. For example, the foot and ankle had a relatively low accuracy of 80%. For medicolegally relevant fractures, the test characteristics showed even greater variation across fracture types: the AI achieved a sensitivity of 100% for proximal tibia fractures but only 68% for radial condyle fractures. AI assistance increased the residents' sensitivity from 84% to 87%, specificity from 91% to 92%, and diagnostic accuracy from 88% to 90%. However, in 1.5% of cases, the residents erroneously changed their initially correct diagnoses after receiving the AI interpretation. No significant difference was observed between first-year pediatric surgical and radiology residents ( P <.05).", 'entities': []}
{'filename': 'EMA - Abstract 17_ Benefit of AI-Based Fracture Detection in a Pediatric ED - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': 'The study\'s strength is in its large sample size (1,672 radiographs) and use of a pragmatic reallife cohort rather than artificially stratified samples. One limitation is that the providers were residents, and how having the AI reads might have influenced the confidence or accuracy of more seasoned providers is unknown. Overall, the influence of the study might be quite high, because some EDs are already using AI to aid in reading x-rays. Consequently, awareness of the potential effects on real-world practice is important. Overall, the authors conclude that, although the technology shows promise by providing "a second set of eyes," emergency departments would need to carefully weigh the modest accuracy gains against the implementation costs.', 'entities': []}
{'filename': 'EMA - Abstract 17_ Benefit of AI-Based Fracture Detection in a Pediatric ED - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': 'PMID:', 'entities': []}
{'filename': 'EMA - Abstract 17_ Benefit of AI-Based Fracture Detection in a Pediatric ED - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': '40192806', 'entities': []}
{'filename': 'EMA - Abstract 17_ Benefit of AI-Based Fracture Detection in a Pediatric ED - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': 'FULL ARTICLE: https://link.springer.com/article/10.1007/s00330-025-11554-9', 'entities': []}
{'filename': 'EMA - Abstract 17_ Benefit of AI-Based Fracture Detection in a Pediatric ED - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': "EDITOR'S COMMENTARY: This study offers valuable insights into the practical implementation of AI for fracture detection in pediatric settings. Although the AI system (RBFracture) showed strong standalone performance (92% sensitivity, 83% specificity, and 87% accuracy), the actual clinical benefit for inexperienced physicians was modest and increased the diagnostic accuracy by only 2.6%. This limited improvement prompts important questions about cost-effectiveness in real-world emergency departments, where resources are often constrained. The finding that the AI occasionally led physicians to incorrectly change their initially correct diagnoses (1.5% of cases) also highlights the importance of maintaining clinical judgment alongside technological assistance in fast-paced emergency settings.", 'entities': []}
{'filename': 'EMA - Abstract 17_ Benefit of AI-Based Fracture Detection in a Pediatric ED - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'section_header', 'text': 'RELATED CONTENT:', 'entities': []}
{'filename': 'EMA - Abstract 17_ Benefit of AI-Based Fracture Detection in a Pediatric ED - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'section_header', 'text': 'CorePendium : Approach to Pediatric Orthopedic Injuries', 'entities': []}
{'filename': 'EMA - Abstract 17_ Benefit of AI-Based Fracture Detection in a Pediatric ED - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': 'Copyright 2025 by Emergency Medical Abstracts - All Rights Reserved 07/25 - #17', 'entities': []}
{'filename': 'EMA - Abstract 17_ Benefit of AI-Based Fracture Detection in a Pediatric ED - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': 'Tag:', 'entities': []}
{'filename': 'EMA - Abstract 17_ Benefit of AI-Based Fracture Detection in a Pediatric ED - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': 'Pediatric X-ray', 'entities': []}
{'filename': 'EMA - Abstract 17_ Benefit of AI-Based Fracture Detection in a Pediatric ED - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'section_header', 'text': 'CorePendium Chapters', 'entities': []}
{'filename': 'EMA - Abstract 17_ Benefit of AI-Based Fracture Detection in a Pediatric ED - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': 'Approach to Pediatric Orthopedic Injuries', 'entities': []}
{'filename': 'EMA - Time to Talk a Little Nerdy_ Network Meta-Analysis - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': 'Introducing the all-new EM:RAP CME experience. Meticulously crafted from the ground up for speed and simplicity. Welcome to a future where meeting your CME needs is faster and easier than ever imagined.', 'entities': []}
{'filename': 'EMA - Time to Talk a Little Nerdy_ Network Meta-Analysis - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'section_header', 'text': 'LEARN MORE', 'entities': []}
{'filename': 'EMA - Time to Talk a Little Nerdy_ Network Meta-Analysis - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': 'Search EMA Episodes', 'entities': []}
{'filename': 'EMA - Time to Talk a Little Nerdy_ Network Meta-Analysis - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'section_header', 'text': 'EMA 2025 July', 'entities': []}
{'filename': 'EMA - Time to Talk a Little Nerdy_ Network Meta-Analysis - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': 'July 2025', 'entities': []}
{'filename': 'EMA - Time to Talk a Little Nerdy_ Network Meta-Analysis - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'section_header', 'text': 'Time to Talk a Little Nerdy: Network Meta-Analysis', 'entities': []}
{'filename': 'EMA - Time to Talk a Little Nerdy_ Network Meta-Analysis - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'section_header', 'text': 'EMA 2025 July', 'entities': []}
{'filename': 'EMA - Time to Talk a Little Nerdy_ Network Meta-Analysis - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': '24 Chapters', 'entities': []}
{'filename': 'EMA - Time to Talk a Little Nerdy_ Network Meta-Analysis - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': 'In this episode of "Time to Talk a Little Nerdy," Ken and Swami break down Network Meta-Analysis (NMA) - a powerful statistical tool that lets researchers compare multiple treatments at once, even when they haven\'t been directly tested against each other. They explain how NMAs work, their benefits over traditional meta-analyses, and their limitations. Plus, they look at a real-world example', 'entities': []}
{'filename': 'EMA - Time to Talk a Little Nerdy_ Network Meta-Analysis - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': "comparing fever treatments for kids. If you've ever wondered how doctors figure out which treatment is best when there's no direct comparison, this episode is for you!", 'entities': []}
{'filename': 'EMA - Time to Talk a Little Nerdy_ Network Meta-Analysis - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'section_header', 'text': 'Time to Talk a Little Nerdy', 'entities': []}
{'filename': 'EMA - Time to Talk a Little Nerdy_ Network Meta-Analysis - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'section_header', 'text': 'Network Meta-Analysis', 'entities': []}
{'filename': 'EMA - Time to Talk a Little Nerdy_ Network Meta-Analysis - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': 'This month, we are tackling a request from our executive producer, EJ Barnes. She noted that Mike and Sanjay have discussed a couple of network meta-analyses (NMAs) in the past year, and that we should discuss a bit about what an NMA is.', 'entities': []}
{'filename': 'EMA - Time to Talk a Little Nerdy_ Network Meta-Analysis - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': 'Way back in December 2020, on Time to Talk a Little Nerdy, we got deep into systematic reviews and meta-analyses (SRMAs). Folks should pop back and check that discussion out. In brief, the benefit of SRMAs is that they can synthesize vast amounts of data to help inform clinical decision-making. A good SRMA follows the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, and rigorously collects and evaluates multiple studies on a given topic.[1] SRMAs provide a structured way to summarize the evidence without a need to read each study on the topic. Thus, a well-conducted systematic review must follow rigorous methodological criteria, including comprehensive literature searches, risk-of-bias assessments, and appropriate statistical analyses, to ensure credible and meaningful results  .', 'entities': []}
{'filename': 'EMA - Time to Talk a Little Nerdy_ Network Meta-Analysis - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': "We do need to recognize the limitations of SRMAs. If the primary studies included have methodological flaws, these flaws can be propagated and magnified in the meta-analysis  . This phenomenon is called 'garbage in, garbage out' (GIGO). A few well-done randomized controlled trials (RCTs) on a topic can be superior to a poorly done SRMA that contains only observational data.", 'entities': []}
{'filename': 'EMA - Time to Talk a Little Nerdy_ Network Meta-Analysis - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': 'An NMA is an advanced statistical technique that allows for the comparison of multiple treatments simultaneously, even if some treatments have never been directly compared in a head-to-head trial.[2] It extends traditional meta-analysis by using a network of direct and indirect evidence to estimate relative treatment effects. This method is particularly useful in medicine when multiple treatment options exist, by helping to rank interventions according to their effectiveness and safety.', 'entities': []}
{'filename': 'EMA - Time to Talk a Little Nerdy_ Network Meta-Analysis - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': 'In a traditional pairwise meta-analysis, researchers compare only 2 treatments at a time, according to direct-evidence studies. However, in real-world clinical decision-making, multiple treatment options are often available for a condition, and not all of them have been directly compared in a study. This is where NMA can become valuable.', 'entities': []}
{'filename': 'EMA - Time to Talk a Little Nerdy_ Network Meta-Analysis - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': 'How NMAs enable multiple comparisons:', 'entities': []}
{'filename': 'EMA - Time to Talk a Little Nerdy_ Network Meta-Analysis - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': 'Direct comparisons : If 2 treatments (eg, A vs B) have been tested in RCTs, their effect sizes can be directly compared.', 'entities': []}
{'filename': 'EMA - Time to Talk a Little Nerdy_ Network Meta-Analysis - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': 'Indirect comparisons : If no direct RCTs have compared 2 treatments (eg, A vs C), but both have been compared with a common comparator (B), NMA can use statistical methods to infer their relative effects (A vs C) through indirect evidence.', 'entities': []}
{'filename': 'EMA - Time to Talk a Little Nerdy_ Network Meta-Analysis - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': 'Mixed evidence (direct and indirect) : When direct and indirect comparisons are available, NMA integrates both sources of evidence to increase precision.', 'entities': []}
{'filename': 'EMA - Time to Talk a Little Nerdy_ Network Meta-Analysis - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': 'A key advantage of NMAs is that they not only estimate treatment effects but also rank treatments by effectiveness or safety. Outputs such as surface under the cumulative ranking (SUCRA) curves are provided, which can help identify the most effective or safest option.[3]', 'entities': []}
{'filename': 'EMA - Time to Talk a Little Nerdy_ Network Meta-Analysis - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': 'One notable aspect of NMAs is that they require consistency in the data being incorporated. This consistency is different from heterogeneity in a traditional SRMA.', 'entities': []}
{'filename': 'EMA - Time to Talk a Little Nerdy_ Network Meta-Analysis - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': 'Heterogeneity in SRMAs refers to differences in study characteristics, such as variations in patient populations, interventions, study designs, or outcomes measured. This heterogeneity occurs within direct comparisons of treatments and can lead to variability in the effect estimates from different studies.', 'entities': []}
{'filename': 'EMA - Time to Talk a Little Nerdy_ Network Meta-Analysis - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': 'Inconsistency, in contrast, is a specific issue in NMAs that arises when direct and indirect evidence provides conflicting results. In other words, if an NMA suggests that treatment A is better than treatment B, according to direct comparisons, but indirect comparisons through a common comparator (eg, treatment C) suggest the opposite, inconsistency exists in the network. This inconsistency can indicate potential biases, differences in study populations, or methodological issues that must be addressed before the results can be trusted  .', 'entities': []}
{'filename': 'EMA - Time to Talk a Little Nerdy_ Network Meta-Analysis - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': "Whereas heterogeneity is a broader concept that applies to variability within studies, inconsistency is a specific challenge in NMAs that arises when different sources of evidence within the network do not align. Both aspects must be assessed carefully to ensure the validity of an NMA's conclusions.", 'entities': []}
{'filename': 'EMA - Time to Talk a Little Nerdy_ Network Meta-Analysis - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': "NMAs have several advantages over traditional systematic reviews and pairwise meta-analyses. The main benefit, which we have mentioned, is that NMAs enable simultaneous comparison of multiple treatments, even when direct head-to-head trials are lacking. Another key advantage is their enhanced statistical power and precision: by synthesizing evidence from a broader set of studies, NMAs often provide more reliable effect estimates and narrower confidence intervals than individual studies or pairwise meta-analyses. Consequently, treatment differences that might not be evident in smaller direct comparisons may be detected. NMAs also help rank treatments by efficacy and safety, thus providing clinicians and policymakers with clear, actionable insights. Instead of simply concluding whether 1 treatment is superior to another, NMAs generate rankings that can guide treatment choices according to each intervention's probability of being the most effective or safest option  . A fourth potential benefit is that NMAs may increase the generalizability of findings by incorporating a wider range of studies and patient populations. This broader evidence base can increase the results' external validity and applicability to real-world clinical practice  .", 'entities': []}
{'filename': 'EMA - Time to Talk a Little Nerdy_ Network Meta-Analysis - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': 'NMAs have several limitations common to SRMAs, such as GIGO, publication bias, and selection bias. A specific major limitation of the NMA study design is the requirement for transitivity,[4] in which all treatments being compared must be sufficiently similar across the included studies. If the patient populations, study designs, or outcome measures substantially differ among trials, the indirect comparisons made in an NMA may be biased or misleading  .', 'entities': []}
{'filename': 'EMA - Time to Talk a Little Nerdy_ Network Meta-Analysis - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': 'Another challenge is inconsistency, which occurs when direct and indirect evidence lead to conflicting conclusions. If studies comparing treatment A vs treatment B yield different results from', 'entities': []}
{'filename': 'EMA - Time to Talk a Little Nerdy_ Network Meta-Analysis - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': 'those inferred from indirect comparisons via treatment C, methodological differences, biases, or unmeasured confounders may be affecting the network  .', 'entities': []}
{'filename': 'EMA - Time to Talk a Little Nerdy_ Network Meta-Analysis - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': 'Statistical complexity is another major barrier. Conducting and interpreting an NMA requires advanced modeling techniques, assumptions about treatment relationships, and careful handling of heterogeneity. Many clinicians and policymakers may find NMAs difficult to interpret without expert guidance  .', 'entities': []}
{'filename': 'EMA - Time to Talk a Little Nerdy_ Network Meta-Analysis - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': "In January, Mike and Sanjay covered 2 NMAs. The first was Paper #5: 'Short-Term Dual Therapy or Monotherapy with Acetaminophen and Ibuprofen for Fever: a Network Meta-Analysis.' [5] The authors of this NMA aimed to evaluate the comparative efficacy and safety of acetaminophen, ibuprofen, and dual therapy (combined or alternating) in decreasing discomfort and temperature in children with fever with a presumed infectious origin  . Combined acetaminophen/NSAID therapy was superior to alternating therapy, which in turn was superior to high-dose ibuprofen, which in turn was superior to acetaminophen alone.", 'entities': []}
{'filename': 'EMA - Time to Talk a Little Nerdy_ Network Meta-Analysis - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': 'NMA was an appropriate methodological choice for this topic, because a standard pairwise SRMA would have enabled direct comparisons between only 2 treatments at a time, whereas the NMA allowed for both direct and indirect comparisons. The NMA also generated a ranking of treatment efficacy to help clinicians choose the best option  .', 'entities': []}
{'filename': 'EMA - Time to Talk a Little Nerdy_ Network Meta-Analysis - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': 'Until next month, stay nerdy!', 'entities': []}
{'filename': 'EMA - Time to Talk a Little Nerdy_ Network Meta-Analysis - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'section_header', 'text': 'RELATED CONTENT:', 'entities': []}
{'filename': 'EMA - Time to Talk a Little Nerdy_ Network Meta-Analysis - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': 'EMA 2025 January Abstract 5: Dual vs Mono Therapy with Acetaminophen and Ibuprofen for Fever', 'entities': []}
{'filename': 'EMA - Time to Talk a Little Nerdy_ Network Meta-Analysis - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': 'EMA 2020 December: Time To Talk A Little Nerdy: Systematic Review and Meta-Analyses', 'entities': []}
{'filename': 'EMA - Time to Talk a Little Nerdy_ Network Meta-Analysis - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'section_header', 'text': 'REFERENCES:', 'entities': []}
{'filename': 'EMA - Time to Talk a Little Nerdy_ Network Meta-Analysis - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': '[1] Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.', 'entities': []}
{'filename': 'EMA - Time to Talk a Little Nerdy_ Network Meta-Analysis - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': '[2] Chaimani A, Caldwell DM, Li T, et al. Chapter 11: Undertaking network meta-analyses [last updated October 2019]. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, eds. Cochrane Handbook for Systematic Reviews of Interventions. Version 6.5. Cochrane; 2024.', 'entities': []}
{'filename': 'EMA - Time to Talk a Little Nerdy_ Network Meta-Analysis - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': 'Salanti G, Nikolakopoulou A, Efthimiou O, et al. Introducing the treatment hierarchy question in network meta-analysis. Am J Epidemiol. 2022; 191(5):930-938.', 'entities': []}
{'filename': 'EMA - Time to Talk a Little Nerdy_ Network Meta-Analysis - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': 'Spineli LM, Kalyvas C, Yepes-Nuez JJ, et al. Low awareness of the transitivity assumption in complex networks of interventions: a systematic survey from 721 network meta-analyses. BMC Med.', 'entities': []}
{'filename': 'EMA - Time to Talk a Little Nerdy_ Network Meta-Analysis - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': '2024;22(1):112.', 'entities': []}
{'filename': 'EMA - Time to Talk a Little Nerdy_ Network Meta-Analysis - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': '[5] De la Cruz-Mena JE, Veroniki AA, Acosta-Reyes J, et al. Short-term dual therapy or mono therapy with acetaminophen and ibuprofen for fever: a network meta-analysis. Pediatrics. 2024;154(4):e2023065390.', 'entities': []}
{'filename': 'EMA - Abstract 19_ Therapy Dogs for Anxiety in Children in the Emergency Department - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': 'Therapy dogs for anxiety in children in the emergency department: a randomized clinical trial Kelker HP, Siddiqui HK, Beck AM, et al. JAMA Netw Open. 2025;8(3):e250636.', 'entities': []}
{'filename': 'EMA - Abstract 19_ Therapy Dogs for Anxiety in Children in the Emergency Department - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'section_header', 'text': 'SUMMARY:', 'entities': []}
{'filename': 'EMA - Abstract 19_ Therapy Dogs for Anxiety in Children in the Emergency Department - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': "The ED can be a stressful and anxiety-provoking place, particularly for young children with a history of anxiety. To improve child and parental experiences, pediatric EDs often employ certified child-life specialists to help mitigate children's fear and anxiety, by using play therapy, visual and auditory distractions, and other situationally appropriate techniques at developmentally appropriate levels.", 'entities': []}
{'filename': 'EMA - Abstract 19_ Therapy Dogs for Anxiety in Children in the Emergency Department - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': 'This single-center, randomized clinical trial evaluated the effectiveness of usual care from a child-life specialist plus approximately 10 minutes with a therapy dog and handler, compared with care from a child-life specialist alone, on the patient-reported outcome of anxiety. Patients 5 to 17 years of age with moderate to high anxiety, according to the Faces Pain Scale, were approached for enrollment. The study excluded patients with a medical emergency and those with violent behavior. All children received standard child-life therapy (eg, age-appropriate explanations, distraction, and comfort) and were randomized to receive either no additional procedures (control) or added exposure to a therapy dog and handler for approximately 10 minutes (intervention).', 'entities': []}
{'filename': 'EMA - Abstract 19_ Therapy Dogs for Anxiety in Children in the Emergency Department - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': 'The study enrolled and randomized 80 patients with a mean age of 10.9 years. At baseline, the mean (SD) Faces Pain Scale scores were 5.4 (2.8) in child reports and 6.4 (2.4) in parent reports. At 45 minutes, child anxiety decreased in both groups, with a mean (SD) change of -1.5 (3.4) points in the control group vs -2.7 (2.5) points in the intervention group ( P = .02, Mann-Whitney U test), with respect to baseline. Similarly, parental reports of child anxiety changed by a mean (SD) of -1.8 (2.7) points in the control group vs -3.2 (2.3) points in the intervention group ( P = .008). A greater than 2.5-point decrease in the Faces Pain Scale score was observed in 9 children (23%) in the control group vs 18 children (46%) in the intervention group ( P = .04).', 'entities': []}
{'filename': 'EMA - Abstract 19_ Therapy Dogs for Anxiety in Children in the Emergency Department - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': "To provide an objective measure, the authors determined salivary cortisol levels. Child and parent salivary cortisol decreased from baseline to 45 minutes in both groups but did not differ between groups. Perhaps unsurprisingly, the parents' salivary cortisol was consistently significantly higher than their children's salivary cortisol.", 'entities': []}
{'filename': 'EMA - Abstract 19_ Therapy Dogs for Anxiety in Children in the Emergency Department - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': 'The authors also assessed chemical sedation, which was used less frequently in the intervention group than the control group (35% vs 18%).', 'entities': []}
{'filename': 'EMA - Abstract 19_ Therapy Dogs for Anxiety in Children in the Emergency Department - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': "Overall, this well-done trial used sound methods, with a randomized design, appropriate outcome measures, and inclusion of both subjective (Faces Pain Scale) and objective (salivary cortisol) metrics. The limitations were reasonable and included the inability to blind participants and the findings' generalizability to only facilities with existing therapy-dog programs.", 'entities': []}
{'filename': 'EMA - Abstract 19_ Therapy Dogs for Anxiety in Children in the Emergency Department - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': 'This study meaningfully contributes to pediatric emergency medicine by providing evidence that therapy dogs can decrease anxiety in children seeking emergency care.', 'entities': []}
{'filename': 'EMA - Abstract 19_ Therapy Dogs for Anxiety in Children in the Emergency Department - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'section_header', 'text': 'PMID: 40085085', 'entities': []}
{'filename': 'EMA - Abstract 19_ Therapy Dogs for Anxiety in Children in the Emergency Department - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': 'FULL ARTICLE: https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2831511', 'entities': []}
{'filename': 'EMA - Abstract 19_ Therapy Dogs for Anxiety in Children in the Emergency Department - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': "EDITOR'S COMMENTARY: In this well-done randomized trial, the authors observed a statistically significant but modest decrease in anxiety with therapy-dog exposure vs standard care from a childlife specialist alone, among children in the ED with moderate to high baseline levels of anxiety. The potential decrease in chemical sedation (35% vs 18%) is interesting (although not statistically significant), because it might translate to fewer medication-related adverse events, shorter ED stays, and improved resource utilization. Future research should examine the cost-effectiveness of implementing therapy-dog programs, as well as their effects on specific high-risk populations, such as children with developmental or psychiatric disorders. Overall, this study supports a low-risk, nonpharmacologic intervention that may improve the pediatric emergency care experience for both children and their caregivers.", 'entities': []}
{'filename': 'EMA - Abstract 19_ Therapy Dogs for Anxiety in Children in the Emergency Department - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': 'Copyright 2025 by Emergency Medical Abstracts - All Rights Reserved 06/25 - #19', 'entities': []}
{'filename': 'EMA - Abstract 15_ Vapocoolant Spray vs Lidocaine-Prilocaine for IV Cannulation Pain - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': 'Comparison of the effects of vapocoolant spray and topical anaesthetic cream (lidocaine-prilocaine) on pain of intravenous cannulation: a randomised controlled trial Akhgar A, Mazidabadi Farahani A, Akbari H, et al. Emerg Med J. Published online March 21, 2025. doi:10.1136/emermed-2024-214479', 'entities': []}
{'filename': 'EMA - Abstract 15_ Vapocoolant Spray vs Lidocaine-Prilocaine for IV Cannulation Pain - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'section_header', 'text': 'SUMMARY:', 'entities': []}
{'filename': 'EMA - Abstract 15_ Vapocoolant Spray vs Lidocaine-Prilocaine for IV Cannulation Pain - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': 'Promising methods to decrease pain in peripheral IV placement include (1) lidocaine-prilocaine cream (2.5% lidocaine and 2.5% prilocaine), which can be applied to the skin and produces local anesthesia within 30 to 45 minutes, and (2) cold vapocoolant spray, which temporarily decreases the skin temperature and desensitizes pain receptors. This study performed a headto-head comparison of the efficacy of these 2 methods.', 'entities': []}
{'filename': 'EMA - Abstract 15_ Vapocoolant Spray vs Lidocaine-Prilocaine for IV Cannulation Pain - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': 'This randomized, nonblinded trial, conducted at a single ED in Iran, enrolled a consecutive sample of adult patients requiring IV placement. All IVs were placed by nurses with at least 3 years of experience, who were allowed to choose the anatomical location of the line. The vapocoolant group received a 5-second spray just before line placement. The cream group received 2.5% lidocaine and 2.5% prilocaine cream applied to a 2  2 cm area, which was covered with an occlusive dressing, 45 minutes before line placement.', 'entities': []}
{'filename': 'EMA - Abstract 15_ Vapocoolant Spray vs Lidocaine-Prilocaine for IV Cannulation Pain - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': 'The study enrolled 80 patients. More than 80% of the lines in both groups were placed in the antecubital fossa. The median cannulation pain score was 2 (IQR, 2-3) in the vapocoolant group and 3 (IQR, 2-3) in the cream group. Although the difference was statistically significant ( P = .04), after adjustment for baseline pain at presentation, no significant differences were observed between groups ( P = .09). Moreover, the difference was not clinically significant, even in the raw numbers. Adverse events were much more frequent in the cream group (56% vs 2.5%), but most involved only temporary paleness of the skin. An assessment of patient preferences regarding lidocaine-prilocaine cream or vapocoolant spray before intravenous cannulation indicated that 43% of patients in the vapocoolant group and 27% of patients in the lidocaine-prilocaine group would select the same analgesic method in the future ( P = .02).', 'entities': []}
{'filename': 'EMA - Abstract 15_ Vapocoolant Spray vs Lidocaine-Prilocaine for IV Cannulation Pain - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': 'This generally well-done study has limitations including its single-center design; small sample size (77 patients); lack of blinding, which might have introduced bias; and lack of a placebo arm to indicate whether either treatment achieved favorable results in this sample.', 'entities': []}
{'filename': 'EMA - Abstract 15_ Vapocoolant Spray vs Lidocaine-Prilocaine for IV Cannulation Pain - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'section_header', 'text': 'PMID: 40118519', 'entities': []}
{'filename': 'EMA - Abstract 15_ Vapocoolant Spray vs Lidocaine-Prilocaine for IV Cannulation Pain - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': "EDITOR'S COMMENTARY: This relatively straightforward randomized trial indicated no difference in pain reduction during IV placement between the use of a vapocoolant spray and lidocaine-prilocaine cream among adult ED patients. If these treatments really have equal performance, vapocoolant spray is actually the clear winner from a practical perspective, because its immediate onset of action affects procedural time, efficiency, and flow, and the study indicated its higher patient acceptability for future use. The real question is how much added value these treatments provide over using nothing at all; this aspect was not addressed in this study but would influence the ability to recommend routine use.", 'entities': []}
{'filename': 'EMA - Abstract 15_ Vapocoolant Spray vs Lidocaine-Prilocaine for IV Cannulation Pain - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': 'Copyright 2025 by Emergency Medical Abstracts - All Rights Reserved 06/25 - #15', 'entities': []}
{'filename': 'EMA - Abstract 15_ Vapocoolant Spray vs Lidocaine-Prilocaine for IV Cannulation Pain - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': 'Tags:', 'entities': []}
{'filename': 'EMA - Abstract 15_ Vapocoolant Spray vs Lidocaine-Prilocaine for IV Cannulation Pain - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': 'Analgesic', 'entities': []}
{'filename': 'EMA - Abstract 15_ Vapocoolant Spray vs Lidocaine-Prilocaine for IV Cannulation Pain - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': 'Pharmacology', 'entities': []}
{'filename': 'EMA - Abstract 15_ Vapocoolant Spray vs Lidocaine-Prilocaine for IV Cannulation Pain - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': 'Procedural Skills', 'entities': []}
{'filename': 'EMA - Abstract 2_ Validating the Sudbury Vertigo Risk Score - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'section_header', 'text': 'March 11, 2025. doi:10.1111/acem.70017', 'entities': []}
{'filename': 'EMA - Abstract 2_ Validating the Sudbury Vertigo Risk Score - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'section_header', 'text': 'SUMMARY:', 'entities': []}
{'filename': 'EMA - Abstract 2_ Validating the Sudbury Vertigo Risk Score - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': 'In November, we introduced the Sudbury Vertigo Risk score, a scheme for helping clinicians differentiate patients with serious central nervous system causes of vertigo from patients without serious diagnoses.', 'entities': []}
{'filename': 'EMA - Abstract 2_ Validating the Sudbury Vertigo Risk Score - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': 'The score, which was derived from 3 Canadian emergency departments between 2019 and 2022, comprises 3 domains: (1) stroke risk factors, including male sex, age >65 years, and diabetes (all 1 point), or hypertension (3 points); (2) any neurologic deficits (motor/sensory; 5 points) or cerebellar signs (6 points); and (3) a benign paroxysmal positional vertigo diagnosis in the ED ( -5 points). In the original derivation, a score <5 had 100% sensitivity in ruling out serious disease and approximately 70% specificity. This study effectively performed an internal validation of this score.', 'entities': []}
{'filename': 'EMA - Abstract 2_ Validating the Sudbury Vertigo Risk Score - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': 'To validate the rule, the authors conducted a retrospective cohort study based on chart review at the same 3 sites from which the rule was derived. Whereas the original study involved cases from these same 3 centers in 2020 to 2022, this validation was conducted on an older cohort of patients from 2014 to 2020. The chart-review methods, as reported, followed best practices, including explicit training of abstractors and measures of interrater reliability.', 'entities': []}
{'filename': 'EMA - Abstract 2_ Validating the Sudbury Vertigo Risk Score - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': 'The entry criteria included adult patients with acute vertigo, dizziness, or imbalance. Patients with a depressed Glasgow Coma Scale score, syncope, active cancer, or recent trauma (<14 days) were excluded.', 'entities': []}
{'filename': 'EMA - Abstract 2_ Validating the Sudbury Vertigo Risk Score - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': 'The outcomes of interest were stroke, transient ischemic attack, brain tumor, and vertebral artery dissection within 30 days. Outcome assessment was performed through a chart review examining site-specific hospital records and autopsy reports.', 'entities': []}
{'filename': 'EMA - Abstract 2_ Validating the Sudbury Vertigo Risk Score - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': 'Abstractors used the ED and consultant notes to determine the Sudbury risk score, and calculated the sensitivity and specificity at various cut points.', 'entities': []}
{'filename': 'EMA - Abstract 2_ Validating the Sudbury Vertigo Risk Score - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': 'Over the study period, 4,559 patients met the entry criteria, 57% of whom were women, and the mean age was approximately 65 years. Most patients had at least hypertension as a cardiovascular risk factor, but very few had a prior stroke diagnosis. Moreover, 36% of the study cohort received neuroimaging, usually noncontrast head CT. Ultimately, 104 patients had a serious diagnosis (2%).', 'entities': []}
{'filename': 'EMA - Abstract 2_ Validating the Sudbury Vertigo Risk Score - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': 'The score performed very well in differentiating patients with vs without serious outcomes. With a cut point of <5, the Sudbery score was 100% sensitive and 69% specific. Even for scores between 5 and 8, the risk of serious outcomes was <1%.', 'entities': []}
{'filename': 'EMA - Abstract 2_ Validating the Sudbury Vertigo Risk Score - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': 'The authors further note that more than half of all CTs were performed on patients with scores <5; therefore, all those CTs might potentially have been avoidable.', 'entities': []}
{'filename': 'EMA - Abstract 2_ Validating the Sudbury Vertigo Risk Score - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': 'This study has a host of limitations worthy of exploration. First, it was a retrospective cohort study derived from chart review. Although the authors adhered to best practices, this method is problematic. More importantly, the outcome assessment was not ideal. Review of site-specific hospital records to determine whether any low-risk patients ultimately had a stroke or transient ischemic attack was not optimal. Any patients who presented to another hospital with 1 of these unfavorable outcomes would have been misclassified as a true negative rather than a false negative. In addition, because this study was performed at the same 3 sites as the original', 'entities': []}
{'filename': 'EMA - Abstract 2_ Validating the Sudbury Vertigo Risk Score - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': 'validation, it indicates only that the score performs well in predicting poor outcomes in the types of patients seen at those 3 sites, in an important initial yet insufficient validation step.', 'entities': []}
{'filename': 'EMA - Abstract 2_ Validating the Sudbury Vertigo Risk Score - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'section_header', 'text': 'PMID: 40070159', 'entities': []}
{'filename': 'EMA - Abstract 2_ Validating the Sudbury Vertigo Risk Score - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'section_header', 'text': 'FULL ARTICLE: https://onlinelibrary.wiley.com/doi/10.1111/acem.70017', 'entities': []}
{'filename': 'EMA - Abstract 2_ Validating the Sudbury Vertigo Risk Score - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': "EDITOR'S COMMENTARY: This study provides the first validation of the recently derived Sudbury Vertigo Score. The score performed very well: scores <5 were associated with 0% risk of serious outcomes, and most patients were in this category. This validation was conducted in a historical cohort of patients at the same 3 sites from which the rule was derived, through retrospective methods leaving much to be desired. I do not think that this rule can be applied to the bedside yet, but it holds promise for helping differentiate this difficult-to-assess patient population.", 'entities': []}
{'filename': 'EMA - Abstract 2_ Validating the Sudbury Vertigo Risk Score - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'section_header', 'text': 'RELATED CONTENT:', 'entities': []}
{'filename': 'EMA - Abstract 2_ Validating the Sudbury Vertigo Risk Score - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': 'EMA 2024 November: Abstract 2: Clinical Risk Score for Serious Vertigo Causes in ER Patients EM:RAP 2024 April: Neurocritical Care Mailbag: Dizziness + the GRACE3 Guidelines - Fallot My Finger CorePendium : Vertigo and Dizziness', 'entities': []}
{'filename': 'EMA - Abstract 2_ Validating the Sudbury Vertigo Risk Score - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': 'Copyright 2025 by Emergency Medical Abstracts - All Rights Reserved 06/25 - #02', 'entities': []}
{'filename': 'EMA - Abstract 2_ Validating the Sudbury Vertigo Risk Score - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': 'Tags: Decision Instruments Ischemic Stroke', 'entities': []}
{'filename': 'EMA - Abstract 2_ Validating the Sudbury Vertigo Risk Score - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': 'Vertigo', 'entities': []}
{'filename': 'EMA - Abstract 2_ Validating the Sudbury Vertigo Risk Score - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'section_header', 'text': 'CorePendium Chapters', 'entities': []}
{'filename': 'EMA - Abstract 2_ Validating the Sudbury Vertigo Risk Score - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': 'Vertigo and Dizziness', 'entities': []}
{'filename': 'EMA - Abstract 4_ High-dose L.Reuteri DSM 17938 for Pediatric Gastroenteritis in ED - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': 'Lactobacillus reuteri protectis DSM 17938 at high doses versus placebo in children with acute gastroenteritis in a pediatric emergency department Iramain R, Jara A, Ortiz J, et al. J Pediatr Gastroenterol Nutr. 2025;80(5):760-766.', 'entities': []}
{'filename': 'EMA - Abstract 4_ High-dose L.Reuteri DSM 17938 for Pediatric Gastroenteritis in ED - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'section_header', 'text': 'SUMMARY:', 'entities': []}
{'filename': 'EMA - Abstract 4_ High-dose L.Reuteri DSM 17938 for Pediatric Gastroenteritis in ED - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': 'The effectiveness of probiotics for diarrheal illness in children is a topic of substantial interest, because the worst and most frequent cases appear to occur in children; however, little evidence supporting probiotic use is available.', 'entities': []}
{'filename': 'EMA - Abstract 4_ High-dose L.Reuteri DSM 17938 for Pediatric Gastroenteritis in ED - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': 'The authors contributed to the evidence base by performing a randomized clinical trial comparing Lactobacillus reuteri DSM 17983 and placebo in young children with mild to moderate diarrhea.', 'entities': []}
{'filename': 'EMA - Abstract 4_ High-dose L.Reuteri DSM 17938 for Pediatric Gastroenteritis in ED - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': 'The study was performed in a single, tertiary pediatric emergency department in Paraguay.', 'entities': []}
{'filename': 'EMA - Abstract 4_ High-dose L.Reuteri DSM 17938 for Pediatric Gastroenteritis in ED - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': 'Children with diarrhea were included. The exclusion criteria were severe dehydration, immunodeficiency syndrome, and antibiotic use, among several other criteria.', 'entities': []}
{'filename': 'EMA - Abstract 4_ High-dose L.Reuteri DSM 17938 for Pediatric Gastroenteritis in ED - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': 'Participants received either probiotic or placebo for 5 days, and clinical outcomes were assessed daily through telephone follow-up.', 'entities': []}
{'filename': 'EMA - Abstract 4_ High-dose L.Reuteri DSM 17938 for Pediatric Gastroenteritis in ED - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': 'The primary outcome of interest was diarrhea duration in days. A total of 137 children were randomized, and 5 were lost to follow-up. The mean age was 29 months, 93% had moderate dehydration, and approximately 25% had severe diarrhea, according to the Vesikari score. The average symptom duration before randomization was 35 hours. The groups were well balanced at baseline.', 'entities': []}
{'filename': 'EMA - Abstract 4_ High-dose L.Reuteri DSM 17938 for Pediatric Gastroenteritis in ED - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': 'The diarrhea duration was very slightly shorter in the probiotic group. The mean duration of 2.8 vs 3.1 days ( P = .03), although statistically significant, has marginal clinical significance.', 'entities': []}
{'filename': 'EMA - Abstract 4_ High-dose L.Reuteri DSM 17938 for Pediatric Gastroenteritis in ED - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': 'Secondary analyses examining diarrhea quantity rather than duration yielded more impressive findings. By day 4, the number of diarrhea episodes in the probiotic group was approximately half that in the placebo group.', 'entities': []}
{'filename': 'EMA - Abstract 4_ High-dose L.Reuteri DSM 17938 for Pediatric Gastroenteritis in ED - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': 'Ultimately, this study yielded positive but not altogether convincing findings favoring use of the probiotic Lactobacillus reuteri DSM 17983. The main limitations are the very small treatment effect; lack of safety assessment; and single-center study design in Peru, where the dominant cause of diarrheal illness might systematically differ from those in other locations, thereby limiting the utility of any specific probiotic.', 'entities': []}
{'filename': 'EMA - Abstract 4_ High-dose L.Reuteri DSM 17938 for Pediatric Gastroenteritis in ED - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'section_header', 'text': 'PMID: 40026275', 'entities': []}
{'filename': 'EMA - Abstract 4_ High-dose L.Reuteri DSM 17938 for Pediatric Gastroenteritis in ED - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': "EDITOR'S COMMENTARY: This relatively small single-site study in children with moderate diarrhea suggested that treatment with Lactobacillus reuteri DSM 17983 slightly hastened recovery and decreased symptoms during treatment. The treatment effect was fairly marginal but consistent with the broader literature on this topic. Therefore, probiotics might be helpful for this patient population.", 'entities': []}
{'filename': 'EMA - Abstract 4_ High-dose L.Reuteri DSM 17938 for Pediatric Gastroenteritis in ED - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'section_header', 'text': 'RELATED CONTENT:', 'entities': []}
{'filename': 'EMA - Abstract 4_ High-dose L.Reuteri DSM 17938 for Pediatric Gastroenteritis in ED - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': 'EM:RAP 2019 April: Pediatric Pearls - Probiotics and Diarrhea', 'entities': []}
{'filename': 'EMA - Abstract 4_ High-dose L.Reuteri DSM 17938 for Pediatric Gastroenteritis in ED - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'section_header', 'text': 'CorePendium : Pediatric Acute Gastroenteritis', 'entities': []}
{'filename': 'EMA - Abstract 4_ High-dose L.Reuteri DSM 17938 for Pediatric Gastroenteritis in ED - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': 'Copyright 2025 by Emergency Medical Abstracts - All Rights Reserved 06/25 - #04', 'entities': []}
{'filename': 'EMA - Abstract 4_ High-dose L.Reuteri DSM 17938 for Pediatric Gastroenteritis in ED - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'code', 'text': 'Tags: Gastroenteritis Pharmacology', 'entities': []}
{'filename': 'EMA - Abstract 4_ High-dose L.Reuteri DSM 17938 for Pediatric Gastroenteritis in ED - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'section_header', 'text': 'CorePendium Chapters', 'entities': []}
{'filename': 'EMA - Abstract 4_ High-dose L.Reuteri DSM 17938 for Pediatric Gastroenteritis in ED - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': 'Pediatric Acute Gastroenteritis', 'entities': []}
{'filename': 'EMA - Abstract 16_ The INSPIRE 3 Skin and Soft Tissue Randomized Clinical Trial - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': 'Improving empiric antibiotic selection for patients hospitalized with skin and soft tissue infection: the INSPIRE 3 skin and soft tissue randomized clinical trial Gohil SK, Septimus E, Kleinman K, et al. JAMA Intern Med. 2025;185(6):680-691.', 'entities': []}
{'filename': 'EMA - Abstract 16_ The INSPIRE 3 Skin and Soft Tissue Randomized Clinical Trial - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'section_header', 'text': 'SUMMARY:', 'entities': []}
{'filename': 'EMA - Abstract 16_ The INSPIRE 3 Skin and Soft Tissue Randomized Clinical Trial - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': 'This is a story of antibiotic stewardship.', 'entities': []}
{'filename': 'EMA - Abstract 16_ The INSPIRE 3 Skin and Soft Tissue Randomized Clinical Trial - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': 'Broad-spectrum antipseudomonal and anti-methicillin-resistant Staphylococcus aureus (MRSA) antibiotics tend to be overprescribed to patients admitted for skin and soft tissue infections. The well-known effects of this practice include adverse drug reactions and selection of ever-moreresistant organisms.', 'entities': []}
{'filename': 'EMA - Abstract 16_ The INSPIRE 3 Skin and Soft Tissue Randomized Clinical Trial - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': 'This study tested the effects of 2 interventions designed to decrease the use of unnecessarily broad antibiotics for patients admitted to Hospital Corporation of America (HCA) hospitals.', 'entities': []}
{'filename': 'EMA - Abstract 16_ The INSPIRE 3 Skin and Soft Tissue Randomized Clinical Trial - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': 'This randomized controlled trial was clustered at the hospital level. Each hospital underwent an antibiotic stewardship program. Hospitals were randomized to either (1) routine stewardship, including updated hospital guidelines, prospective feedback to deescalate antibiotic use, requiring physicians to enter the reason for antibiotic choice, and other asynchronous educational efforts; or (2) a complex computerized physician order entry (CPOE) bundle intervention. This CPOE intervention was triggered when a physician ordered a broad antibiotic for the diagnosis of skin and soft tissue infections. The computer then calculated MRSA risk if vancomycin was prescribed and Pseudomonas infection risk if an antipseudomonal beta-lactam was prescribed. The intervention used real data from the HCA data warehouse to make these risk estimates. If the risk estimate was <10%, the CPOE suggested using a narrow-spectrum antibiotic.', 'entities': []}
{'filename': 'EMA - Abstract 16_ The INSPIRE 3 Skin and Soft Tissue Randomized Clinical Trial - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': "The key outcome of interest was the number of days of administration of extended-spectrum antibiotics in the first 3 days of therapy-the so-called 'empiric days.' Balancing outcomes included the need for ICU admission and overall length of stay.", 'entities': []}
{'filename': 'EMA - Abstract 16_ The INSPIRE 3 Skin and Soft Tissue Randomized Clinical Trial - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': 'The routine-care group included 29,595 patients in the pre phase and 31,337 in the post phase, who were treated at 46 hospitals. The CPOE group consisted of 28,242 patients treated in the pre phase and 29,388 patients treated in the post phase, at 44 hospitals. The groups were well balanced.', 'entities': []}
{'filename': 'EMA - Abstract 16_ The INSPIRE 3 Skin and Soft Tissue Randomized Clinical Trial - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': 'The primary outcome of extended-spectrum days was 511/1,000 days in the routine-stewardship group during the pre period and slightly decreased, to 489/1,000 days, in the post period. In the CPOE bundle group, the baseline was similar, at 496/1,000 days, but dramatically decreased to 350/1,000 days in the post period.', 'entities': []}
{'filename': 'EMA - Abstract 16_ The INSPIRE 3 Skin and Soft Tissue Randomized Clinical Trial - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': 'Safety outcomes, including length of stay and ICU transfer, remained stable in both groups before and after the interventions.', 'entities': []}
{'filename': 'EMA - Abstract 16_ The INSPIRE 3 Skin and Soft Tissue Randomized Clinical Trial - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': 'Most of the benefit appeared to be due to physicians initially ordering the proper antibiotic in the CPOE group rather than to changes prompted by the CPOE (although this outcome also occurred). The authors suggest that the CPOE intervention worked by (1) using hospital-specific drug-resistance estimates, (2) placing those estimates in the chart, and (3) providing regular feedback.', 'entities': []}
{'filename': 'EMA - Abstract 16_ The INSPIRE 3 Skin and Soft Tissue Randomized Clinical Trial - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': 'The study has a variety of limitations, primarily that the CPOE intervention would be difficult to replicate in other settings, given that the HCA warehouse data were necessary to determine the actual risk of MDRO. Nonetheless, the study provides an example of how electronic health records can help provide a patient-centered approach while also decreasing exposure to potentially harmful treatments.', 'entities': []}
{'filename': 'EMA - Abstract 16_ The INSPIRE 3 Skin and Soft Tissue Randomized Clinical Trial - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'section_header', 'text': 'PMID: 40208610', 'entities': []}
{'filename': 'EMA - Abstract 16_ The INSPIRE 3 Skin and Soft Tissue Randomized Clinical Trial - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': "EDITOR'S COMMENTARY: This experimental study demonstrated the effectiveness of a bundle CPOE program for antibiotic stewardship. The benefits appeared to be driven mostly by the use of patient-specific risk tools and computerized prompts. This intervention was much more effective than typical educational activities. Overall, this program is unlikely to be easily replicated but may serve as a best-practice model for developing computerized nudges that can change physician behavior.", 'entities': []}
{'filename': 'EMA - Abstract 16_ The INSPIRE 3 Skin and Soft Tissue Randomized Clinical Trial - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'section_header', 'text': 'RELATED CONTENT:', 'entities': []}
{'filename': 'EMA - Abstract 16_ The INSPIRE 3 Skin and Soft Tissue Randomized Clinical Trial - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': 'EM:RAP 2021 April: Skin and Soft Tissue Infections', 'entities': []}
{'filename': 'EMA - Abstract 16_ The INSPIRE 3 Skin and Soft Tissue Randomized Clinical Trial - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': 'CorePendium : Skin and Soft Tissue Infections', 'entities': []}
{'filename': 'EMA - Abstract 16_ The INSPIRE 3 Skin and Soft Tissue Randomized Clinical Trial - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': 'Copyright 2025 by Emergency Medical Abstracts - All Rights Reserved 07/25 - #16', 'entities': []}
{'filename': 'EMA - Abstract 16_ The INSPIRE 3 Skin and Soft Tissue Randomized Clinical Trial - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': 'Tags: Antibiotics Pharmacology', 'entities': []}
{'filename': 'EMA - Abstract 16_ The INSPIRE 3 Skin and Soft Tissue Randomized Clinical Trial - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'section_header', 'text': 'CorePendium Chapters', 'entities': []}
{'filename': 'EMA - Abstract 16_ The INSPIRE 3 Skin and Soft Tissue Randomized Clinical Trial - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': 'Skin and Soft Tissue Infections', 'entities': []}
{'filename': 'EMA - Abstract 19_ Short Message Services for Patient Discharge Instructions in the ED - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': 'Using short message services for patient discharge instructions in the emergency department: a descriptive correlational study Lu C-H, Kuo Y-S, Tang J-S, et al. Am J Emerg Med. 2025;90:192-199.', 'entities': []}
{'filename': 'EMA - Abstract 19_ Short Message Services for Patient Discharge Instructions in the ED - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'section_header', 'text': 'SUMMARY:', 'entities': []}
{'filename': 'EMA - Abstract 19_ Short Message Services for Patient Discharge Instructions in the ED - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': 'Comprehension of discharge instructions is important to improve patient outcomes and prevent unnecessary ED return visits. However, more than three-quarters of patients do not understand at least 1 domain of their aftercare instructions. This deficit is probably due to a combination of factors, including limited health literacy, language barriers, insufficient time available to review key elements, and the sheer volume of printed material provided to patients.', 'entities': []}
{'filename': 'EMA - Abstract 19_ Short Message Services for Patient Discharge Instructions in the ED - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': "Sending tailored text messages to patients' mobile phones has gained attention for potentially increasing comprehension of discharge instructions. In this study from Taiwan, conducted at the height of the COVID-19 pandemic (2021-2022), the authors developed an Emergency Message Health Discharge Instruction System, which linked their hospital information system and sent SMS messages to patients' mobile phones. This system was used to send condition-specific discharge instructions to patients presenting with fever and airway infection. This article reports on their experience.", 'entities': []}
{'filename': 'EMA - Abstract 19_ Short Message Services for Patient Discharge Instructions in the ED - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': 'A total of 618 patients completed a survey designed to assess effects on anxiety, knowledge, care confidence, and satisfaction. The article largely suggests that the text messages improved all these metrics, but how this conclusion was drawn is unclear, given the absence of a control group receiving no messages. However, in the fever group, higher levels of self-reported anxiety were negatively correlated with care confidence and satisfaction ( r = -0.213 and r = 0.189, respectively). Knowledge was positively correlated with care confidence and satisfaction ( r = 0.217 and r = 0.192, respectively). The results were similar in the airway infection group.', 'entities': []}
{'filename': 'EMA - Abstract 19_ Short Message Services for Patient Discharge Instructions in the ED - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': 'This study might have added to the literature on this topic if it had included a preintervention group or a diagnosis that did not receive messages as a comparator; if it had assessed satisfaction with the messages; or if it had tested patient knowledge to verify that the messages actually improved knowledge and were not merely perceived to have done so; or if it had reported opt-in or opt-out rates or message-delivery rates, to assess technical feasibility.', 'entities': []}
{'filename': 'EMA - Abstract 19_ Short Message Services for Patient Discharge Instructions in the ED - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': 'Furthermore, the methods inherently excluded patients without mobile phones capable of receiving text messages and accessing the internet, thus potentially missing vulnerable populations that might stand to benefit most from enhanced discharge instructions. Additionally, self-selection bias might have influenced the results: because only patients who consented to participate were included, patients who were already satisfied with the text-message system might potentially have been overrepresented.', 'entities': []}
{'filename': 'EMA - Abstract 19_ Short Message Services for Patient Discharge Instructions in the ED - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'section_header', 'text': 'PMID: 39908685', 'entities': []}
{'filename': 'EMA - Abstract 19_ Short Message Services for Patient Discharge Instructions in the ED - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': "EDITOR'S COMMENTARY: In this study from Taiwan, the authors describe their use of a textmessage-based instruction system for patients discharged from the ED with fever and airway infections during the COVID-19 pandemic. The authors concluded that the messages improved knowledge, care confidence, and satisfaction, but I am not sure what served as a control. I do believe that patients have overall poor understanding of discharge instructions, return precautions, and", 'entities': []}
{'filename': 'EMA - Abstract 19_ Short Message Services for Patient Discharge Instructions in the ED - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': "follow-up recommendations, and I believe that text messages might enhance comprehension for vulnerable populations. However, I don't think we learn much about the practice from this study.", 'entities': []}
{'filename': 'EMA - Abstract 19_ Short Message Services for Patient Discharge Instructions in the ED - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': 'Copyright 2025 by Emergency Medical Abstracts - All Rights Reserved 07/25 - #19', 'entities': []}
{'filename': 'EMA - Abstract 1_ Paralytic Choice Effects on ED Postintubation Sedation & Analgesia - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': 'Impact of paralytic choice on postintubation sedation and analgesia in the emergency department Hwang C, Michaels B, Park K, et al. Am J Health Syst Pharm. Published online March 3, 2025. doi:10.1093/ajhp/zxaf037', 'entities': []}
{'filename': 'EMA - Abstract 1_ Paralytic Choice Effects on ED Postintubation Sedation & Analgesia - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'section_header', 'text': 'SUMMARY:', 'entities': []}
{'filename': 'EMA - Abstract 1_ Paralytic Choice Effects on ED Postintubation Sedation & Analgesia - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': 'Rapid sequence intubation (RSI), an important part of clinical practice in the ED, is usually performed with a combination of a sedative and a neuromuscular blocker. After intubation, the next management step is prompt administration of analgesic and sedative agents, to minimize pain and discomfort from the tube, paralysis, underlying conditions, and resuscitative procedures. Failure to accomplish this step can result in a horrifying situation in which patients are intubated and cannot move, but are awake and aware of their surroundings.', 'entities': []}
{'filename': 'EMA - Abstract 1_ Paralytic Choice Effects on ED Postintubation Sedation & Analgesia - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': 'Rocuronium is associated with this awake and paralyzed state, because the prolonged paralysis can prevent patients from making even subtle movements that may remind providers to start postintubation sedation after rocuronium administration. We have covered several articles supporting the occurrence of this phenomenon.', 'entities': []}
{'filename': 'EMA - Abstract 1_ Paralytic Choice Effects on ED Postintubation Sedation & Analgesia - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': "The authors of this article sought to expand the evidence base on the topic by conducting a retrospective cohort study from 3 EDs to test the hypothesis that patients paralyzed with rocuronium experience delayed postintubation analgesia and sedation. The authors identified all patients intubated in the ED in an approximately 10-year period and extracted study variables from electronic health records, including baseline demographics; length of stay; ED and hospital survival; patient weight; systolic blood pressure after administration of the paralytic agent; hypotension, which was transformed into a dichotomous variable based on a cutoff of a nadir systolic blood pressure of 100 mm Hg; and medications administered. An additional datapoint was whether a pharmacist was present, as assumed from the pharmacists' work schedules but not directly assessed.", 'entities': []}
{'filename': 'EMA - Abstract 1_ Paralytic Choice Effects on ED Postintubation Sedation & Analgesia - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': 'The study presents data on 2,059 patients; 61.6% were men, and the median age was 64 years. Overall, 74.4% of patients received rocuronium, and 25.6% received succinylcholine. The median time to postintubation sedation was 12 minutes with rocuronium and 10 minutes with succinylcholine. The median time to postintubation analgesia was 24 minutes with rocuronium and 21 minutes with succinylcholine.', 'entities': []}
{'filename': 'EMA - Abstract 1_ Paralytic Choice Effects on ED Postintubation Sedation & Analgesia - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': 'Additional outcomes of interest indicated that succinylcholine (adjusted hazard ratio [aHR], 1.3; 95% CI, 1.2-1.5) and bedside presence of an ED pharmacist (aHR, 1.1; 95% CI, 1.0-1.3) were associated with relatively shorter times to sedation. Hypotension was predictive of omission of sedation (aHR, 0.7; 95% CI, 0.5-0.8). Succinylcholine was also associated with relatively shorter times to analgesia (aHR, 1.4; 95% CI, 1.1-1.6), whereas hypotension (aHR, 1.0; 95% CI, 0.8-1.3) and pharmacist presence (aHR, 1.0; 95% CI, 0.9-1.2) were not.', 'entities': []}
{'filename': 'EMA - Abstract 1_ Paralytic Choice Effects on ED Postintubation Sedation & Analgesia - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': 'Other interesting findings from this large retrospective cohort study were that only 44.8% of patients received both postintubation sedation and analgesia at any point during the ED stay, and the median starting propofol dose was relatively low, at 20  g/kg/mL (1.4 mg/min). Examination of the participating EDs individually indicated that patients treated at the single nontrauma center were much less likely to be given analgesia than patients at the other centers.', 'entities': []}
{'filename': 'EMA - Abstract 1_ Paralytic Choice Effects on ED Postintubation Sedation & Analgesia - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': "The strengths of this well-done retrospective study include a large sample size (2,059 patients) across multiple centers and robust statistical analysis with a Cox proportional hazards model. However, limitations such as a retrospective design and potential unmeasured confounders merit consideration. The study also highlights the positive effects of ED pharmacist presence on timely sedation administration, although the strength of this finding is slightly undermined by the design in which pharmacist presence was extrapolated from work schedules but not measured directly. Finally, although the authors assumed that longer times to postintubation sedation and analgesia might have increased patients' risk of being awake and paralyzed, this possibility was not assessed in patient interviews, because it was beyond the scope of the study.", 'entities': []}
{'filename': 'EMA - Abstract 1_ Paralytic Choice Effects on ED Postintubation Sedation & Analgesia - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'section_header', 'text': 'PMID: 40037283', 'entities': []}
{'filename': 'EMA - Abstract 1_ Paralytic Choice Effects on ED Postintubation Sedation & Analgesia - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': "EDITOR'S COMMENTARY: This multicenter retrospective cohort study provides compelling evidence that the choice of paralytic agent in RSI significantly influences postintubation sedation and analgesia practices. The findings that use of rocuronium vs succinylcholine delayed analgesia and sedation were in line with those from other studies on the topic. This result is particularly concerning from an emergency medicine perspective, because it suggests that patients might experience awareness during paralysis-a potentially traumatic experience. The authors suggest that the presence of an ED pharmacist during intubation might mitigate this issue, but this conclusion cannot be made with certainty, because pharmacist presence was not assessed directly in the data. We need to be aware of these findings when performing RSI, to remember the importance of postintubation medication administration and the need to be especially careful when using rocuronium.", 'entities': []}
{'filename': 'EMA - Abstract 1_ Paralytic Choice Effects on ED Postintubation Sedation & Analgesia - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'section_header', 'text': 'RELATED CONTENT:', 'entities': []}
{'filename': 'EMA - Abstract 1_ Paralytic Choice Effects on ED Postintubation Sedation & Analgesia - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': 'EM:RAP 2019 April: Critical Care Mailbag - Post-Intubation Sedation + Analgesia', 'entities': []}
{'filename': 'EMA - Abstract 1_ Paralytic Choice Effects on ED Postintubation Sedation & Analgesia - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'section_header', 'text': 'CorePendium : Airway Management', 'entities': []}
{'filename': 'EMA - Abstract 1_ Paralytic Choice Effects on ED Postintubation Sedation & Analgesia - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': 'Copyright 2025 by Emergency Medical Abstracts - All Rights Reserved 06/25 - #01', 'entities': []}
{'filename': 'EMA - Abstract 1_ Paralytic Choice Effects on ED Postintubation Sedation & Analgesia - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': 'Tags:', 'entities': []}
{'filename': 'EMA - Abstract 1_ Paralytic Choice Effects on ED Postintubation Sedation & Analgesia - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': 'Analgesic', 'entities': []}
{'filename': 'EMA - Abstract 1_ Paralytic Choice Effects on ED Postintubation Sedation & Analgesia - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': 'Intubation', 'entities': []}
{'filename': 'EMA - Abstract 1_ Paralytic Choice Effects on ED Postintubation Sedation & Analgesia - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': 'Pharmacology', 'entities': []}
{'filename': 'EMA - Abstract 1_ Paralytic Choice Effects on ED Postintubation Sedation & Analgesia - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'section_header', 'text': 'CorePendium Chapters', 'entities': []}
{'filename': 'EMA - Abstract 1_ Paralytic Choice Effects on ED Postintubation Sedation & Analgesia - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': 'Airway Management', 'entities': []}
{'filename': 'EMA - Abstract 17_ Hounsfield Units for Differentiating Pleural Effusion Types in ED - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': 'Use of the Hounsfield unit scale in differentiating transudate and exudate in pleural effusion in the emergency department Isik N  , zkan E, Ugun A, et al. Medicine (Baltimore). 2025;104(10):e41822.', 'entities': []}
{'filename': 'EMA - Abstract 17_ Hounsfield Units for Differentiating Pleural Effusion Types in ED - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'section_header', 'text': 'SUMMARY:', 'entities': []}
{'filename': 'EMA - Abstract 17_ Hounsfield Units for Differentiating Pleural Effusion Types in ED - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': 'Pleural effusions can result from relatively benign conditions or much more serious conditions, such as viral pleuritis, congestive heart failure, malignancy, or tuberculosis. The first step in identifying the cause is determining whether the fluid is a transudate or an exudate. Traditionally, a sample of the fluid is collected via thoracentesis for laboratory testing. This procedure can be performed in the ED, but complications can occur, particularly when providers are inexperienced.', 'entities': []}
{'filename': 'EMA - Abstract 17_ Hounsfield Units for Differentiating Pleural Effusion Types in ED - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': 'Many patients with pleural effusion receive CT as part of the initial workup. Therefore, this study was aimed at investigating whether simply examining the Hounsfield units (HUs) of the fluid might be sufficient to identify transudates vs exudates, given that higher HUs indicate greater density.', 'entities': []}
{'filename': 'EMA - Abstract 17_ Hounsfield Units for Differentiating Pleural Effusion Types in ED - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': 'This retrospective observational study from Turkey identified ED patients with pleural effusion who underwent thoracentesis, according to a query of electronic health records. The authors report the variables collected in the chart review, but provide no information on how they were collected or whether they were checked for accuracy. The average HU value was recorded from measurements taken at 3 different points.', 'entities': []}
{'filename': 'EMA - Abstract 17_ Hounsfield Units for Differentiating Pleural Effusion Types in ED - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': 'The study included 207 patients in the final analysis. The mean patient age was significantly lower in the exudate group (66.00  15.63 years) than the transudate group (72.98  10.38 years) ( P <.001). According to the area under the curve, the optimal HU cut point was 14.2, which had 62.7% sensitivity, 75% specificity, and a 90.2% PPV.', 'entities': []}
{'filename': 'EMA - Abstract 17_ Hounsfield Units for Differentiating Pleural Effusion Types in ED - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': 'Several other studies on this topic have reported relatively similar results. However, this effort is novel because it was conducted in the ED setting. Nonetheless, the study has many limitations, including poor description of the data-collection strategy and statistical approach; the retrospective, single-center design, which limits generalizability of the findings; and the substantial overlap in HU values between exudates and transudates, thus underscoring why this technique cannot stand alone. Additionally, the strong skew of the study population toward exudative effusions (162 exudates vs 45 transudates) might potentially have affected the statistical reliability of the conclusions.', 'entities': []}
{'filename': 'EMA - Abstract 17_ Hounsfield Units for Differentiating Pleural Effusion Types in ED - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': 'The authors correctly conclude that although the HU might be a helpful adjunct to a full clinical assessment, it cannot be used as a standalone test.', 'entities': []}
{'filename': 'EMA - Abstract 17_ Hounsfield Units for Differentiating Pleural Effusion Types in ED - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'section_header', 'text': 'PMID: 40068056', 'entities': []}
{'filename': 'EMA - Abstract 17_ Hounsfield Units for Differentiating Pleural Effusion Types in ED - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': 'FULL ARTICLE: https://journals.lww.com/mdjournal/fulltext/2025/03070/use_of_the_hounsfield_unit_scale_in.37.aspx', 'entities': []}
{'filename': 'EMA - Abstract 17_ Hounsfield Units for Differentiating Pleural Effusion Types in ED - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': "EDITOR'S COMMENTARY: This retrospective observational study investigated whether HUs from a CT might serve as a standalone test to differentiate between an exudative and transudative pleural effusion. The short answer is no: the calculated test characteristics at an optimal cut point (75%", 'entities': []}
{'filename': 'EMA - Abstract 17_ Hounsfield Units for Differentiating Pleural Effusion Types in ED - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': 'specificity, 90.18% PPV, and 62.73% sensitivity) were modest at best. Clinicians should view HU measurements as just 1 component of a comprehensive clinical assessment rather than a definitive diagnostic tool for pleural effusion classification.', 'entities': []}
{'filename': 'EMA - Abstract 17_ Hounsfield Units for Differentiating Pleural Effusion Types in ED - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': 'Copyright 2025 by Emergency Medical Abstracts - All Rights Reserved 06/25 - #17', 'entities': []}
{'filename': 'EMA - Abstract 17_ Hounsfield Units for Differentiating Pleural Effusion Types in ED - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': 'Tag:', 'entities': []}
{'filename': 'EMA - Abstract 17_ Hounsfield Units for Differentiating Pleural Effusion Types in ED - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': 'Imaging', 'entities': []}
{'filename': 'EMA - Abstract 14_ Diagnostic Accuracy of ED ECGs in Hyperkalemia Detection - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': 'Diagnostic accuracy of emergency department ECGs in hyperkalemia detection: a cross-sectional study nl L, Stephan F-P, Riede FN, et al. Eur J Intern Med. 2025;136:56-62.', 'entities': []}
{'filename': 'EMA - Abstract 14_ Diagnostic Accuracy of ED ECGs in Hyperkalemia Detection - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'section_header', 'text': 'SUMMARY:', 'entities': []}
{'filename': 'EMA - Abstract 14_ Diagnostic Accuracy of ED ECGs in Hyperkalemia Detection - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': 'This study was aimed at determining the accuracy of ECG in hyperkalemia diagnosis. However, the simple idea on which the study was based was complicated by the methods used.', 'entities': []}
{'filename': 'EMA - Abstract 14_ Diagnostic Accuracy of ED ECGs in Hyperkalemia Detection - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': 'The authors obtained a sample of 1,600 patients receiving potassium measurement and ECG at approximately the same time. Patients who received potassium-altering drugs between the potassium measurement and ECG were excluded. The sample was restricted to 800 patients with hyperkalemia (potassium >5 mmol/L) and 800 patients with normal potassium levels.', 'entities': []}
{'filename': 'EMA - Abstract 14_ Diagnostic Accuracy of ED ECGs in Hyperkalemia Detection - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': 'The authors then asked 2 independent cardiologists (who were not blinded to the study purpose or the percentage of the sample with hyperkalemia) to review the ECGs and rate the probability of the patient having hyperkalemia by using a hyperkalemia probability scoring scale developed by the authors. Essentially, the physicians interpreting the ECG simply estimated the probability of the ECG reflecting hyperkalemia, from 0 to 100.', 'entities': []}
{'filename': 'EMA - Abstract 14_ Diagnostic Accuracy of ED ECGs in Hyperkalemia Detection - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': "The cardiologists' estimated hyperkalemia probability scores were plotted against the actual potassium levels.", 'entities': []}
{'filename': 'EMA - Abstract 14_ Diagnostic Accuracy of ED ECGs in Hyperkalemia Detection - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': 'The curves were unconvincing and nearly flat. Even when the serum potassium was 8 meq/L, the average hyperkalemia score was <40% for each cardiologist. In numerous cases, the potassium exceeded 6 mmol/L, and the cardiologists estimated a hyperkalemia risk of 0, despite actually knowing that 50% of the cases (representing a far higher risk than usual) had hyperkalemia.', 'entities': []}
{'filename': 'EMA - Abstract 14_ Diagnostic Accuracy of ED ECGs in Hyperkalemia Detection - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': 'The authors conducted a variety of statistical analyses, including the generation of a receiver operating characteristic curve, and repeating the ECG interpretation with just T-wave analysis rather than the entire ECG. Nonetheless, the expert ECG interpretation was highly inaccurate.', 'entities': []}
{'filename': 'EMA - Abstract 14_ Diagnostic Accuracy of ED ECGs in Hyperkalemia Detection - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': 'Providers with any concern for hyperkalemia should check the blood value. ECG might help determine whether a patient is in imminent cardiovascular collapse yet appears to have little use as a screening tool for serum hyperkalemia.', 'entities': []}
{'filename': 'EMA - Abstract 14_ Diagnostic Accuracy of ED ECGs in Hyperkalemia Detection - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'section_header', 'text': 'PMID: 40210527', 'entities': []}
{'filename': 'EMA - Abstract 14_ Diagnostic Accuracy of ED ECGs in Hyperkalemia Detection - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'section_header', 'text': 'FULL ARTICLE: https://www.ejinme.com/article/S0953-6205(25)00132-3/fulltext', 'entities': []}
{'filename': 'EMA - Abstract 14_ Diagnostic Accuracy of ED ECGs in Hyperkalemia Detection - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': "EDITOR'S COMMENTARY: This extremely limited single-site study examined the ability of ECG to identify serum hyperkalemia. The design is complicated, and the results are limited by the methods. However, the findings still convincingly showed that, even when the ECGs were interpreted by cardiologists aware of the high risk of hyperkalemia in the cohort, the ECG interpretation was hugely insensitive and unreliable. Just order a potassium test if you are concerned.", 'entities': []}
{'filename': 'EMA - Abstract 14_ Diagnostic Accuracy of ED ECGs in Hyperkalemia Detection - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'section_header', 'text': 'RELATED CONTENT:', 'entities': []}
{'filename': 'EMA - Abstract 14_ Diagnostic Accuracy of ED ECGs in Hyperkalemia Detection - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': 'EM:RAP 2024 February: Cardiology Corner: Hyperkalemia Myths', 'entities': []}
{'filename': 'EMA - Abstract 14_ Diagnostic Accuracy of ED ECGs in Hyperkalemia Detection - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'section_header', 'text': 'CorePendium : Hyperkalemia', 'entities': []}
{'filename': 'EMA - Abstract 14_ Diagnostic Accuracy of ED ECGs in Hyperkalemia Detection - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': 'Copyright 2025 by Emergency Medical Abstracts - All Rights Reserved 07/25 - #14', 'entities': []}
{'filename': 'EMA - Abstract 14_ Diagnostic Accuracy of ED ECGs in Hyperkalemia Detection - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': 'Tags: ECG Hyperkalemia', 'entities': []}
{'filename': 'EMA - Abstract 14_ Diagnostic Accuracy of ED ECGs in Hyperkalemia Detection - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'section_header', 'text': 'CorePendium Chapters', 'entities': []}
{'filename': 'EMA - Abstract 14_ Diagnostic Accuracy of ED ECGs in Hyperkalemia Detection - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': 'Hyperkalemia', 'entities': []}
{'filename': 'EMA - Abstract 10_ RCT of Thoracentesis in Acute Heart Failure - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'section_header', 'text': 'SUMMARY:', 'entities': []}
{'filename': 'EMA - Abstract 10_ RCT of Thoracentesis in Acute Heart Failure - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': 'The authors of this study note that in patients with heart failure and pleural effusion of at least one-third the lung volume, pleurocentesis is frequently performed despite a lack of solid evidence of its effectiveness.', 'entities': []}
{'filename': 'EMA - Abstract 10_ RCT of Thoracentesis in Acute Heart Failure - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': 'Therefore, the authors conducted the\xa0Thoracentesis to Alleviate Cardiac Pleural EffusionIntervention Trial (TAP-IT).', 'entities': []}
{'filename': 'EMA - Abstract 10_ RCT of Thoracentesis in Acute Heart Failure - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': "This single-site, unblinded trial in Denmark included participants with 'non-negligible' effusion. Patients with pleural effusion exceeding two-thirds of the lung volume were excluded, because they are believed to require thoracentesis.", 'entities': []}
{'filename': 'EMA - Abstract 10_ RCT of Thoracentesis in Acute Heart Failure - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': 'The intervention group received an ultrasound-guided pigtail, whereas the control group received usual diuresis.', 'entities': []}
{'filename': 'EMA - Abstract 10_ RCT of Thoracentesis in Acute Heart Failure - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': 'The primary outcome was the number of days out of hospital during the next 90 calendar days. Multiple secondary outcomes included length of stay at the index visit.', 'entities': []}
{'filename': 'EMA - Abstract 10_ RCT of Thoracentesis in Acute Heart Failure - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': 'Over a 2-year study period, 136 patients were randomized. The mean age was 81 years. Most patients had bilateral pleural effusions. The groups were fairly well balanced at baseline.', 'entities': []}
{'filename': 'EMA - Abstract 10_ RCT of Thoracentesis in Acute Heart Failure - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': 'Thoracentesis did not work. No difference was observed in the number of days out of hospital (84 vs 82). The index visit duration (5 days), mortality rates, quality-of-life assessments, and patient satisfaction were also similar between groups.', 'entities': []}
{'filename': 'EMA - Abstract 10_ RCT of Thoracentesis in Acute Heart Failure - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': "Unfortunately for those of you who still enjoy procedures, this intervention did not work and is not likely to come to an ED near you any time soon. However, the patients' very advanced age might have placed them at elevated risk of complications from the procedures, thus offsetting the potential benefits. If performed in younger people, a net positive effect might potentially exist, but that possibility remains conjectural.", 'entities': []}
{'filename': 'EMA - Abstract 10_ RCT of Thoracentesis in Acute Heart Failure - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'section_header', 'text': 'PMID: 40166829', 'entities': []}
{'filename': 'EMA - Abstract 10_ RCT of Thoracentesis in Acute Heart Failure - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'section_header', 'text': 'FULL ARTICLE: https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.124.073521', 'entities': []}
{'filename': 'EMA - Abstract 10_ RCT of Thoracentesis in Acute Heart Failure - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': "EDITOR'S COMMENTARY: In this innovative trial, the authors did not observe improved clinical outcomes among patients with acute decompensated heart failure with significant pleural effusion who were treated with thoracentesis rather than standard medical management.", 'entities': []}
{'filename': 'EMA - Abstract 10_ RCT of Thoracentesis in Acute Heart Failure - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'section_header', 'text': 'RELATED CONTENT:', 'entities': []}
{'filename': 'EMA - Abstract 10_ RCT of Thoracentesis in Acute Heart Failure - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'section_header', 'text': 'EM:RAP 2024 October: Crit Bits: Chest Tubes + Drains', 'entities': []}
{'filename': 'EMA - Abstract 10_ RCT of Thoracentesis in Acute Heart Failure - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'section_header', 'text': 'CorePendium : Heart Failure', 'entities': []}
{'filename': 'EMA - Abstract 10_ RCT of Thoracentesis in Acute Heart Failure - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': 'Copyright 2025 by Emergency Medical Abstracts - All Rights Reserved 07/25 - #10', 'entities': []}
{'filename': 'EMA - Abstract 10_ RCT of Thoracentesis in Acute Heart Failure - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': 'Tag: Procedural Skills', 'entities': []}
{'filename': 'EMA - Abstract 10_ RCT of Thoracentesis in Acute Heart Failure - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'section_header', 'text': 'CorePendium Chapters', 'entities': []}
{'filename': 'EMA - Abstract 10_ RCT of Thoracentesis in Acute Heart Failure - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'section_header', 'text': 'Heart Failure', 'entities': []}
{'filename': "EMA - Abstract 3_ Probiotics' Effect on Fever Duration in Pediatric URTIs_ RCT - EMA 2025 June _ EM_RAP.pdf", 'page': None, 'block_label': 'text', 'text': 'Probiotics and fever duration in children with upper respiratory tract infections: a randomized clinical trial Bettocchi S, Comotti A, Elli M, et al. JAMA Netw Open. 2025;8(3):e250669.', 'entities': []}
{'filename': "EMA - Abstract 3_ Probiotics' Effect on Fever Duration in Pediatric URTIs_ RCT - EMA 2025 June _ EM_RAP.pdf", 'page': None, 'block_label': 'section_header', 'text': 'SUMMARY:', 'entities': []}
{'filename': "EMA - Abstract 3_ Probiotics' Effect on Fever Duration in Pediatric URTIs_ RCT - EMA 2025 June _ EM_RAP.pdf", 'page': None, 'block_label': 'list_item', 'text': 'On average, a child may have as many as 5 to 8 upper respiratory tract infections (URTIs) per year, particularly until the age of 5 years. URTI symptoms usually peak within 3 to 5 days, and resolve within 14 days. The symptoms include nasal congestion and discharge, sore throat, eye redness or drainage, cough, hoarseness, irritability, decreased appetite, sleep disturbance, and fever. Fever, a particularly common feature of URTIs, is important for parents, because it usually prevents children from returning to school or daycare.', 'entities': []}
{'filename': "EMA - Abstract 3_ Probiotics' Effect on Fever Duration in Pediatric URTIs_ RCT - EMA 2025 June _ EM_RAP.pdf", 'page': None, 'block_label': 'list_item', 'text': 'In the past few decades, medical interest in the use of probiotics to mitigate a variety of symptoms has increased. This study was aimed at assessing the efficacy of a probiotic mixture containing Bifidobacterium breve M-16V, Bifidobacterium lactis HN019, and Lactobacillus rhamnosus HN001 in shortening fever duration among children with URTIs.', 'entities': []}
{'filename': "EMA - Abstract 3_ Probiotics' Effect on Fever Duration in Pediatric URTIs_ RCT - EMA 2025 June _ EM_RAP.pdf", 'page': None, 'block_label': 'list_item', 'text': 'This investigator-initiated, triple-blind, placebo-controlled randomized clinical trial was conducted between November 19, 2021, and June 20, 2023, at a pediatric emergency department in Milan, Italy. Patients were eligible if they had a fever, received a URTI diagnosis by the treating provider, and were discharged from the ED. The enrolled patients were randomized to receive a single daily dose of either an over-the-counter probiotic or a liquid placebo for 14 days. Caregivers were asked to obtain rectal temperatures 3 times per day until the fever had subsided for 24 hours without the use of antipyretic agents. The study enrolled 128 patients, 54% of whom were boys, and the mean age was 2.5 years. Unfortunately, only 55% of enrolled patients fully adhered to the study protocol, 13% partially adhered, and 32% dropped out after randomization.', 'entities': []}
{'filename': "EMA - Abstract 3_ Probiotics' Effect on Fever Duration in Pediatric URTIs_ RCT - EMA 2025 June _ EM_RAP.pdf", 'page': None, 'block_label': 'list_item', 'text': 'The median (and IQR) fever duration was shorter in the probiotic group than the placebo group (median [IQR], 3 [2-4] days vs 5 [4-6] days; adjusted risk ratio, 0.64; 95% CI, 0.51-0.80) in the intent-to-treat analysis. This finding held in a per-protocol analysis and across several other sensitivity checks. Among patients receiving antibiotics at enrollment, no patients in the intervention group and 3 patients in the control group developed diarrhea. Adverse effects were minimal and minor, and did not differ across groups.', 'entities': []}
{'filename': "EMA - Abstract 3_ Probiotics' Effect on Fever Duration in Pediatric URTIs_ RCT - EMA 2025 June _ EM_RAP.pdf", 'page': None, 'block_label': 'list_item', 'text': "Study strengths include the randomized design, maintenance of blinding, and use of over-thecounter probiotics. However, the study's many weaknesses prevent its findings from being definitive, including that the involvement of only a single center in Italy limits the generalizability of the findings to other health care systems and patient populations; its reliance on on caregiver-reported temperature measurements introduced potential reliability concerns; and its substantial dropout rate (32%) prompts questions regarding treatment acceptability and the robustness of the findings. In addition, the authors did not have a protocol for, or provide any data on, other medications and antipyretics used in either study arm.", 'entities': []}
{'filename': "EMA - Abstract 3_ Probiotics' Effect on Fever Duration in Pediatric URTIs_ RCT - EMA 2025 June _ EM_RAP.pdf", 'page': None, 'block_label': 'section_header', 'text': 'PMID: 40085083', 'entities': []}
{'filename': "EMA - Abstract 3_ Probiotics' Effect on Fever Duration in Pediatric URTIs_ RCT - EMA 2025 June _ EM_RAP.pdf", 'page': None, 'block_label': 'text', 'text': 'FULL ARTICLE: https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2831509', 'entities': []}
{'filename': "EMA - Abstract 3_ Probiotics' Effect on Fever Duration in Pediatric URTIs_ RCT - EMA 2025 June _ EM_RAP.pdf", 'page': None, 'block_label': 'text', 'text': "EDITOR'S COMMENTARY: In this blinded randomized trial from a single center in Italy, an over-thecounter probiotic mixture resulted in a significant 2-day decrease in fever duration among kids clinically diagnosed with URTI. This difference is important, because it might potentially decrease return visits, parental anxiety, and absenteeism from school or daycare. However, substantial study limitations included a high dropout rate and reliance on caregivers to assess the primary outcome, thus making the data far from conclusive. Although larger studies are needed to confirm the findings, probiotics do seem to be a safe and low-cost intervention if you have a parent wanting to try something new and different.", 'entities': []}
{'filename': "EMA - Abstract 3_ Probiotics' Effect on Fever Duration in Pediatric URTIs_ RCT - EMA 2025 June _ EM_RAP.pdf", 'page': None, 'block_label': 'section_header', 'text': 'RELATED CONTENT:', 'entities': []}
{'filename': "EMA - Abstract 3_ Probiotics' Effect on Fever Duration in Pediatric URTIs_ RCT - EMA 2025 June _ EM_RAP.pdf", 'page': None, 'block_label': 'section_header', 'text': 'CorePendium : Common Pediatric Respiratory Tract Infections', 'entities': []}
{'filename': "EMA - Abstract 3_ Probiotics' Effect on Fever Duration in Pediatric URTIs_ RCT - EMA 2025 June _ EM_RAP.pdf", 'page': None, 'block_label': 'text', 'text': 'Copyright 2025 by Emergency Medical Abstracts - All Rights Reserved 06/25 - #03', 'entities': []}
{'filename': "EMA - Abstract 3_ Probiotics' Effect on Fever Duration in Pediatric URTIs_ RCT - EMA 2025 June _ EM_RAP.pdf", 'page': None, 'block_label': 'text', 'text': 'Tags: Fever Pharmacology', 'entities': []}
{'filename': "EMA - Abstract 3_ Probiotics' Effect on Fever Duration in Pediatric URTIs_ RCT - EMA 2025 June _ EM_RAP.pdf", 'page': None, 'block_label': 'text', 'text': 'Respiratory', 'entities': []}
{'filename': "EMA - Abstract 3_ Probiotics' Effect on Fever Duration in Pediatric URTIs_ RCT - EMA 2025 June _ EM_RAP.pdf", 'page': None, 'block_label': 'section_header', 'text': 'CorePendium Chapters', 'entities': []}
{'filename': "EMA - Abstract 3_ Probiotics' Effect on Fever Duration in Pediatric URTIs_ RCT - EMA 2025 June _ EM_RAP.pdf", 'page': None, 'block_label': 'text', 'text': 'Common Pediatric Respiratory Tract Infections', 'entities': []}
{'filename': 'EMA - Time to Talk a Little Nerdy_ Burden of Proof - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': 'Introducing the all-new EM:RAP CME experience. Meticulously crafted from the ground up for speed and simplicity. Welcome to a future where meeting your CME needs is faster and easier than ever imagined.', 'entities': []}
{'filename': 'EMA - Time to Talk a Little Nerdy_ Burden of Proof - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'section_header', 'text': 'LEARN MORE', 'entities': []}
{'filename': 'EMA - Time to Talk a Little Nerdy_ Burden of Proof - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': 'Search EMA Episodes', 'entities': []}
{'filename': 'EMA - Time to Talk a Little Nerdy_ Burden of Proof - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'section_header', 'text': 'EMA 2025 June', 'entities': []}
{'filename': 'EMA - Time to Talk a Little Nerdy_ Burden of Proof - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': 'June 2025', 'entities': []}
{'filename': 'EMA - Time to Talk a Little Nerdy_ Burden of Proof - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'section_header', 'text': 'Time to Talk a Little Nerdy: Burden of Proof', 'entities': []}
{'filename': 'EMA - Time to Talk a Little Nerdy_ Burden of Proof - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'section_header', 'text': 'EMA 2025 June', 'entities': []}
{'filename': 'EMA - Time to Talk a Little Nerdy_ Burden of Proof - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': '24 Chapters', 'entities': []}
{'filename': 'EMA - Time to Talk a Little Nerdy_ Burden of Proof - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': 'This month Ken and Swami discuss how citation errors, occurring at rates of 11-15% in biomedical literature, propagate false information and create "academic urban legends." They provide compelling examples, including the spinach iron myth and opioid addiction misconceptions, while explaining how these errors undermine scientific integrity.', 'entities': []}
{'filename': 'EMA - Time to Talk a Little Nerdy_ Burden of Proof - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'section_header', 'text': 'Time to Talk a Little Nerdy', 'entities': []}
{'filename': 'EMA - Time to Talk a Little Nerdy_ Burden of Proof - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'section_header', 'text': 'Burden of Proof', 'entities': []}
{'filename': 'EMA - Time to Talk a Little Nerdy_ Burden of Proof - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': 'Today, we are dropping into an important issue in the medical literature: inaccurate citations and the burden of proof. We were spurred to tackle this topic after reading an article by Peoples and colleagues in the BMJ in 2023.[i]', 'entities': []}
{'filename': 'EMA - Time to Talk a Little Nerdy_ Burden of Proof - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': "The title of the article is 'Burden of Proof: Combating Inaccurate Citations in Biomedical Literature . ' We often need to remind listeners that anyone making a claim has the burden of supporting the position with evidence. It is not called a burden because it is easy, and shifting the burden of proof onto another person is a logical fallacy.", 'entities': []}
{'filename': 'EMA - Time to Talk a Little Nerdy_ Burden of Proof - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': 'The premise of the article is that authors often cite literature to support a claim, yet the cited literature does not support the statement or claim. Obviously, we see this as a problem, but Peoples and colleagues point out 2 main reasons why we need to pay attention to citation errors:', 'entities': []}
{'filename': 'EMA - Time to Talk a Little Nerdy_ Burden of Proof - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': 'Propagation of false or misinterpreted data: Inaccurate citations can lead to the spread of incorrect or misinterpreted data, which can create "academic urban legends." As a result, the publication of accurate findings may be delayed, and incorrect ideas can be treated as facts.', 'entities': []}
{'filename': 'EMA - Time to Talk a Little Nerdy_ Burden of Proof - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': 'Undermining the integrity of scientific literature review : The widespread presence of citation errors weakens trust in the process of literature review and reduces it to a "box-ticking exercise." This lack of trust diminishes the quality of scholarly work, and makes the background and discussion sections of articles less valuable. Additionally, it encourages sloppy research practices among young investigators and trainees, and further perpetuates the cycle of poor citation practices.', 'entities': []}
{'filename': 'EMA - Time to Talk a Little Nerdy_ Burden of Proof - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': "A great example of an academic urban legend is the classic teaching that when a posterior nasal pack is placed for epistaxis, patients must be closely monitored, because they are at risk of severe bradycardia. Yet, when we trace this claim back, every article cites a 1971 publication as the source of the information, but that article does not even contain the word 'bradycardia.' After an extensive search with a medical librarian, we could not find an iota of data supporting this phenomenon.", 'entities': []}
{'filename': 'EMA - Time to Talk a Little Nerdy_ Burden of Proof - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': 'Peoples and colleagues discuss the misrepresentation of a 1980 New England Journal of Medicine letter on the risk of opioid addiction. The letter, written by Porter and Jick, stated that addiction was rare in patients treated with narcotics.[ii] However, this brief statement was widely misquoted and misrepresented in the medical literature over time. Research by Leung[iii] et al documents how the original statement was distorted through inaccurate citation. The misrepresentation contributed to shaping a narrative that downplayed the risks of opioid addiction and reassured prescribers that longterm opioid therapy carried minimal addiction risk.', 'entities': []}
{'filename': 'EMA - Time to Talk a Little Nerdy_ Burden of Proof - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': 'The citation-error rates in the biomedical literature range from 11% to 15%, whereas in the general scientific literature, as many as 25% of citations may be inaccurate.', 'entities': []}
{'filename': 'EMA - Time to Talk a Little Nerdy_ Burden of Proof - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': 'A review of 4,912 citations has indicated the following:', 'entities': []}
{'filename': 'EMA - Time to Talk a Little Nerdy_ Burden of Proof - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': '38% of errors involved citation of nonexistent findings', 'entities': []}
{'filename': 'EMA - Time to Talk a Little Nerdy_ Burden of Proof - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': '15% of the citations were incorrect interpretations of findings', 'entities': []}
{'filename': 'EMA - Time to Talk a Little Nerdy_ Burden of Proof - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': '20% were chains of inaccurate citations copied from one article to another', 'entities': []}
{'filename': 'EMA - Time to Talk a Little Nerdy_ Burden of Proof - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': 'Additionally, 1 surgical study was misquoted by 40% of the articles citing it, thus leading to an unsupported but widely accepted guideline for an orthopedic procedure  .', 'entities': []}
{'filename': 'EMA - Time to Talk a Little Nerdy_ Burden of Proof - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': 'The BMJ article provides a long list of reasons why this phenomenon occurs. Importantly, the authors are not claiming that citation errors are always made maliciously. The below table summarizes 13 reasons for citation errors.', 'entities': []}
{'filename': 'EMA - Time to Talk a Little Nerdy_ Burden of Proof - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'table', 'text': 'TABLE', 'entities': []}
{'filename': 'EMA - Time to Talk a Little Nerdy_ Burden of Proof - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'caption', 'text': 'Full Size Image', 'entities': []}
{'filename': 'EMA - Time to Talk a Little Nerdy_ Burden of Proof - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': "The article describes how an academic myth about the high iron content of spinach persisted for decades because of inaccurate citations. In 1981, Hamblin published an article titled 'Fake!' in which he attempted to debunk a common misconception regarding the iron content of spinach.[iv] However, unbeknownst to him, the information that he used was itself incorrect. Other authors subsequently cited his work, often without verifying the original source, and his statements became increasingly distorted over time. By 1995, an article by Larsson further misrepresented Hamblin's findings, thus turning an accidental error into widely accepted misinformation.[v]", 'entities': []}
{'filename': 'EMA - Time to Talk a Little Nerdy_ Burden of Proof - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': 'This process continued for nearly 3 decades, in which various researchers built on incorrect references and reinforced the myth. It was not until 2010 that the claim was definitively debunked, yet even then, Hamblin struggled to correct the misinformation before his passing in 2012. I did an SGEM Xtra episode in 2015 diving into the details of the myth about spinach containing superhigh levels of iron. The episode is SGEM#141: Popeye and the Paperclip.', 'entities': []}
{'filename': 'EMA - Time to Talk a Little Nerdy_ Burden of Proof - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': 'Among the reasons listed for citation errors in the biomedical literature, 3 important ones, according to their potential impact on scientific integrity and knowledge dissemination, are as follows:', 'entities': []}
{'filename': 'EMA - Time to Talk a Little Nerdy_ Burden of Proof - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': 'Misinterpretation : Incorrectly summarizing or understanding a source can distort scientific conclusions and propagate misinformation. This distortion is particularly dangerous because it can lead to false medical guidelines or treatment recommendations.', 'entities': []}
{'filename': 'EMA - Time to Talk a Little Nerdy_ Burden of Proof - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': 'Hallucinatory citations : The rise of AI-generated citations that do not exist or misrepresent actual data presents a growing risk. If unchecked, the spread of misinformation in the scientific literature could accelerate at an unprecedented scale.', 'entities': []}
{'filename': 'EMA - Time to Talk a Little Nerdy_ Burden of Proof - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': 'Lazy author syndrome : When authors cite references without reading them in full, errors accumulate and spread. A " copy-paste" culture can result, in which inaccurate claims become widely accepted simply because they are frequently cited.', 'entities': []}
{'filename': 'EMA - Time to Talk a Little Nerdy_ Burden of Proof - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': 'One error that we commonly see is secondary citation, in which an author refers to a review article without pulling the original data. This effect can snowball as the article is continually cited, but no one ever pulls the original data to review. This is an excellent reason why we often encourage readers to go back to the primary source to confirm its validity.', 'entities': []}
{'filename': 'EMA - Time to Talk a Little Nerdy_ Burden of Proof - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': "To fix the situation, it seems that readers would need to pull and review every article cited to make sure the authors' claims are accurate. This, of course, would be massively time-consuming and impossible to do. We think that this review should be performed at the journal level when an article is submitted for publication.", 'entities': []}
{'filename': 'EMA - Time to Talk a Little Nerdy_ Burden of Proof - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': 'AI is a potential method for addressing the issue of citation errors. The scite.ai website provides a citation-checker tool. Users can upload a PDF of the publication, and scite.ai will classify any citations according to their context. This tool can identify whether each citation supports, contradicts, or simply mentions the referenced article.', 'entities': []}
{'filename': 'EMA - Time to Talk a Little Nerdy_ Burden of Proof - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'section_header', 'text': 'REFERENCES:', 'entities': []}
{'filename': 'EMA - Time to Talk a Little Nerdy_ Burden of Proof - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': '[i] Peoples N, stbye T, Yan LL. Burden of proof: combating inaccurate citation in biomedical literature. BMJ. 2023;383:e076441.', 'entities': []}
{'filename': 'EMA - Time to Talk a Little Nerdy_ Burden of Proof - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': '[ii] Porter J, Jick H. Addiction rare in patients treated with narcotics. N Engl J Med. 1980;302(2):123.', 'entities': []}
{'filename': 'EMA - Time to Talk a Little Nerdy_ Burden of Proof - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': '[iii] Leung PTM, Macdonald EM, Stanbrook MB, Dhalla IA, Juurlink DN. A 1980 Letter on the Risk of Opioid Addiction. N Engl J Med. 2017 Jun 1;376(22):2194-2195. doi: 10.1056/NEJMc1700150. PMID:', 'entities': []}
{'filename': 'EMA - Time to Talk a Little Nerdy_ Burden of Proof - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': '28564561', 'entities': []}
{'filename': 'EMA - Time to Talk a Little Nerdy_ Burden of Proof - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': '[iv] Hamblin TJ. Fake! Br Med J (Clin Res Ed). 1981;283(6307):1671-1674.', 'entities': []}
{'filename': 'EMA - Time to Talk a Little Nerdy_ Burden of Proof - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': '[v] Larsson KS. The dissemination of false data through inadequate citation. J Intern Med. 1995;238(5):445-450.', 'entities': []}
{'filename': 'EMA - Time to Talk a Little Nerdy_ Burden of Proof - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'section_header', 'text': 'Related Media', 'entities': []}
{'filename': 'EMA - Time to Talk a Little Nerdy_ Burden of Proof - EMA 2025 June _ EM_RAP.pdf', 'page': None, 'block_label': 'section_header', 'text': 'Image', 'entities': []}
{'filename': 'EMA - Abstract 3_ GFAP and UCH-L1 as Predictors of Brain Injury After Mild TBI - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': 'Can the association of the biomarkers GFAP and UCH-L1 predict intracranial injury after mild traumatic brain injury in adults? A systematic review and meta-analysis Puravet A, Oris C, Pereira B, et al. Ann Emerg Med. Published online April 23, 2025. doi:10.1016/j.annemergmed.2025.03.018', 'entities': []}
{'filename': 'EMA - Abstract 3_ GFAP and UCH-L1 as Predictors of Brain Injury After Mild TBI - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'section_header', 'text': 'SUMMARY:', 'entities': []}
{'filename': 'EMA - Abstract 3_ GFAP and UCH-L1 as Predictors of Brain Injury After Mild TBI - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': 'In treating patients with head injuries in the ED, the most relevant clinical question is whether a CT is necessary to rule out an intracranial injury. Limiting unnecessary radiation exposure is paramount to good clinical practice, and many validated clinical decision instruments have been designed to do so. Interest in biomarkers to guide ED management has increased, and the data on the topic are now sufficient to warrant meta-analysis.', 'entities': []}
{'filename': 'EMA - Abstract 3_ GFAP and UCH-L1 as Predictors of Brain Injury After Mild TBI - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': 'The authors of this article followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines to identify published studies in adults with mild head injury who underwent measurement of glial fibrillary acidic protein (GFAP) and/or ubiquitin carboxy-terminal hydrolase L1 (UCH-L1), and received head CT. These 2 biomarkers are found in brain tissue and neurons, and are released into the bloodstream after injury. The data were extracted by 2 authors and verified by a third author.', 'entities': []}
{'filename': 'EMA - Abstract 3_ GFAP and UCH-L1 as Predictors of Brain Injury After Mild TBI - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': 'Of the 16 articles identified for inclusion, 14 reported prospective studies. The total number of patients was 7,828, and the median time from head injury to blood-sample collection was 1 to 11 hours. No included studies were assessed to be at high risk of bias.', 'entities': []}
{'filename': 'EMA - Abstract 3_ GFAP and UCH-L1 as Predictors of Brain Injury After Mild TBI - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': 'For GFAP alone, the overall pooled sensitivity and specificity were 94% (95% CI, 91%-97%) and 40% (95% CI, 34%-46%), respectively. For UCH-L1 alone, the overall pooled sensitivity and specificity were 83% (95% CI, 69%-94%) and 51% (95% CI, 40%-63%), respectively. The overall pooled sensitivity and specificity for a combination of GFAP and UCH-L1 were 100% (95% CI, 99%-100%) and 31% (95% CI, 26% to 36%), respectively, and the NPV was 100% (95% CI, 100%-100%).', 'entities': []}
{'filename': 'EMA - Abstract 3_ GFAP and UCH-L1 as Predictors of Brain Injury After Mild TBI - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': 'The high performance of these 2 biomarkers might been due to the different and complementary half-lives of the 2 proteins: UCH-L1 enables early detection (peak concentration immediately after injury) in patients with intracranial injury, whereas GFAP identifies patients after 8 hours.', 'entities': []}
{'filename': 'EMA - Abstract 3_ GFAP and UCH-L1 as Predictors of Brain Injury After Mild TBI - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'list_item', 'text': "The biomarkers' recommended 12-hour sampling window, in contrast to S100B's 3-hour window, provides flexibility in emergency settings. Moreover, unlike S100B, these biomarkers are not affected by skin pigmentation and therefore are more universally applicable across diverse patient populations. However, several limitations warrant consideration: given the heterogeneity in sampling times, varying cutoff values across studies, and poor specificity, using these biomarkers indiscriminately might increase the number of unnecessary head CT scans, and the use of different analytical techniques would complicate standardization for clinical implementation.", 'entities': []}
{'filename': 'EMA - Abstract 3_ GFAP and UCH-L1 as Predictors of Brain Injury After Mild TBI - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'section_header', 'text': 'PMID: 40272329', 'entities': []}
{'filename': 'EMA - Abstract 3_ GFAP and UCH-L1 as Predictors of Brain Injury After Mild TBI - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': "EDITOR'S COMMENTARY: Interest is increasing in using biomarkers as tools to identify which patients with minor head trauma need a CT scan. The published data are now sufficient for a proper", 'entities': []}
{'filename': 'EMA - Abstract 3_ GFAP and UCH-L1 as Predictors of Brain Injury After Mild TBI - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': 'meta-analysis. Across 16 included studies, the combination of GFAP and UCH-L1 had a sensitivity of 100% and an NPV of 100% for ruling out intracranial injury among adult patients with head trauma. Unfortunately, firm recommendations for use cannot be made, largely because of heterogeneity among studies. We also need to keep in mind that using these biomarkers indiscriminately might paradoxically increase the number of unnecessary head CT scans, because of their poor specificity of approximately 30%. Although these biomarkers represent a promising advance for emergency medicine, additional prospective implementation studies are needed to confirm the real-world effects on decreasing CT scans and to establish standardized protocols before widespread adoption in emergency departments.', 'entities': []}
{'filename': 'EMA - Abstract 3_ GFAP and UCH-L1 as Predictors of Brain Injury After Mild TBI - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'section_header', 'text': 'RELATED CONTENT:', 'entities': []}
{'filename': 'EMA - Abstract 3_ GFAP and UCH-L1 as Predictors of Brain Injury After Mild TBI - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': 'EM:RAP 2025 May: Neurocritical Care Mailbag: TBI Biomarkers - Bad Blood', 'entities': []}
{'filename': 'EMA - Abstract 3_ GFAP and UCH-L1 as Predictors of Brain Injury After Mild TBI - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': 'CorePendium : Traumatic Brain Injury (Minor)', 'entities': []}
{'filename': 'EMA - Abstract 3_ GFAP and UCH-L1 as Predictors of Brain Injury After Mild TBI - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': 'Copyright 2025 by Emergency Medical Abstracts - All Rights Reserved 07/25 - #03', 'entities': []}
{'filename': 'EMA - Abstract 3_ GFAP and UCH-L1 as Predictors of Brain Injury After Mild TBI - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': 'Tags: Brain Injury', 'entities': []}
{'filename': 'EMA - Abstract 3_ GFAP and UCH-L1 as Predictors of Brain Injury After Mild TBI - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': 'Lab Medicine', 'entities': []}
{'filename': 'EMA - Abstract 3_ GFAP and UCH-L1 as Predictors of Brain Injury After Mild TBI - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'section_header', 'text': 'CorePendium Chapters', 'entities': []}
{'filename': 'EMA - Abstract 3_ GFAP and UCH-L1 as Predictors of Brain Injury After Mild TBI - EMA 2025 July _ EM_RAP.pdf', 'page': None, 'block_label': 'text', 'text': 'Traumatic Brain Injury (Minor)', 'entities': []}
